simvastatin has been researched along with lovastatin in 1152 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 60 (5.21) | 18.7374 |
| 1990's | 752 (65.28) | 18.2507 |
| 2000's | 220 (19.10) | 29.6817 |
| 2010's | 102 (8.85) | 24.3611 |
| 2020's | 18 (1.56) | 2.80 |
| Authors | Studies |
|---|---|
| Hsiang, B; Kirchgessner, TG; Sasseville, V; Wang, Z; Wu, Y; Yang, WP; Zhu, Y | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Campbell, SD; Chen, C; Lin, J; Mills, JB; Mireles, RJ; Smolarek, TA; Xu, JJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Baret, E; Briolant, S; Fontaine, A; Fusai, T; Henry, M; Mosnier, J; Pradines, B; Rogier, C; Torrentino-Madamet, M | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Harada, T; Nakagawa, Y; Potter, PM; Wadkins, RM; Wheelock, CE | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bode, C; Hidalgo, IJ; Li, J; Owen, A; Volpe, DA; Wang, Y; Zhang, W | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, CC; Chen, JB; Chern, TR; Fang, JM; Lin, JH; Wei, TT | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Behnam, MA; Boldescu, V; Klein, CD; Nitsche, C | 1 |
| Balogh, I; Kim, HY; Koczok, K; Korade, Z; Liu, W; Mirnics, K; Porter, NA; Tallman, KA; Xu, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Talele, TT | 1 |
| Sashidhara, KV; Singh, SP | 1 |
| Biordi, L; Bologna, M; Carlucci, G; Mazzeo, P | 1 |
| Bruce, R; Crook, D; Mulcahy, D; Patterson, D; Worthington, M; Wynn, V | 1 |
| Agosti, A; Azzarito, C; Biagi, R; Boiardi, L; Dotti, C; Portioli, I; Zini, M | 1 |
| Bilheimer, DW | 2 |
| Boulton-Jones, JM; Grierson, D; Murray, L; Packard, CJ; Shepherd, J; Stewart, JP; Warwick, GL | 1 |
| Bruce, R; Crook, D; Sidhu, M | 1 |
| Oliver, MF | 3 |
| Brasseur, D; Chaudron, JM; Deslypere, JP; Ducobu, J; Harvengt, C; Muls, E; Thomson, M | 1 |
| Collen, D; De Geest, H; Jacobs, H; Lesaffre, E; Van de Werf, F | 1 |
| Gaw, A; Wosornu, D | 1 |
| Castelnovo, C; Colombini, M; De Vecchi, A; Paparella, M; Pini, C; Rovellini, A; Scalamogna, A | 1 |
| Chartrain, M; Ferris, F; Greasham, R; Hirsch, C; Houck, D; Marcin, C; Sykes, R; White, R | 1 |
| Becker, PJ; Firth, J; Marais, AD; Ubbink, JB; Ungerer, JP; Van Lathem, JM; Vermaak, WJ | 1 |
| Fukami, M; Fukuda, K; Koga, T; Koike, H; Shimada, Y; Tsujita, Y | 1 |
| Parfitt, A; Simons, J; Simons, LA | 1 |
| Behrens-Baumann, W; Fieseler, HG; Seidel, D; Thiery, J; Wieland, E | 1 |
| Bacon, S; Illingworth, DR; Pappu, AS; Sexton, GJ | 1 |
| Cattaneo, R; Colombo, F; Geroli, L; Marnini, P; Venco, A | 1 |
| Alberts, AW; Bostedor, R; Chao, YS; Duggan, ME; Fitzpatrick, SL; Halczenko, W; Hartman, GD; Imagire, JS; Pitzenberger, SM; Smith, RL | 1 |
| Lubrich-Birkner, I; Schollmeyer, P; Summ, O; Wanner, C; Wieland, H | 1 |
| Kerr-Muir, M; Lewis, B; Quiney, J; Slavin, B; Watts, GF | 1 |
| Cohen, L; Crommelin, D; Geelhoed-Mieras, T; Griffioen, M; Joles, J; Koomans, H; Krajnc-Franken, M; Van Bloois, L; Van Tol, A; Willekes-Koolschijn, N | 1 |
| Dahlén, GH; Johnson, O; Slunga, L | 1 |
| Alessandri, C; Peverini, F | 2 |
| Curran, L; Marais, AD; Schoeman, HS; Smart, AJ; Walters, L | 1 |
| Bonnici, F; Fourie, J; Kotze, TJ; Lourens, W; Omar, MA; Stander, I; Steyn, K; van Lathem, J; Vermaak, WJ; Weich, HF | 1 |
| Arndtz, N; Meiser, BM; Reichart, B; Seidel, D; Thiery, J; Wenke, K | 1 |
| Arimura, K; Higuchi, I; Kuriyama, M; Nagado, T; Nagata, K; Nakagawa, M; Nakahara, K; Osame, M; Yoshidome, H | 1 |
| Corsini, A; Paoletti, R; Soma, MR | 1 |
| Eichinger, M; Feussner, G; Ziegler, R | 1 |
| Lehto, S; Leino, M; Pyörälä, K; Rantala, A | 1 |
| Anderson, JV; Besser, GM; Maher, VM; Scoppola, A; Thompson, GR; Trainer, PJ | 1 |
| Amin, RD; Cheng, H; Dobrinska, MR; Quan, H; Rogers, JD; Stein, EA; Sweany, AE; Tate, AC | 1 |
| Corsini, A; Gabbiani, G; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Aiello, C; De Lucia, R; Dragonetti, C; Irace, L; Papa, A; Petraglia, L; Sannino, A | 1 |
| Beghè, F; Frustaci, G; Notarangelo, R; Pentimone, F; Pipicelli, G | 1 |
| Ball, MJ; Lewis-Barned, NJ | 1 |
| Billey, T; Dromer, C; Fournié, A; Fournié, B; Pages, M; Vedrenne, C | 1 |
| Bannwarth, B; Miremont, G; Papapietro, PM | 1 |
| Andersen, P; Dyerberg, J; Gall, MA; Hommel, E; Jensen, B; Nielsen, F; Parving, HH; Rossing, P | 1 |
| Baziz, A; Becot, F; Piquemal, A; Roblin, X | 1 |
| Haug, E; Lund, H; Norseth, J; Ose, L; Purvis, K; Rui, H; Tollefsrud, A; Viksmoen, L | 1 |
| Lee, E; Lepre, F | 1 |
| Angelé, B; Bellinghieri, G; Savica, V | 1 |
| Bellinghieri, G; Lamanna, F; Savica, V | 1 |
| Angelé, B; Brunelleschi, G; Galeone, F; Giuntoli, F; Lamanna, F; Saba, P; Spagnolo, G | 1 |
| Behrens-Baumann, W; Thiery, J | 1 |
| Averna, M; Barbagallo, C; Catalano, I; Ciabattoni, G; Davì, G; Ganci, A; Notarbartolo, A; Patrono, C | 1 |
| Hagen, C; Hangaard, J; Kjaer, K; Petersen, NE | 1 |
| Desager, JP; Harvengt, C; Horsmans, Y | 3 |
| Bard, JM; Bruckert, E; Camare, R; Dachet, C; Douste-Blazy, P; Drouin, P; Jacotot, B; Luc, G; Parra, HJ; Ziegler, O | 2 |
| Foo, WM; Lim, MC | 1 |
| Aldini, R; Bazzoli, F; Cipolla, A; Festi, D; Mazzella, G; Parini, P; Roda, A; Roda, E; Salzetta, A; Tonelli, D | 1 |
| Kotze, MJ; Kriek, JA; Steyn, K; van Zyl, LJ; Weight, MJ | 1 |
| Clifton, PM; Nestel, PJ; Wight, MB | 1 |
| Amin, RD; Brunner-Ferber, F; Pentikainen, PJ; Rogers, JD; Saraheimo, M; Schwartz, JI; Schwartz, MS | 1 |
| Infante, J; Infante, R; Qin, W; Wang, SR | 1 |
| Tamburrini, LR | 1 |
| Eda, T; Hidaka, Y; Kamei, T; Yonemoto, M | 1 |
| Butti, G; Fumagalli, R; Pagliarini, P; Paoletti, P; Paoletti, R; Soma, MR | 1 |
| Bagolin, E; Bizzaro, N; Cereser, C; Finco, B; Milani, L | 1 |
| Bertolini, S; Capurso, A; Cattin, L; Da Col, PG; Descovich, GC; Feruglio, FS; Gaddi, A; Masturzo, P; Resta, F; Urbinati, GC | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ | 1 |
| Walker, JF | 3 |
| Hidaka, Y; Horie, M; Hotta, H; Iwasawa, Y; Kamei, T; Nagata, Y | 1 |
| Antosiewicz, J; Mazzanti, L; Polenta, M; Rabini, RA; Staffolani, R; Testa, I | 1 |
| Davies, JE; Ng, LL | 2 |
| Bakker, HD; Bruin, T; Kastelein, JJ; Lansberg, PJ; Schaap, MC | 1 |
| Arakawa, K; Hidaka, K; Matsunaga, A; Sasaki, J; Takada, Y | 1 |
| Catapano, AL; Corsini, A; Fumagalli, R; Mazzotti, M; Romano, C; Romano, L | 1 |
| La Belle, P; Mantel, G | 1 |
| Illingworth, DR | 1 |
| Cerf, M; Chagnon, JP | 1 |
| Bereziat, G; Chambaz, J; Janvier, B; Loriette, C; Mangeney, M; Pepin, D; Ribeiro, A; Thomas, G | 1 |
| Akl, S; Barbir, M; Kushwaha, S; Mitchell, A; Rose, M; Yacoub, M | 1 |
| Lintott, CJ; Scott, RS; Wilson, MJ | 1 |
| Clémençon, D; Dubach, UC; Rüttimann, S | 1 |
| Duncan, CA; Vickers, S | 1 |
| Aviram, M; Brook, GJ; Keidar, S | 1 |
| Escousse, A; Goudonnet, H; Mercenne, F; Mounie, J; Truchot, RC | 1 |
| Gevers Leuven, JA; Hollaar, L; Smelt, AH; van 't Hooft, FM; van der Laarse, A; Zhao, SP | 1 |
| Deluca, JG; Germershausen, JI; Gerson, RJ; Gordon, LR; Grossman, SJ; MacDonald, JS; Majka, JA; Smith, PF; Wang, RW | 1 |
| Agay, D; Duhamel, O; Faure, D; Gislon, J; Legroux, P; Liautard, J; Pariente, EA; Ramdani, M; Schmitt, AM | 1 |
| Bauret, P; Blanc, P; Couderc, M; Larrey, D; Michel, H; Rouillon, JM | 1 |
| Bruckert, E; De Gennes, JL; Truffert, J | 1 |
| Johansson, J; Mölgaard, J; Olsson, AG | 1 |
| Neuman, HR; Neuman, J; Neuman, MP | 1 |
| Lundh, BL; Mölgaard, J; Olsson, AG; von Schenck, H | 1 |
| Hockwin, O; Schmidt, J; Schmitt, C | 2 |
| Mahoney, EM; Ranadive, SA; Serajuddin, AT | 1 |
| Antonicelli, R; Ippoliti, PF; Leone, L | 1 |
| Charmoillaux, M; Goudonnet, H; Mercenne, F; Mounié, J; Truchot, RC | 1 |
| Gallagher, JJ; Maher, VM; Myant, NB; Thompson, GR | 1 |
| Schlienger, JL | 1 |
| Cigala, O; Della Valle, M; Malarbi, AL; Marasco, A; Pancallo, MT | 1 |
| Illingworth, DR; Pappu, AS; Prihoda, JS; Smith, FE | 1 |
| Alessandri, C; Balsano, F; Barsi, R; Basili, S; Censi, C; Cordova, C; Marotta, P; Paradiso, M; Peverini, F | 1 |
| Ballaré, M; Bordin, G; Campanini, M; Catania, E; Monteverde, A; Zaccala, G | 1 |
| Brocard, JJ; Keller, U; Oberhänsli, A; Riesen, WF | 1 |
| Bakker, HD; Gorter, JW; Kastelein, JJ; Lansberg, PJ; Schilte, PP | 1 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM | 3 |
| Beisiegel, U; Labeur, C; Lamberigts, G; Lameire, N; Matthys, E; Rosseneu, M; Schurgers, M; Vandecasteele, N | 1 |
| Alberts, AW; Bostedor, R; Chao, YS; Duggan, ME; Germershausen, JI; Gilfillan, JL; Halczenko, W; Hartman, GD; Hunt, V; Imagire, JS | 1 |
| Fukuzumi, H; Horie, M; Iizuka, Y; Kamei, T; Sawasaki, Y; Tsuchiya, Y; Watanabe, K | 1 |
| Collins, P; Johnson, A; Owens, D; Robinson, K; Tighe, O; Tomkin, GH | 1 |
| Kuijpens, JL; Martens, LL; Rutten, FF; Winter, J | 1 |
| Ditschuneit, H; Ditschuneit, HH; Kuhn, K | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; Kari, PH; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ; Vyas, KP | 1 |
| Corsini, A; Fumagalli, R; Paoletti, R; Raiteri, M; Soma, M | 1 |
| Brooks, MA; Compton, DA; Compton, SV; Ryan, JA | 1 |
| Kalinowski, SS; Mosley, ST; Tanaka, RD | 1 |
| Charleson, H; French, JK; Lewis, GR; Lintott, CJ; Maling, TJ; Nye, ER; Reuben, S; Scott, RS; Sharpe, DN; White, HD | 1 |
| Fix, JA; McClelland, GA; Pogany, SA; Stubbs, RJ; Zentner, GM | 1 |
| Yeatman, E | 1 |
| Abate, N; Bertolotti, M; Carubbi, F; Carulli, N; Digrisolo, A; Dilengite, M; Loria, P; Pinetti, A | 1 |
| Maher, VM; Rendell, NB; Scoppola, A; Taylor, GW; Thompson, GR | 1 |
| Ewing, SL; Gebhard, RL; Hunninghake, DB; Prigge, WF; Schlasner, LA | 1 |
| Harris, DC; Mitchell, P; Simons, LA; Stewart, JH | 1 |
| Bocanegra, TS; Boccuzzi, SJ; Keegan, ME; Shapiro, DR; Walker, JF | 1 |
| Agheli, N; Jacotot, B | 1 |
| Hidaka, Y; Kamei, T; Satoh, T | 1 |
| Balestrieri, G; Candrina, R; Di Stefano, O; Giustina, G; Salvi, A; Spandrio, S | 1 |
| Mol, MJ; Stalenhoef, AF | 1 |
| Kruse, W; Schlierf, G; Weber, E | 1 |
| Erkelens, DW; Hené, RJ; Joles, JA; Koomans, HA; Rabelink, AJ | 2 |
| Moorhead, JF; Thomas, M | 1 |
| Bain, SC; Jones, AF; Lemon, M; Walker, MR | 1 |
| Bateson, MC | 1 |
| Delanghe, J; Deslypere, JP; Vermeulen, A | 1 |
| Deslypere, JP; Vermeulen, A | 1 |
| Beynen, AC; Haller, M; Meijer, GW; Van Lith, HA | 1 |
| Welborn, TA | 1 |
| De Liege, P; Gambert, P; Laurent, A; Lecoz, P; Legrand, A; Mikol, J; Peynet, J; Warnet, A | 1 |
| Bo, M; Bonino, F; Fabris, F; Gottero, M; Molaschi, M; Neirotti, M; Pernigotti, L | 1 |
| Fukuzumi, H; Hase, K; Ishida, F; Kamei, T; Sato, A; Watanabe, K | 1 |
| Chousterman, M; Lons, T | 1 |
| Bogomoletz, WV; Feydy, P | 1 |
| Baz, M; Berland, Y; Durand, C; Laugier, R; Musso, JL; Vacher Coponat, H | 1 |
| Lontie, JF; Lutton, C; Magot, T; Malmendier, CL; Ouguerram, K | 1 |
| Oogushi, K | 1 |
| Joshua, H; Schwartz, MS; Wilson, KE | 1 |
| MacDonald, JL; Mauro, VF | 1 |
| Benraad, TJ; Kloppenborg, PW; Smals, AG; Weusten, JJ | 1 |
| Tikkanen, MJ; Tilly-Kiesi, M | 1 |
| Alberts, AW; Chao, Y; Chen, JS; Hunt, VM; Karkas, JD; Kuron, GW; Liou, R | 1 |
| Bo, M; Fabris, F; Fiandra, U; Pedrazzini, V; Pernigotti, L; Poli, L; Zanocchi, M | 1 |
| Firth, JC; Fourie, J; Kotze, TJ; Marais, AD; Omar, MA; Stander, I; Steyn, K; Van Gelder, AL; Vermaak, WJ; Weich, HF | 1 |
| Kagami, Y; Ohtawa, M; Saitoh, Y; Uchiyama, N | 1 |
| Hörl, WH; Luley, CH; Wanner, C; Wieland, H | 1 |
| Archibald, MP; McDowell, IF; Nicholls, DP; Shortt, JA; Smye, M; Trimble, ER; Trinick, T | 1 |
| D'Onofrio, F; De Riu, S; Gambardella, A; Paolisso, G; Sgambato, S; Varricchio, M; Verza, M | 1 |
| England, JD; Labib, S; Viles, A | 1 |
| Alberts, AW | 1 |
| Erkelens, DW | 1 |
| Drouin, P; Ziegler, O | 1 |
| Amadio, L; Antonicelli, R; Lipponi, G; Paciaroni, E | 1 |
| Lundh, BL; Nilsson, SE | 1 |
| Goa, KL; Todd, PA | 1 |
| Fragoso, YD; Skinner, ER | 1 |
| Hidaka, Y; Ishida, F; Kamei, T; Nagata, Y | 2 |
| Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G | 1 |
| Ishida, F; Kakubari, K; Kamei, T; Kitani, K; Sato, A; Taguchi, K; Watanabe, K | 1 |
| Ascoop, CA; Erkelens, DW; Martens, LL; Rutten, FF | 2 |
| Aronson, JK; Ng, LL | 1 |
| Maher, VM; Thompson, GR | 1 |
| Bocanegra, TS; Tobert, JA | 1 |
| Hagemenas, FC; Illingworth, DR; Pappu, AS | 1 |
| Hasegawa, K; Koga, T; Kuroda, M; Shimada, Y; Tsujita, Y; Yamazaki, M | 1 |
| Hayaishi, O; Islam, F; Watanabe, Y | 1 |
| Kreisberg, RA | 1 |
| Caridis, R; Catalano, A; Gavelli, MS; Guarini, G; Rossi, FG; Santini, G; Serra, T; Tozzi, J; Vitaliano, E | 1 |
| Caridis, R; Gavelli, MS; Rizzuti, A; Rossi, FG; Serra, T; Tozzi, J; Vitaliano, E | 1 |
| Dachet, C; De Gennes, JL; Douste-Blazy, P; Drouin, P; Fricker, J; Keller, U | 1 |
| Ansuini, R; Barone, A; Francolini, G; Frausini, G; Pupita, F | 1 |
| Harvengt, C | 1 |
| Aubert, I; Bauduceau, B; Chanu, B; Dachet, C; Emmerich, J; Erlich, D; Gautier, D; Jacotot, B; Rouffy, J | 1 |
| Shapiro, DR; Walker, JF | 1 |
| Thiery, J | 1 |
| Jankelow, D; Myburgh, DP; Neutel, JM; Smith, DH | 1 |
| Clifton, P; Cooper, ME; Jennings, GL; Jerums, G; Nestel, PJ; O'Brien, RC; Simons, LA; Sullivan, D | 1 |
| Jones, PH | 1 |
| Creutzfeldt, C; Creutzfeldt, W; Seidel, D; Thiery, J; Walli, AK | 1 |
| Abe, S; Hata, S; Takano, T | 1 |
| Barth, JD; Kruisbrink, OA; Van Dijk, AL | 1 |
| England, JD; Stewart, PM; Viles, A; Walsh, JC | 1 |
| Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L | 1 |
| Degenaar, CP; Nieuwenhuijzen Kruseman, AC; van Deursen, RT; Wolffenbuttel, BH | 1 |
| Barlow, CW; Friedman, BM; Myburgh, DP; Smith, DH; Soicher, ER; Steenkamp, WF | 1 |
| de Góes, JM; Dereviack, BE; Diament, J; Forti, N; Giannini, SD; Machado, C | 1 |
| Nye, ER | 1 |
| French, J; White, H | 2 |
| French, JK; Greaves, SC; White, HD | 1 |
| Bercher, L; Bovet, P; Brunner, HR; Darioli, R | 1 |
| Kari, PH; Pitzenberger, SM; Vyas, KP | 1 |
| Alberts, AW; Bokelman, DL; Chen, J; Gerson, RJ; Greenspan, MD; MacDonald, JS; Rubin, LF; Yudkovitz, JB | 1 |
| Burrichter, H; Geisel, J; Oette, K | 1 |
| Carlson, LA | 1 |
| Anderson, A; Hopper, J; Macaskill, G; McDonald, P; Morgan, T | 1 |
| Kaufman, MJ | 1 |
| Carlsson, M; Mölgaard, J; Nilsson, J; Olsson, AG | 1 |
| Iizuka, Y; Ishida, F; Kakubari, K; Kamei, T; Kurahashi, Y; Sawasaki, Y | 1 |
| Demacker, PN; Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Bondjers, G; Fager, G; Wiklund, O | 1 |
| Demacker, PN; Mol, MJ; Stalenhoef, AF; Stuyt, PM; Van 't Laar, A | 1 |
| Armstrong, V; Bosch, T; Eisenhauer, T; Schuff-Werner, P; Seidel, D; Thiery, J | 1 |
| De Knijff, P; Erkelens, DW; Frants, RR; Gevers Leuven, JA; Havekes, LM; Mol, MJ; Schouten, J; Smit, J; Stalenhoef, AF | 1 |
| Bach, LA; Cooper, ME; Jerums, G; O'Brien, RC | 1 |
| Kreisberg, R; Mantell, G; Miller, V; Shapiro, DR; Stein, E; Washington, L | 1 |
| Descoeudres, C; Girod, MA; Mordasini, R; Riesen, WF | 1 |
| Löbel, P; Schrör, K; Steinhagen-Thiessen, E | 1 |
| Baker, SG; Berger, GM; Joffe, BI; Marais, AD; Mendelsohn, D; Seftel, HC; Welsh, NH | 1 |
| Behrens-Baumann, W; Creutzfeldt, C; Morawietz, A; Seidel, D; Thiery, J | 1 |
| Alberts, AW; Bailey, PJ; Bostedor, RG; Germershausen, JI; Hunt, VM; Karkas, JD | 1 |
| Mölgaard, J; Olsson, AG; von Schenck, H | 2 |
| Keller, U; Riesen, WF; Stohler, R | 1 |
| Kalinowski, SS; Mosley, ST; Schafer, BL; Tanaka, RD | 1 |
| Louis, WJ | 1 |
| Bolzano, K; Breslow, JL; Gavish, D; Kostner, GM; Leopold, B; Weintraub, MS | 1 |
| Demacker, PN; Hermus, AR; Mol, MJ; Stalenhoef, AF; Stuyt, PM; Van 'T Laar, A | 1 |
| Hormbrey, JM; Young, J | 1 |
| Galbraith, W; Watt, G | 1 |
| Delcroix, C; Lontie, JF; Magot, T; Malmendier, CL | 1 |
| Abrignani, MG; Alaimo, G; Averna, MR; Barbagallo, CM; Davì, G; Marino, G; Notarbartolo, A; Novo, S; Strano, A | 1 |
| Alexander, S; Cook, TJ; Mantell, G; Pietro, DA; Staggers, JE | 1 |
| Brown, WV | 1 |
| Faergeman, O; Haghfelt, T | 2 |
| Lintott, CJ; Nye, ER; Robertson, MC; Scott, RS; Sutherland, WH | 1 |
| Alberts, AW; Bokelman, DL; Gerson, RJ; Kornbrust, DJ; MacDonald, JS; Majka, JA; Stubbs, RJ | 1 |
| Bocanegra, TS; Cook, T; Tikkanen, MJ; Walker, JF | 1 |
| Nordøy, A; Ytre-Arne, K | 1 |
| Deslypere, JP | 1 |
| Bard, JM; Dachet, C; De Gennes, JL; Douste-Blazy, P; Drouin, P; Fruchart, JC; Jacotot, B; Luc, G; Ziegler, O | 1 |
| Ammann, F; Baur, HR; Bertel, O; Del Bufalo, A; Golay, A; Keller, U; Kistler, H; Kummer, H; Reutter, FW; Riesen, WF | 1 |
| Brusca, A; Caruzzo, C; Caruzzo, E; Marcolongo, M; Uslenghi, E; Varbella, F | 1 |
| Ishida, F; Kamei, T; Kobayashi, M; Ohmura, I; Taguchi, K; Takahashi, T; Watanabe, K | 1 |
| Atsmon, A; Bomstein, Y; Green, P; Lurie, Y; Mamet, R; Schoenfeld, N | 1 |
| Iizuka, Y; Ishida, F; Kamei, T; Kitani, K; Sato, A; Sawasaki, Y | 1 |
| Bos, WJ; Doorenbos, H; Muskiet, FA; van Doormaal, JJ | 1 |
| Averna, M; Barbagallo, CM; Davì, G; Mogavero, A; Notarbartolo, A; Novo, S; Strano, A | 1 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM; van 't Laar, A | 1 |
| Bojanovski, D; Bojanovski, M; Canzler, H; Jochim, A; Schulzeck, P | 1 |
| Harvengt, C; Leclercq, V | 1 |
| Aubert, I; Besseau, M; Chanu, B; Charpak, Y; Dachet, C; Emmerich, J; Herlich, D; Jacotot, B; Rouffy, J | 1 |
| Armstrong, VW; Creutzfeldt, C; Creutzfeldt, W; Schleef, J; Seidel, D; Thiery, J | 1 |
| Bard, JM; Devulder, B; Douste-Blazy, P; Fruchart, JC; Harvengt, C; Lecerf, JM; Leclerc, V | 1 |
| MacDonald, JS; Slater, EE | 1 |
| Tobert, JA | 2 |
| Aizawa, A; Iizuka, Y; Ishida, F; Kamei, T; Sato, A; Sawasaki, Y | 1 |
| Gevers Leuven, JA; Glatz, JF; Katan, MB; Kempen, HJ; van der Voort, HA | 1 |
| Mölgaard, J; Olsson, AG | 1 |
| Cucuiano, M | 1 |
| Weisweiler, P | 1 |
| Baggen, MG; Erkelens, DW; Kettner, M; Koningsberger, JC; Mol, MJ; Van Doormaal, JJ | 1 |
| Erkelens, DW; Gevers Leuven, JA; Mol, MJ; Schouten, JA; Stalenhoef, AF | 1 |
| Bacon, S; Illingworth, DR | 1 |
| Tobert, JA; Walker, JF | 1 |
| de Greef, WJ; Jansen, H | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Kikuchi, T; Koga, T; Koike, H; Miyazaki, A | 1 |
| Chisholm, A; Crooke, M; Jackson, R; Mann, J; Neutze, J; North, D; Swinburn, B; White, H; Wilcox, J | 1 |
| Galiana, J; Marchán, E; Montés, I; Pato, S | 1 |
| Iwasaki, T; Kato, S; Sasaki, H; Tada, N | 1 |
| Thompson, GR | 2 |
| Larsen, ML | 1 |
| Cremer, P; Holl, J; Klueppelberg, UG; Koelbl, R; Pauletzki, J; Paumgartner, G; Sackmann, M; Sauter, G; Seidel, D; von Ritter, C | 1 |
| Abrahamson, D; Detrano, RC; Franklin, SS; Henein, N; Kashyap, ML; Kukes, G; Rosenzweig, B; Teng, W; Willner, R; Wong, ND | 1 |
| Abiko, Y; Ichihara, K; Satoh, K | 1 |
| Adachi, H; Arai, H; Fukasawa, M; Hirota, K; Inoue, K; Mimura, K; Murakami-Murofushi, K; Tsujimoto, M | 1 |
| Jay, RH | 1 |
| Hippisley-Cox, J | 1 |
| Fukuo, Y; Ikejima, T; Nagashima, M; Soya-Ohmura, N; Takagi, S; Terashi, A | 1 |
| Duncan, A; Murphy, MJ; O'Reilly, DS; Packard, CJ; Vallance, BD | 1 |
| Smart, AJ; Walters, L | 1 |
| Tonkin, AM | 1 |
| Simes, RJ | 1 |
| Kjekshus, J; Pedersen, TR | 1 |
| Forti, N | 1 |
| Altman, R; Bolzano, K; Davignon, J; DeWailly, P; Giannini, S; Jerums, G; Kastelein, JJ; Lansberg, PJ; Mitchel, YB; Shapiro, D | 1 |
| Branchi, A; Fiorenza, AM; Rovellini, A; Sommariva, D | 1 |
| Garnett, WR | 2 |
| Cummings, MH; Naoumova, R; Quiney, JR; Sönksen, PH; Thompson, GR; Umpleby, M; Watts, GF | 1 |
| Olbricht, CJ | 1 |
| Ravnskov, U | 3 |
| Jacobson, TA | 2 |
| Colquhoun, DM | 1 |
| Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Appel, S; Hitzenberger, G; Kalafsky, G; Kallay, Z; Kutz, K; Rüfenacht, T; Tetzloff, W | 1 |
| Homma, Y; Kobayashi, T; Nakamura, H; Ozawa, H; Sakane, H; Yamaguchi, H | 1 |
| Campana, C; Gavazzi, A; Iacona, I; Montemartini, C; Perani, G; Raddato, V; Regazzi, MB; Viganò, M | 1 |
| Adachi, Y; Kamisako, T | 1 |
| Catovsky, D; Clutterbuck, RD; DeLord, C; Millar, JL; Newman, A; Powles, RL | 1 |
| Block, G; Cutler, N; Lines, C; Sramek, J; Stauffer, L; Veroff, A | 1 |
| Boumendil, E; Tubert-Bitter, P | 1 |
| Brack, T; Krähenbühl, S; Maggiorini, M; Meier, C; Risti, B; Stey, C | 1 |
| Dowell, FJ; Hamilton, CA; Lindop, GB; Reid, JL | 1 |
| Haffner, S; LaBelle, P; Orchard, T; Schmidt, D; Stein, E | 1 |
| Seidelin, KN | 1 |
| Amigues, O; Bour Guichenez, G; Cambazard, F; Guy, C; Perrot, JL; Servoz, J | 1 |
| de Bruin, TW; Koomans, HA; Rabelink, TJ; Stroes, ES | 1 |
| Levenstein, S | 1 |
| Amano, M; Ino, T; Kasuga, M; Kazumi, T; Matsuba, K; Ohki, A; Yoshino, G | 1 |
| Rasmusson, BU | 1 |
| Barbir, M; Hunt, BJ; Kehely, A; MacMahon, M; Prescott, RJ; Thompson, GR; Wray, R | 1 |
| Abdalla, AH; al-Hawas, FA; al-Khader, AA; al-Sulaiman, MH; Mousa, DH; Rassoul, Z; Rehman, MA | 1 |
| Bonal, J; Cantarell, C; Capdevila, L; Lauzurica, R; Pastor, C; Sierra, C | 1 |
| Ostergaard Kristensen, B | 1 |
| Agner, E; Agner, T; Malinowski, J; Meibom, J; Ramsing, D | 1 |
| Buja, LM; Casscells, SW; Goff, DC; Gould, KL | 1 |
| Durrington, PN | 1 |
| Shepherd, J | 4 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Bernini, F; Bonfadini, G; Fumagalli, R; Scurati, N | 1 |
| Richter, WO; Schwandt, P | 1 |
| Billingham, ME; Devens, C; Hammer, C; Meiser, BM; Reichart, B; Seidel, D; Thiery, J; Wenke, K; Wolf, S | 1 |
| Oyri, A | 1 |
| Jorge, PA; Metze, K; Ozaki, MR | 1 |
| Pedersen, TR | 2 |
| Assadollahi, F; Beaumont, JL; Buxtorf, JC; Cavallero, E; Jacotot, B | 1 |
| Eizyk, E; Kalén, J; Katzman, P; Nilsson, A; Sartor, G; Ugander, L; Ursing, D | 1 |
| Hockwin, O; Paulus, U; Schmidt, J; Schmitt, C; von Bergmann, K | 1 |
| Arndtz, N; Meiser, B; Reichart, B; Seidel, D; Thiery, J; Wenke, K | 1 |
| Ishikawa, S; Kawasumi, M; Saito, T | 1 |
| MacDonald, JS | 1 |
| Boumendil, EF | 1 |
| Bastin, P; Coppens, I; Courtoy, PJ; Levade, T | 1 |
| Shaughnessy, AF; Slawson, DC | 1 |
| Bär, PR; Erkelens, DW; Geerdink, RA; Smit, JW | 1 |
| Gram, JB | 1 |
| Bär, PR; Contermans, J; Erkelens, DW; Smit, JW | 1 |
| Halpern, JP; McLeod, JG; Peiris, O; Phan, T; Pollard, JD; Rohan, A | 1 |
| Bodd, E; Hyams, DE; Krüger, K; Roylance, PJ | 1 |
| Averna, M; Barbagallo, CM; Davì, G; Ganci, A; Giammarresi, C; La Placa, FP; Notarbartolo, A; Patrono, C | 1 |
| Bargossi, AM; Battino, M; Di Giulio, R; Fiorella, PL; Gaddi, A; Grossi, G | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Knops, RE; Kroon, AA; Mol, MJ; Stalenhoef, AF; Stuyt, PM | 1 |
| Ben Khalifa, F; Ftouhi, B; Kaabachi, A; Mebazaa, R; Mekaouer, A; Turki, S | 1 |
| Gram, J; Jespersen, J | 1 |
| Löfmark, R | 1 |
| Catapano, AL; Corsini, A; Maggi, FM | 1 |
| Amouyel, P; Brousseau, T; Devulder, B; Fruchart, JC; Lecerf, JM; Luc, G | 1 |
| Ceska, R; Kvasilová, M; Procházková, R; Sobra, J | 1 |
| Brandl, U; Detter, C; Kreuzer, E; Kur, F; Mair, H; Meiser, BM; Seidel, D; Thiery, J; Uberfuhr, P; Wenke, K | 1 |
| Arndtz, N; Meiser, B; Reichart, B; Seidel, D; Thiery, J; von Scheidt, W; Wenke, K | 1 |
| Caterson, RJ; Ibels, LS; Mahony, JF; Ong, CS; Pollock, CA; Waugh, DA | 2 |
| Akkerman, JW; De Laat, SW; Gorter, G; Schootemeijer, A; Tertoolen, LG | 1 |
| Ichihara, K; Satoh, K | 1 |
| Dabpetch, O; Jeamanukoolkit, N; Kakong, P; Koanantakul, B; Nontakanun, S; Yipintsoi, S | 1 |
| Ichihara, K; Nakai, T; Satoh, K | 1 |
| Cohen, LH; Huisman, RH; Moshage, H; van Thiel, GC; van Vliet, AK; Yap, SH | 1 |
| Castelluccio, A; Fiorini, F; Patrone, E | 1 |
| Bargossi, AM; Barozzi, G; Battino, M; Descovich, G; Di Giulio, R; Fiorella, PL; Gaddi, A; Genova, ML; Grossi, G; Sassi, S | 1 |
| Stehbens, WE | 1 |
| Himberg, JJ; Jokelainen, K; Laaksonen, R; Sahi, T; Tikkanen, MJ | 1 |
| Baetta, R; Butti, G; Davegna, C; De Renzis, MR; Fumagalli, R; Magrassi, L; Mazzini, G; Paoletti, R; Pezzotta, S; Soma, MR | 1 |
| Ceska, R; Justová, V; Jůzová, Z; Kvasilová, M; Procházková, R; Sobra, J; Wilczek, H | 1 |
| Castro Cabezas, M; De Bruin, TW; Erkelens, DW; Kock, LA | 1 |
| Bredie, SJ; de Bruin, TW; Demacker, PN; Kastelein, JJ; Stalenhoef, AF | 1 |
| Clifton, PM; Nestel, PJ; Noakes, M | 1 |
| Chin, JP; Dart, AM | 1 |
| Johansson, J; Lithell, H; Ohrvall, M; Vessby, B | 1 |
| Kulbertus, H; Legrand, V; Martinez, C | 1 |
| Reynolds, T; Wierzbicki, A | 1 |
| de la Rey, N; Eckert, HG; Luus, HG; Metzger, H; Meyer, BH; Müller, FO; Scholtz, HE; Seibert-Grafe, M | 1 |
| Arndtz, N; Reichart, B; Seidel, D; Thiery, J; Wenke, K | 1 |
| Hutchesson, AC; Jones, AF; Moran, A | 1 |
| Carmena, R | 1 |
| Durham, SK; Flint, OP; Gregg, RE; Masters, BA; Palmoski, MJ; Wang-Iverson, D | 1 |
| Faccini, G; Moghetti, P; Muggeo, M; Negri, C; Tosi, F; Travia, D | 1 |
| Olsson, AG | 2 |
| Wennmalm, A | 1 |
| Wood, DA | 1 |
| Beamish, RE; Dhalla, NS | 1 |
| Brennan, GM; Bruce, I; Johnston, GD; McDowell, IF; McEneny, J; McVeigh, GE; Nicholls, DP; Trimble, ER; Young, IS | 1 |
| Guimaraes, AC; Kettner, H; Lithell, H; Pitkänen, M; Sailer, D; Tuomilehto, J; Van Gaal, LF | 1 |
| Davies, G; Kitano, Y; Maher, VM; Matthews, S; Mir, A; Neuwirth, C; Prescott, RJ; Rees, A; Shortt, MB; Thompson, GR | 1 |
| Meiser, B; Reichart, B | 1 |
| Amigo, L; Garrido, J; González, S; Greco, A; Mingrone, G; Nervi, F; Núñez, L; Puglielli, L; Rigotti, A; Santos, M | 1 |
| Erkelens, DW; Illingworth, DR; Keller, U; Thompson, GR; Tikkanen, MJ | 1 |
| Rosenson, RS; Stein, JH | 1 |
| Cremer, P; Seidel, D | 1 |
| Herings, RM; Leufkens, HG; Urquhart, J | 1 |
| Elliott, HL; Marshall, S; Meredith, PA | 1 |
| Fukaura, Y; Ishikawa, C; Narisawa, T; Tanida, N; Terada, K; Umezawa, A; Yazawa, K | 1 |
| Panuccio, D; Romani, A; Trabatti, MR | 1 |
| Davis, P; Exner, M; Kerjaschki, D; Neale, TJ; Ojha, PP; Poczewski, H; Rüger, B; Witztum, JL | 1 |
| Argenio, GF; Bernini, GP; Franchi, F; Gasperi, M; Salvetti, A; Vivaldi, MS | 1 |
| Campana, C; Gavazzi, A; Iacona, I; Perani, G; Regazzi, MB; Viganò, M | 1 |
| Frants, RR; Gevers Leuven, JA; Havekes, LM; Smelt, AH; Van 't Hooft, FM; Van den Maagdenberg, AM; Van der Laarse, A; Van Tol, A; Vroom, TF; Zhao, SP | 1 |
| Himberg, JJ; Laaksonen, R; Ojala, JP; Tikkanen, MJ | 1 |
| Goldsmith, MF | 1 |
| Clutterbuck, RD; Millar, JL; Newman, A; Powles, RL | 1 |
| Dotti, MT; Federico, A | 1 |
| Service, RF | 1 |
| Cummings, MH; Watts, GF | 1 |
| Blazejewski, S; Dhumeaux, D; Mallat, A; Mavier, P; Preaux, AM; Rosenbaum, J | 1 |
| Steinhagen-Thiessen, E | 1 |
| Arnadottir, M; Eriksson, LO; Germershausen, JI; Thysell, H | 1 |
| Armitage, J; Collins, R; Fatemian, M; Kearney, E; Keech, A; Lawson, A; Lyon, V; MacMahon, S; Mindell, J; Wallendszus, K | 1 |
| De Luca, N; Del Mirto, C; Fontana, D; Gisonni, P; Iovino, G; Marchegiano, R; Pompeo, F; Trimarco, B | 1 |
| Avner, R; Butbul, E; Eisenberg, S; Levkovitz, H; Sehayek, E | 1 |
| Daenen, W; De Geest, H; Van Cleemput, J; Van Lierde, J; Vanhaecke, J | 1 |
| Keller, U; Miserez, AR; Rossi, FA | 1 |
| Arimura, K; Gotow, T; Kuriyama, M; Nakahara, K; Osame, M; Sonoda, Y | 1 |
| Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C | 1 |
| Kuriyama, M; Nakahara, K; Osame, M; Yada, T | 1 |
| Namiki, M; Nishino, N; Obara, T; Okamura, K; Tanno, S; Ura, H | 1 |
| Daubresse, JC; Machowski, R; Pulinx, E | 1 |
| Grellier, P; Millerioux, V; Rigomier, D; Schrevel, J; Valentin, A | 1 |
| Alberti, KG; Evans, K; Farrer, M; Kesteven, P; Laker, MF; Neil, HA; Winocour, PH | 1 |
| Sirtori, CR | 1 |
| Chapman, BA; Hurrell, MA; Wilson, IR | 1 |
| Ma, L; Morita, I; Murota, S | 1 |
| Bos, FM; Duits, N | 2 |
| de Graaf, J; Demacker, PN; Stalenhoef, AF | 1 |
| Bonnefous, F; Debbas, N; Farnier, M; Irvine, A | 1 |
| Benhizia, F; Griglio, S; Lagrange, D; Malewiak, MI | 1 |
| Lambrecht, LJ; Malini, PL | 1 |
| Bertolotti, M; Bozzoli, M; Carubbi, F; Carulli, N; Cassinadri, MT; Concari, M; Dilengite, MA; Guicciardi, ME; Loria, P | 1 |
| Hoeg, JM; Nelson, LM; Robins, ED | 1 |
| Ball, M; Chisholm, A; Sutherland, W | 1 |
| Bellosta, S; Bernini, F; Bonfadini, G; Didoni, G; Fumagalli, R | 1 |
| Mollinedo, F; Pérez-Sala, D | 1 |
| al-Jubouri, MA; Briston, PG; Chinn, RH; Sinclair, D; Young, RM | 1 |
| Branford, WA; Khattak, FH; Morris, IM | 1 |
| Barbir, M; Galloway, D; Hunt, BJ; Ilsley, C; Mitchell, A; Taylor, A; Yacoub, M | 1 |
| Saheki, A; Tamai, I; Terasaki, T; Tsuji, A | 2 |
| Emmerich, J | 1 |
| Alessandri, C; Andreozzi, P; Basili, S; Bracaglia, D; Cordova, C; Maurelli, M | 1 |
| Atsma, DE; Bastiaanse, EM; Kuijpers, MM; Van der Laarse, A | 1 |
| Day, AP; Stansbie, D | 1 |
| Baetta, R; Battaini, F; Bergamaschi, S; Davegna, C; De Renzis, MR; Fumagalli, R; Govoni, S; Soma, MR | 1 |
| Böhler, J; Eckardt, HG; Schollmeyer, P; Wanner, C; Wieland, H | 1 |
| Lu, ZL | 1 |
| Ashton, CH; Harrison, RW | 1 |
| Carbonieri, E; Cemin, C; Franceschini, L; Ghebremariam-Tesfau, K; Rossi, L; Tomei, R; Zardini, P | 1 |
| Corsini, A; Fumagalli, R; Gabbiani, G; Mazzotti, M; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Camarda, G | 1 |
| Foresta, C; Guarneri, G; Lavagnini, T; Padovan, D; Rossato, M | 1 |
| Abboud, HE; Biswas, P; Choudhury, GG; Grandaliano, G | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Bremer, J; Lintott, CJ; Scott, RS; Sutherland, WH | 1 |
| Hodgson, JM; Marks, SJ; Matthews, PG; Myers, KA; Wahlqvist, ML | 1 |
| Alberti, KG; Klausen, IC; Mogensen, CE; Møller, N; Nielsen, S; Pørksen, N; Schmitz, O | 1 |
| Baum, H; Castelluccio, C; Quinn, PJ; Rice-Evans, C; Taub, NA; Watts, GF | 1 |
| Mazzanti, L; Polenta, M; Rabini, RA; Signore, R; Staffolani, R; Testa, I; Tocchini, M | 1 |
| Harris, KP; Hattersley, JM; Moorhead, JF; Ramaswamy, C; Thomas, ME; Varghese, Z; Walls, J; Wheeler, DC; Williams, JD | 1 |
| Fukami, M; Fukushige, J; Kogure, Y; Maeda, N; Ogawa, T; Shimada, Y; Tsujita, Y | 1 |
| Felgines, C; Lutton, C; Mathé, D; Mazur, A; Sérougne, C | 1 |
| Arnadottir, M; Eriksson, LO; Karkas, JD; Thysell, H | 1 |
| Amin, RD; Cheng, H; Grasing, K; Mitchel, YB; Pipkin, JD; Rogers, JD; Schwartz, JI; Schwartz, MS; Sutton, SC; Zentner, GM | 1 |
| Feher, MD; Knight, BL; Lant, AF; Mayne, PD; Patel, DD; Soutar, AK; Webb, JC | 1 |
| Bais, R; Clifton, PM; Coyle, P; Hosking, J; Kusenic, B; Nestel, PJ; Roach, PD; Thomas, DW; Wight, MB | 1 |
| Davies, JE; Ng, LL; Wojcikiewicz, RJ | 1 |
| De Cuyper, I; van Doormaal, JJ; Wijnandts, PN; Wolthers, BG | 1 |
| Carrier, M; Cartier, R; Genest, J; Leclerc, Y; Pelletier, GB; Pelletier, LC | 1 |
| Bonnetblanc, JM; Brosset, A; Labrousse, F; Roger, D; Rolle, F | 1 |
| De Haan, AF; Kastelein, JJ; Kortmann, B; Kroon, AA; Lansberg, PJ; Stalenhoef, AF; Stuyt, PM | 1 |
| McDonagh, J; Walker, DJ; Winocour, P | 1 |
| Mauro, VF | 1 |
| Horie, M; Iwasawa, Y; Kamei, T; Nagata, Y; Satoh, T; Shimizu, A | 1 |
| Blank, D; Brun, LD; Campeau, L; Crockford, P; Curnew, G; Dafoe, W; Davignon, J; Dufour, R; Emery, G; Frohlich, J | 1 |
| De Haan, AF; Demacker, PN; Kleinveld, HA; Stalenhoef, AF | 1 |
| Holdcroft, C | 1 |
| Buttery, PJ; Huggett, CD; Salter, AM | 1 |
| Golay, A; James, R; Lehmann, T; Pometta, D | 1 |
| Baigts, F; Devulder, B; Lecerf, JM; Luc, G | 1 |
| Kerry, NL; Nestel, PJ; Roach, PD; Whiting, MJ | 1 |
| Davignon, J; Giroux, LM; Naruszewicz, M | 1 |
| Martinez Hernandez, BE; Moorhead, JF; Persaud, JW; Varghese, Z | 1 |
| Cimino, R; Civardi, F; Maltagliati, L; Marangoni, R; Masi, F; Romei Longhena, G | 1 |
| Antoniou, S; Dimitriadis, A; Hatzisavvas, N; Kaldi, I; Pastore, F; Stangou, M | 1 |
| Abadia, R; Agnus, D; Chariot, P; Charpentier, C; Danan, C; Gherardi, RK | 1 |
| Caslake, MJ; Gaw, A; Griffin, BA; Lindsay, GM; Lorimer, AR; Murray, EF; Packard, CJ; Shepherd, J; Vallance, BD | 1 |
| Bayne, WF; Gilbert, JD; Hsieh, JY; Matuszewski, BK; Morris, MJ; Ramjit, HG | 1 |
| Bloemendal, H; Cohen, LH; de Vries, AC; Vermeer, MA | 1 |
| Alsina, J; Andrés, E; Castelao, AM; Castiñeiras, MJ; Galcerán, JM; Gilvernet, S; González, MT; Griñó, JM; Roca, M; Serón, D | 1 |
| Bézard, J; Blond, JP; Georges, B; Maniongui, C | 1 |
| Kazumi, T; Maeda, E; Matsushita, M; Morita, M; Murata, Y; Nagata, K; Naka, Y; Yoshino, G | 1 |
| de Villiers, W; Graadt van Roggen, F; Jeenah, M; Marais, D; Seftel, H; September, W | 1 |
| Simons, LA | 2 |
| Cordonnier, D; Denis, MC; Mouneimne, A; Richard, MJ; Sirajeddine, K; Tricot, F | 1 |
| Alemanno, N; Cassader, M; Gambino, R; Pagano, G; Ruiu, G; Veglia, F | 1 |
| Fidge, N; Griffiths, P; Mitchell, A | 1 |
| Caputo, S; Ghirlanda, G; Greco, AV; Lippa, S; Littarru, GP; Manto, A; Oradei, A; Uccioli, L | 1 |
| Donetti, E; Ferrari, C; Fumagalli, R; Mazzini, G; Paoletti, R; Parolini, C; Soma, MR | 1 |
| Block, GA; Eckernäs, SA; Eriksson, LO; Haigh, JR; Kvidal, P; Neafus, RP; Roos, BE | 1 |
| Falaschi, F; Finardi, G; Franco, C; Perani, G; Ricciardi, R; Tramarin, R | 1 |
| Cabezas, MC; de Bruin, TW; Erkelens, DW; Jansen, H; Kock, LA; Kortlandt, W; Van Linde-Sibenius Trip, M | 1 |
| Stricker, BH; Wolterbeek, R | 1 |
| Cramb, R; Head, A; Jakeman, PM; Kendall, MJ; Maxwell, S | 1 |
| Pessina, AC; Rossi, G; Semplicini, A; Serena, L; Valle, R | 1 |
| Bär, PR; Bredman, JJ; Cohen, LH; De Vries, AC; Vermeer, MA | 1 |
| Ahnadi, CE; Berthezène, F; Ponsin, G | 1 |
| Hayashi, M; Horie, M; Hotta, H; Ishida, F; Kamei, T; Nagata, Y; Satoh, T | 1 |
| Castro Cabezas, M; de Bruin, TW; Erkelens, DW; Jansen, H; Kock, LA; Van Linde-Sibenius Trip, M | 1 |
| Faggiano, P; Gardini, A; Ghizzoni, G; Oneglia, C; Rusconi, C; Sabatini, T | 1 |
| Burg, G; Elsner, P; Krasovec, M | 1 |
| Feldmann, R; Mainetti, C; Saurat, JH | 1 |
| Cohen, LH; Griffioen, M; Jansen, LM; Roodenburg, L; van Vliet, A | 1 |
| Guptha, S | 1 |
| McTavish, D; Plosker, GL | 1 |
| Hoshi, K; Ichihara, K; Nakai, T; Satoh, K; Yamato, A | 1 |
| Camerino, DC; De Luca, A; Ferrannini, E; Laico, M; Natuzzi, F; Pierno, S; Roselli, A; Tricarico, D | 1 |
| Armitage, JM; Bron, AJ; Brown, NA; Collins, R; Harris, ML; Keech, AC; MacMahon, S; Snibson, G; Wallendszus, KR | 1 |
| Martínez-Castelao, A | 1 |
| Shand, JH; West, DW | 1 |
| Corretti, MC; Plotnick, GD; Vogel, RA | 1 |
| Boyd, I; England, JD; Halmagyi, GM; Rohan, A; Stewart, P; Walsh, JC | 1 |
| Gotto, AM; Hay, JW | 1 |
| Gudnason, V; Humphries, SE; Lloyd, JK; Muller, DP | 1 |
| Boop, BS; Hart, RG; Sherman, DG | 1 |
| Erkelens, DW; Portincasa, P; Renooij, W; Smit, JW; Van Berge-Henegouwen, GP; Van Erpecum, KJ | 1 |
| Averna, M; Barbagallo, C; Calà, A; Catalano, I; Davì, G; Ganci, A; Giammarresi, C; Notarbartolo, A | 1 |
| Irsigler, H; Klein, W; Lechleitner, M; Patsch, JR; Sailer, S | 1 |
| Arnaboldi, L; Corsini, A; Fumagalli, R; Paoletti, R; Quarato, P; Raiteri, M | 1 |
| Belloni, P; Corsini, A; Folco, G; Fumagalli, R; Granata, A; Hernandez, A; Paoletti, R; Viganõ, T | 1 |
| Del Puppo, M; Galli Kienle, M; Rauli, S | 1 |
| Nigg, C | 1 |
| Coppens, I; Courtoy, PJ | 1 |
| Abadir, R; Liebmann, J | 1 |
| Wilson, CS | 1 |
| Brandl, U; Meiser, BM; Reichart, B; Seidel, D; Thiery, J; Wenke, K | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Lewis, LS | 1 |
| MacDonald, TM; MacFadyen, RJ; Mollon, I; Pringle, SD | 1 |
| Grau, E; Pastor, E; Perella, M | 1 |
| Cooper, ME; Gilbert, RE; Jerums, G | 1 |
| Addeo, R; Altucci, L; Battista, T; Bonapace, IM; Bresciani, F; Cancemi, M; Cicatiello, L; Germano, D; Pacilio, C; Salzano, S; Weisz, A | 1 |
| Benders, AA; Oosterhof, A; Smit, JW; Veerkamp, JH | 1 |
| Caslake, MJ; Colquhoun, I; Gaw, A; Griffin, BA; Lindsay, GM; Lorimer, AR; Murray, EF; Packard, CJ; Shepherd, J; Wheatley, DJ | 1 |
| Vandenbroucke, JP; Westendorp, RG | 1 |
| Harkonen, M; Himberg, JJ; Jokelainen, K; Laakso, J; Laaksonen, R; Sahi, T; Tikkanen, MJ | 1 |
| Addeo, R; Altucci, L; Bifulco, M; Bonapace, IM; Bresciani, F; Cicatiello, L; Laezza, C; Salzano, S; Sica, V; Weisz, A | 1 |
| Berg, K; Faergeman, O; Haghfelt, T; Jönsson, B; Kjekshus, J; Miettinen, T; Olsson, AG; Pedersen, TR; Pyörälä, K; Schwartz, JS; Thorgeirsson, G; Wedel, H; Wilhelmsen, L | 1 |
| Aengevaeren, WR; Bruschke, AV; Kroon, AA; Reiber, JH; Stalenhoef, AF; Uijen, GJ; van der Werf, T | 1 |
| Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L | 1 |
| Burgmer, U; Mohr, K | 1 |
| Addeo, R; Altucci, L; Beato, M; Bresciani, F; Cicatiello, L; Dauvois, S; Parker, MG; Sica, V; Truss, M; Weisz, A | 1 |
| Balestrieri, GP; Di Stefano, O; Maffi, V; Salvi, A; Scalvini, T; Sleiman, I; Spandrio, S | 1 |
| Holme, I | 1 |
| Windler, E | 1 |
| Banba, H; Hiruma, M; Ishibashi, A; Kawada, A; Morimoto, K | 1 |
| Cohen, LH; Naaktgeboren, N; van Thiel, GC; van Vliet, AK | 1 |
| Fehmers, MC; Koornstra, JJ; Ottervanger, JP; Stricker, BH | 1 |
| Hendry, BM; Owen, JS; Scoble, JE; Streather, CP | 1 |
| Huttunen, J | 1 |
| Grundy, SM; Mazzaferri, EL | 1 |
| Ripoll, MA | 1 |
| Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A | 1 |
| Kruse, P | 1 |
| Armitage, J; Collins, R; Keech, A; Lawson, A; Wallendszus, K; Wardle, J | 1 |
| Coleman, JE; Watson, AR | 1 |
| Brügemann, J; Crijns, HJ; de Graeff, PA; May, JF; van Boven, AJ | 1 |
| Pedersen, TR; Tobert, JA | 1 |
| Kimura, T; Komai, T; Masuda, H; Nomoto, K; Shinkai, K | 1 |
| Berardesca, E; Brazzelli, V; Distante, F; Perani, G | 1 |
| Bending, JJ; Leitersdorf, E; Mitchell, WD; Reshef, A; Watts, GF | 1 |
| Dayer, P; Leemann, T; Transon, C | 1 |
| Azzarito, C; Boiardi, L; Portioli, I; Vergoni, W; Zini, M | 1 |
| Fidge, N; Mitchell, A | 1 |
| Wray, R | 1 |
| Hosomi, N; Izumi, Y; Kitadai, M; Satoh, K; Takahashi, T; Tsuda, Y | 1 |
| Colette, C; Crastes De Paulet, A; Descomps, B; Farnier, M; Feillet, C; Monnier, LH; Percheron, C | 1 |
| Hill, C; Kirkham, B; Zeitz, C | 1 |
| Boissonnat, P; de Lorgeril, M; Dureau, G; Monjaud, I; Salen, P | 1 |
| De Groot, RE; Dijkman, JH; Willems, LN | 1 |
| Campagnoli, G; Dorigotti, F; Franceschini, G; Gianfranceschi, G; Pazzucconi, F; Sirtori, CR; Sirtori, M | 1 |
| Clem, JR | 1 |
| Ballantyne, CM; Bourge, RC; Domalik, LJ; Eisen, HJ; Fishbein, DP; Kubo, SH; Lake, KD; Radovancevic, B; Taylor, DO; Ventura, HO; Yancy, CW; Young, JB | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Davie, AP; McMurray, JJ | 1 |
| Johannesson, M; Jönsson, B; Kjekshus, J; Olsson, AG; Pedersen, TR; Wedel, H | 2 |
| Coulter, DM | 1 |
| Eisele, B; Maier, R; Mark, M; Muller, P | 1 |
| Bateman, TM; Conn, RD; Lavie, CJ; O'Keefe, JH | 1 |
| Bredie, SJ; de Bruin, TW; Kastelein, JJ; Knipscheer, HC; Stalenhoef, AF; Westerveld, HT | 1 |
| Foo, JI; Mamotte, CD; Sturm, M; Taylor, RR; van Bockxmeer, FM | 1 |
| Assie, N; Bruniquel, F; Degryse, AD; Delhon, A; Oms, P; van Haverbeke, G | 1 |
| Chanussot, F; Clerc, T; Diaconescu, N; Domingo, N; Hasselot, N; Jadot, G; Lafont, H; Laruelle, C; Moutardier, V; Rault, JP; Sbarra, V | 1 |
| Hehnke, U; Kaffarnik, H; Schwartz, T; Steinmetz, A | 1 |
| Bionda, A; Galetta, F; Sampietro, T | 1 |
| Carotenuto, A; Carreras, G; de Divitiis, M; de Divitiis, O; Di Somma, S; Galderisi, M; Greco, V; Iannuzzo, G; Liguori, V; Montefusco, S; Rubba, P | 1 |
| Benoist, F; Grand-Perret, T | 1 |
| Horn, M | 1 |
| Hayashi, K; Walker, AM | 1 |
| Berg, K; Cook, TJ; Faergeman, O; Haghfelt, T; Kjekshus, J; Miettinen, T; Musliner, TA; Olsson, AG; Pedersen, TR; Pyörälä, K; Thorgeirsson, G; Tobert, JA; Wedel, H; Wilhelmsen, L | 1 |
| Akçiçek, F; Alev, M; Atabay, G; Basçi, A; Duman, S; Kürsad, S; Ok, E; Unsal, A | 1 |
| Angelin, B; Eklundh, T; Eriksson, M; Nordin, C; Sjöberg, S | 1 |
| Hughes, AD | 1 |
| Gaw, A | 1 |
| Buckley, BM; Murphy, MB; Vaughan, CJ | 1 |
| Rackley, CE | 1 |
| Kada, M; Komai, T; Kurakata, S; Nomoto, K; Shimada, Y | 1 |
| Branchi, A; Fiorenza, AM; Gandini, R; Maraffi, F; Rovellini, A; Sommariva, D | 1 |
| Ichikawa, M; Matsuyama, K; Nakai, A; Nishikata, M | 1 |
| Glueck, CJ; Lang, JE; Wang, P | 1 |
| Armitage, JM; Collins, R; Hauer, AJ; Keech, AC; Lawson, A; Parish, SE; Wallendszus, KR | 1 |
| Byrne, MJ; Rayner, BL; van Zyl Smit, R | 1 |
| Dotti, MT; Federico, A; Lindenthal, B; Lütjohann, D; Simatupang, A; von Bergmann, K | 1 |
| Donetti, E; Fumagalli, R; Paoletti, R; Parolini, C; Soma, MR | 1 |
| Altieri, PI; Castro, M; Escobales, N; Sanabria, P | 1 |
| Pederson, JP; Weintraub, WS | 1 |
| McMurray, JJ; Morrison, CE | 1 |
| Masters, P; Shetty, A | 1 |
| De Soete, C; Segaert, MF; Vandewiele, I; Verbanck, J | 1 |
| Wanner, C | 1 |
| Bolhuis, PA; Cohen, LH; Nègre-Aminou, P; van Thiel, GC; van Vliet, AK | 1 |
| Gorrie, MJ; MacGregor, MS; Rodger, RS | 1 |
| Aumont, MC; Seknadji, P | 1 |
| Ganotatis, ES; Jagroop, IA; Mikhailidis, DP; Winder, AF | 1 |
| Rosenson, RS; Tangney, CC | 2 |
| Miura, Y; Nakano, H; Nishimura, M; Sakai, O; Shibasaki, T; Suzuki, S; Tuchida, H; Wakabayashi, Y; Yamada, K | 1 |
| Komatsu, N; Kunitama, M; Miura, Y | 1 |
| Dwight, JF; Hendry, BM; Mendes Ribeiro, AC | 1 |
| Aengevaeren, WR; Kroon, AA; Stalenhoef, AF; Uijen, GJ; van der Werf, T | 1 |
| Kroon, AA; Stalenhoef, AF; van Asten, WN | 1 |
| Grieve, LA; Jenkins, GH; Singer, DR; Yacoub, MH | 1 |
| Murota, S; Sato-Suzuki, I | 1 |
| Harano, Y; Ikeda Ryomoto, K; Suzuki, M; Tsushima, M; Yamamoto, A | 1 |
| Jackson, PR; Payne, JN; Pickin, DM; Ramsay, LE; Ul Haq, I; Yeo, WW | 1 |
| Ikegami, T; Kano, M; Matsuzaki, Y; Miyamoto, J; Miyazaki, H; Osuga, T; Shoda, J; Tanaka, N | 1 |
| Athyros, VG; Boudoulas, H; Hatzikonstandinou, HA; Kontopoulos, AG; Mayroudi, MC; Papageorgiou, AA | 1 |
| Hamilton, TD; Keefer, BE; Spicer, LJ | 1 |
| Kuroiwa, A; Nakashima, Y; Tanaka, S; Tasaki, H; Toyokawa, Y; Yamashita, K; Yashiro, A | 1 |
| Du Buf-Vereijken, PW; Spooren, PF; van Doormaal, JJ; van Puijenbroek, EP | 1 |
| Ichikawa, M; Matsuyama, K; Nakai, A; Nishikata, M; Uchida, T | 1 |
| Amin, RD; Davidson, MH; Dobrinska, MR; Dujovne, CA; Hunninghake, DB; Illingworth, DR; Knopp, RH; Melino, MR; Mitchel, YB; Stein, EA; Tobert, JA; Weiss, SR; Zupkis, RV | 1 |
| MacMahon, S; Robson, RA; Sutherland, WH; Walker, HL; Walker, RJ | 1 |
| Dol, F; Herbert, J; Mares, A | 1 |
| del Valle Górnez Martínez, M; Gallardo, F; González Maqueda, I; Martín-Jadraque, L; Mostaza, JM; Plaza Celermín, L; Salazar, ML | 1 |
| Acton, SM; Barr, HA; Davidson, KG; Nicholas, TE | 1 |
| Benesch, L; Bestehorn, HP; Betz, P; Blümchen, G; Claus, J; Kappenberger, L; Mathes, P; Neiss, A; Rensing, UF; Roskamm, H; Schemeitat, K; Wieland, H | 1 |
| Armitage, JM; Collins, R; Lawson, A; Meade, TW; Mitropoulos, KA; Peto, R; Reeves, BE; Wallendszus, KR; Wilson, SS | 1 |
| Autier, P; Muls, E; Van Gaal, L; Vansant, G | 1 |
| Johannesson, M; Jönsson, B | 1 |
| Green, D; O'Driscoll, G; Taylor, RR | 1 |
| Lingenhel, A; Pilcher, G; Raal, FJ; Rubinsztein, DC; Utermann, G | 1 |
| Catapano, AL; Jacoviello, C; Longoni, C; Pirillo, A; Radaelli, A | 1 |
| Angelin, B; Juliusson, G; Vitols, S | 1 |
| Birkenhäger, JC; De Heide, L; Deckers, JW; Hoogerbrugge, N; Jansen, H; Zillikens, MC | 1 |
| Angelin, B; Bröijersén, A; Eriksson, M; Hjemdahl, P; Leijd, B | 1 |
| Catovsky, D; Clutterbuck, RD; Millar, JL; Newman, A; Powles, RL | 1 |
| Haffner, SM | 1 |
| Faergeman, O; Kjekshus, J; Olsson, AG; Pedersen, TR; Pyŏrälä, K; Thorgeirsson, G | 1 |
| Fitzsimon, C; Leclerc, C; Rivière, M; Tretiak, R; Wang, S | 1 |
| Giroux, I; Jacques, H; Lavigne, C; Moorjani, S | 1 |
| Barter, P; Clifton, P; Colquhoun, D; Hamilton-Craig, I; Nestel, P; Sikaris, K; Simons, L; Sullivan, D | 1 |
| Desager, JP; Horsmans, Y | 1 |
| Dal Piaz, A; De Venuto, G; Focher, C; Miori, R; Ramponi, C; Spagnolli, W; Torboli, P | 1 |
| Ganotakis, ES; Mikhailidis, DP; Winder, AF | 1 |
| Henion, J; Korfmacher, WA; Lapiguera, AP; Lin, CC; Wu, Y; Zhao, J | 1 |
| Applegate, WB; Cushman, W; Elam, MB; Heimberg, M | 1 |
| de Jong, J; Jira, P; Rubio-Gozalbo, E; Smeitink, J; Wevers, R | 1 |
| Tonstad, S | 1 |
| Cohen, LH; Nègre-Aminou, P; van Erck, M; van Leeuwen, RE; van Thiel, GC; van Vliet, AK | 1 |
| Bellavia, S; Day, AP; Jones, OT; Stansbie, D | 1 |
| Isley, W; Rajeshawari, M; Tal, A | 1 |
| Fager, G; Lennernäs, H | 1 |
| Aebi, JD; Dehmlow, H; Gains, N; Himber, J; Ji, YH; Lengsfeld, H; Morand, OH | 1 |
| Dujovne, CA | 1 |
| Battisti, E; Gennari, C; Giordano, N; Mattii, G; Senesi, M; Villanova, M | 1 |
| Arnaboldi, L; Corsini, A; Ferraboschi, P; Fumagalli, R; Gelb, MH; McGeady, P; Paoletti, R; Quarato, P; Raiteri, M; Santaniello, E; Tagliabue, C; Verri, D | 1 |
| Abbott, D; Daher, A; Howes, LG; Manwaring, P | 1 |
| Dabroś, W; Dudek, D; Stachura, J; Wicher-Muniak, E; Zmudka, K | 1 |
| Gotto, AM | 3 |
| Byington, RP; Crouse, JR; Furberg, CD; Hoen, HM | 1 |
| Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M | 1 |
| Roberts, WC | 1 |
| Chan, P; Huang, TY; Lee, C; Lee, YS; Tomlinson, B | 1 |
| Calès, P; Feldmann, G; Gallois, Y; Girault, A; le Bouil, A; Le Jeune, JJ; Maïga, MY; Moreau, A; Oberti, F; Pilette, C; Rifflet, H; Saumet, JL | 1 |
| Burnett, JR; Huff, MW | 1 |
| Buchalter, M | 1 |
| Bhatnagar, D | 1 |
| Buller, C; Burton, JR; Montague, TJ; Plante, S; Teo, KK; Yokoyama, S | 1 |
| Dahl, ML; Eriksson, M; Nordin, C; Sjöberg, S | 1 |
| Durrington, P | 1 |
| Jeck, T; Keller, U; Riesen, WF | 1 |
| Assmann, G | 1 |
| Crepaldi, G | 1 |
| Pauciullo, P | 1 |
| Hata, S; Imagaki, K; Kamei, T; Ochiai, H; Uchiyama, N | 1 |
| Ma, L; Morita, I; Murota, S; Sato, I | 1 |
| Fernández-Barreiro, A; Martín-Fernández, J; Martinez-García, FA; Moltó, JM; Morales, A; Villaverde, R | 1 |
| Cairns, SR; Fensom, AH; Iverson, SA; Ward, CP | 1 |
| Delport, R; Human, JA; Jerling, JJ; Lagendijk, J; Potgieter, HC; Ubbink, JB; Vermaak, WJ; Vorster, HH | 1 |
| Galli, C; Marangoni, F; Petroni, A; Risé, P; Visioli, F | 1 |
| Colombo, C; Galli, C; Risé, P | 1 |
| Ideura, T; Inui, K; Iwasaki, S; Nabeshima, K; Sugenoya, Y; Uda, S; Yoshimura, A | 1 |
| Biwa, T; Hakamata, H; Horiuchi, S; Kobori, S; Matsumura, T; Sakai, M; Sato, Y; Shichiri, M; Takemura, T | 1 |
| Abe, T; Kikuchi, T; Nagata, Y | 1 |
| de Graaf, J; Stalenhoef, AF; Stuyt, PM | 1 |
| Itoh, H; Kuriyama, K; Nakagawa, M; Nakata, T; Sasaki, S; Sawada, S; Takeda, K | 1 |
| Grundy, SM | 2 |
| Darling, GM; Davis, SR; Johns, JA; McCloud, PI | 1 |
| Mann, JI | 1 |
| Hanyecz, V; Kondacs, A; Márk, L; Simondán, G | 1 |
| Scheen, AJ | 1 |
| Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA | 1 |
| Aoki, T; Kimata, H; Kitahara, M; Kojima, J; Nakagawa, S; Nishimura, H; Saito, Y; Sakashita, M; Sato, F; Suzuki, H; Tamaki, T; Toyoda, K; Wada, Y; Yokoo, N | 1 |
| Horiuchi, Y; Maruoka, H | 1 |
| Meiser, B; Nagel, D; Reichart, B; Seidel, D; Steinbeck, G; Thiery, J; von Scheidt, W; Wenke, K | 1 |
| Davidson, MH; Hall, HA; Macariola-Coad, JR; Maki, KC; McDonald, AM | 1 |
| Croft, KD; Kelly, JM; Naoumova, RP; Riches, FM; Thompson, GR; Watts, GF | 1 |
| Erl, W; Weber, C; Weber, KS; Weber, PC | 1 |
| Wagner, MB | 1 |
| Ceska, R; Petrásek, J; Sobra, J; Spácil, J | 1 |
| Heidinger, K; Jovin, IS; Muller-Berghaus, G; Taborski, U | 1 |
| Feleszko, W; Jakobisiak, M; Zagozdzon, R | 1 |
| Kvetnoi, IM; Martinsen, TC; Sandvik, AK; Schulze, B; Sylte, R; Waldum, HL | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| De Caterina, R; Lenzi, S | 1 |
| La Fata, V; Laufs, U; Liao, JK; Plutzky, J | 1 |
| Albers, J; Brown, BG; Chait, A; Cheung, M; DeAngelis, D; Dowdy, A; Fisher, LD; Frohlich, J; Heise, N; Zhao, XQ | 1 |
| Evans, MF; Por, CP; Sabharwal, M | 1 |
| Pearson, TA | 1 |
| Mabuchi, H | 1 |
| Endres, M; Huang, P; Huang, Z; Laufs, U; Liao, JK; Moskowitz, MA; Nakamura, T | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Pincus, J | 1 |
| Samari, HR; Seglen, PO | 1 |
| Davignon, J; Farnier, M | 1 |
| Hunninghake, DB | 1 |
| Davignon, J; Hanefeld, M; Hunninghake, DB; Insull, W; Nakaya, N; Ose, L | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L | 1 |
| Eriksson, M | 1 |
| Luc, G | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Sinzinger, H | 2 |
| Otto, C; Schwandt, P | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Echeandia, C; Figuerola, A; Marta-Moreno, J; Mola, S; Oliveros-Cid, A | 1 |
| Goldschmidt-Clermont, PJ; Kandzari, DE | 1 |
| Cianflone, K; Sniderman, AD; Zhang, Z | 1 |
| Bottorff, MB; Cave, DG; Yenkowsky, JP | 1 |
| Reckless, JP | 1 |
| Barradell, LB; Goa, KL; McTavish, D | 1 |
| Kirchgässler, KU; Schiffner-Rohe, J; Stahlheber, U | 1 |
| Bakker-Arkema, RG; Black, DM; Davidson, MH; Henley, RW; Hunninghake, DB; Koren, MJ; McKenney, JM; McLain, RW; Schrott, HG; Smith, DG; Tresh, P; Weiss, SR | 1 |
| Bush, AC; Carr-Lopez, S; Exstrum, T; Morse, T; Shepherd, M | 1 |
| Assang, C; Baillie, TA; Lin, JH; Lu, P; Ma, B; Meng, Y; Prueksaritanont, T; Reider, PJ; Tang, C | 1 |
| O'Grady, J; Schmid, P; Sinzinger, H | 1 |
| Cenedella, RJ; Mitchell, J | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Blanco-Colio, LM; Egido, J; Guijarro, C; Kasiske, BL; Keane, WF; Massy, ZA; O'Donnell, MP | 1 |
| Pino, E; Prat, H; Román, O | 1 |
| Guo, J; Kou, W; Lu, Z | 1 |
| Haneda, T; Kashiwagi, Y; Kawabe, J; Kikuchi, K; Nakamura, Y; Oi, S; Osaki, J | 1 |
| Asenjo-Barrón, JC; Cárdenas-Vázquez, R; Díaz-Zagoya, JC; Juárez-Oropeza, MA; Martínez, F | 1 |
| Axel, DI; Fenchel, M; Herzog, UU; Karsch, KR; Riessen, R; Rossmann, H | 1 |
| Dereu, N; Hamilton, AD; Lavelle, F; Mailliet, P; Maume, BF; Maume, G; Mazet, JL; Osman, H; Padieu, M; Sebti, SM | 1 |
| César, LA; Mansur, AP; Nicolau, JC; Ramires, JA; Serrano, CV | 1 |
| Boyce, B; Chan, J; Chen, D; Garrett, R; Gutierrez, G; Harris, S; Mundy, G; Rossini, G; Zhao, M | 1 |
| Farnier, M | 1 |
| Vogel, G | 1 |
| Elkin, RG; Yan, Z | 1 |
| Aboushadi, N; Gentile, A; Jessani, N; Krisans, SK; Shackelford, JE | 1 |
| Bakker-Arkema, RG; Black, DM; Nawrocki, JW | 1 |
| Stalenhoef, AF; Stehouwer, CD | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Rosenson, RS | 3 |
| Auch-Schwelk, W; Elsner, M; Mach, S; Schächinger, V; Walter, DH; Zeiher, AM | 1 |
| Abe, K; Asami, S; Kodama, T; Konishi, K; Oikawa, S; Sugiyama, M | 1 |
| Breithardt, G; Fan, L; March, KL; Müller, JG; Schmidt, A; Sindermann, JR; Troyer, D; Weigel, KA | 1 |
| Smith, SC | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Cobos, A; García-Altés, A; García-Closas, R; Jovell, AJ; Serra-Majem, L | 1 |
| Albani, D; Bruno, A; Diomede, L; Fruscella, P; Guglielmotti, A; Mantovani, A; Massimiliano, L; Pinza, M; Polentarutti, N; Romano, M; Salmona, M; Sironi, M; Sottocorno, M; Vecchi, A | 1 |
| Aspichueta, P; Hernández, ML; Isusi, E; Martínez, MJ; Ochoa, B | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| Fugit, RV; Resch, ND | 1 |
| Karki, SB; Kaufman, MJ; Treemaneekarn, V | 1 |
| Matsuda, T; Muraki, Y; Nagasawa, K; Ohnishi, N; Yokoyama, T | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Basak, G; Bury, M; Feleszko, W; Giermasz, A; Jakóbisiak, M; Mlynarczuk, I; Omura, S; Pleban, E; Stoklosa, T; Wójcik, C | 1 |
| García-Altés, A; Jovell, AJ | 1 |
| Davidson, MH | 1 |
| Stein, EA | 2 |
| Black, DM | 1 |
| Cheng, JW; Sotiriou, CG | 1 |
| Aspichueta, P; Díaz, C; Hernández, G; Hernández, ML; Isusi, E; Liza, M; Martínez, MJ; Ochoa, B | 1 |
| Lefer, AM; Lefer, DJ; Scalia, R | 1 |
| Wang, H; Wu, Y; Zhao, Z | 1 |
| Kersting, F; Selenka, A; Walch, S | 1 |
| Crouch, MA | 1 |
| Harangi, M; Paragh, G | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Dyall-Smith, ML; Ferrer, C; Wendoloski, D | 1 |
| Wierzbicki, AS | 1 |
| Horlitz, M; Niebauer, J; Sigwart, U | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Garrett, IR; Gutierrez, G; Mundy, GR | 1 |
| Bastarda, A; Grahek, R; Kracun, M; Milivojevic, D | 1 |
| Golomb, BA; Jaworski, B | 1 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Eberlein, M; Goppelt-Struebe, M; Heusinger-Ribeiro, J | 1 |
| Susekov, AV | 1 |
| Feleszko, W; Mlynarczuk, I; Nowis, D | 1 |
| Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH | 1 |
| Le, NA | 1 |
| Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Auer, J; Eber, B | 1 |
| Bottorff, M; Worz, CR | 1 |
| Alton, KB; Burrier, RE; Davis, HR; Pula, KK; Watkins, RW | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| McCarey, DW; McInnes, IB; Sattar, N | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bazalo, GR | 1 |
| Gierens, H; März, W; Nauck, M; Scharnagl, H; Schinker, R; Wieland, H | 1 |
| Ekiert, A; Górski, A; Jezak, P; Kasprzycka, M; Korczak-Kowalska, G; Kłodos, K; Kłosowska, D; Nowaczyk, M; Wierzbicki, P | 1 |
| Platts, J | 1 |
| Resch, NK | 1 |
| Iwaki, K; Kakumoto, M; Nakamura, T; Ohmoto, N; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y | 1 |
| Böhm, M; Hamm, CW; Heeschen, C; Laufs, U; Snapinn, S; White, HD | 1 |
| Andersen, M; Gaist, D; García Rodríguez, LA; Hallas, J; Jeppesen, U; Sindrup, SH | 1 |
| Altieri, PI; Crespo, MJ; Escobales, N; Furilla, RA | 1 |
| Mach, F | 2 |
| Raju, AN; Reddy, GO; Srinivasu, MK | 1 |
| Bedford, D; Caslake, MJ; Forster, LF; Packard, CJ; Rogers, E; Shepherd, J; Stewart, G; Stewart, JP | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Illingworth, DR; Pappu, AS | 1 |
| Bannykh, S; England, JD; Gray, NL; Haas, RH; Hathaway, S; Kimura, BJ; Phillips, PS; Vladutiu, GD | 1 |
| Ahn, C; Aronow, WS | 1 |
| Chmielewski, M; Rutkowski, B; Zdrojewski, Z | 1 |
| Dicker, DT; El-Deiry, WS; Jin, Z | 1 |
| Feyen, JH; French, MH; Frith, JC; Güngör, T; Harrity, TW; Rogers, MJ; Staal, A; Swartz, J; Tamasi, J | 1 |
| Holme, I; Tonstad, S | 1 |
| Alber, HF; Ares, MP; Dichtl, W; Dulak, J; Frick, M; Nilsson, J; Pachinger, O; Schwarzacher, SP; Weidinger, F | 1 |
| Feng, Y; Luan, Y; Yang, H | 1 |
| Ferrières, J | 1 |
| Eckert, GP; Kirsch, C; Mueller, WE | 1 |
| Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R | 1 |
| McBurney, CR; Smith, DG | 1 |
| Clark, LT | 1 |
| Chase, AJ; Luan, Z; Newby, AC | 1 |
| Bacon, SP; Illingworth, DR; Pappu, AS | 1 |
| Lipton, AM; Lutjohann, D; Moore, C; Svetlik, D; Vega, GL; Von Bergmann, K; Weiner, MF | 1 |
| Geerts, A; Hellemans, K; Kisanga, E; Rombouts, K; Schuppan, D; Wielant, A | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Hatakeyama, D; Hirade, K; Ito, H; Kato, K; Kozawa, O; Niwa, M; Tokuda, H; Wang, X | 1 |
| Baskin, F; Fang, X; Hynan, LS; Moore, CB; Rosenberg, RN; Vega, GL; Weiner, M | 1 |
| Arvik, BM; Doraiswamy, PM; Mitton, MW; Wagstaff, LR | 1 |
| Draganov, DI; La Du, BN; Teiber, JF | 1 |
| Bergdahl, A; Hellstrand, P; Persson, E; Swärd, K | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Mishra, TK; Routray, S | 1 |
| Bays, HE; McGovern, ME | 2 |
| Alber, H; Cisowski, J; Dichtl, W; Dulak, J; Frick, M; Józkowicz, A; Pachinger, O; Schwarzacher, SP; Weidinger, F; Zwick, R | 1 |
| Bloem, AC; Kamphuis, MM; Lokhorst, HM; Schotte, D; van de Donk, NW; van Kessel, B; van Marion, AM | 1 |
| Darvesh, S; Martin, E; Rockwood, K; Walsh, R | 1 |
| Aicher, A; Badorff, C; Dimmeler, S; Fichtlscherer, S; Koyanagi, M; Rupp, S; Urbich, C; Zeiher, AM | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Dammers, E; Horkovics-Kovats, S; Merkx, I; Ryska, M; Ulc, I; Vree, TB | 1 |
| Edwards, JE; Moore, RA | 1 |
| Horiuchi, S; Iida, KT; Matsuzaka, K; Nakagawa, Y; Nakakuki, M; Okazaki, H; Sakai, M; Sakamoto, Y; Shimano, H; Shu, M; Sone, H; Suzuki, H; Takahashi, A; Toyoshima, H; Yamada, N; Yokoo, T | 1 |
| Fang, CH; Li, JJ | 1 |
| Tellier, P | 1 |
| Clark, DS; Gerber, R; Ryan, JD | 1 |
| Mück, AO; Seeger, H; Wallwiener, D | 1 |
| Bernier, L; Chamberland, A; Davignon, J; Dubuc, G; Prat, A; Seidah, NG; Wassef, H | 1 |
| Jacobson, MS; Kohn, M | 1 |
| Eichelbaum, M; Fromm, MF; Kivistö, KT; Niemi, M; Pitkälä, K; Schaeffeler, E; Schwab, M; Strandberg, T; Tilvis, R | 1 |
| Dimmeler, S; Haendeler, J; Hoffmann, J; Zeiher, AM | 1 |
| Goldberg, IJ; Husemann, J; Loike, JD; Lu, E; Malitzky, S; Neuhut, R; Shabtai, DY; Silverstein, SC | 1 |
| Eckert, GP; Fechner, T; Franke, C; Igbavboa, U; Johnson-Anuna, LN; Karas, M; Keller, JH; Müller, WE; Schubert-Zsilavecz, M; Wood, WG | 1 |
| Baudry, M; Bi, X; Brucher, F; Fu, L; Liu, J; Lynch, G; Yao, Y | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Deng, Y; DeRose, RA; Farber, SA; Ho, SY; Santana, E; Thorpe, JL | 1 |
| Bennett, S; Lipka, L; Melani, L; Sager, P; Suresh, R; Veltri, E | 1 |
| Gonyeau, MJ | 1 |
| Chen, H; Hu, DY; Xing, Y | 1 |
| Gibb, H; Scialli, AR | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Bastemir, M; Emral, R; Gullu, S; Lazarus, JH; Parkes, AB | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H; Straussberg, R | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Benson, V; Campen, D; Chan, J; Cheetham, TC; Levin, E; Richmond, C | 1 |
| Burnett, DM; Cunningham, ML; Osborne, MJ; Pollack, PS; Shields, KE; Stepanavage, ME | 1 |
| Billups, SJ; Kerzee, J; Koehler, TJ; Olson, KL; Plushner, SL | 1 |
| Davidson, M | 1 |
| Gibson, K; Rindone, JP | 1 |
| Chihara, K; Kaji, H; Kanatani, M; Sugimoto, T | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Boucher, K; Hauschka, PV; Sharma, P; Siegel, CS; Solomon, KR | 1 |
| Crespo, MJ; Quidgley, JA | 1 |
| Brophy, JM; Costa, V | 1 |
| Betta, PG; Bosia, A; Ghigo, D; Orecchia, S; Pescarmona, G; Riganti, C | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Otsuka, Y | 1 |
| Csempesz, F; Süle, A; Szente, L | 2 |
| Auger, C; Bernard, M; Bouthillier, A; Cayrol, R; Duquette, P; Ifergan, I; Kébir, H; Moumdjian, R; Prat, A; Wosik, K | 1 |
| Burns, MP; Duff, K; Igbavboa, U; Wang, L; Wood, WG | 1 |
| Plans-Rubió, P | 1 |
| Huang, CH; Lai, WT; Lin, TH; Sheu, SH; Su, HM; Voon, WC; Yen, HW | 1 |
| Adeagbo-Sheikh, J; Austen, BM; Farrant, JK; Parsons, RB; Price, GC; Subramaniam, D | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Gurbanov, E; Shiliang, X | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Abbas, T; Dutta, A; Sivaprasad, U | 1 |
| Morais, MG; Pedrosa, R; Sena, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Tang, Y; Wang, CC; Watanabe, K; Wojcicki, WA; Xie, X | 1 |
| Chan, YH; Lim, SC; Sum, CF; Tavintharan, S | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Galgóczy, L; Leiter, E; Lukács, G; Papp, T; Pócsi, I; Vágvölgyi, C | 1 |
| Antoun, TA; Badr, KF; Badreddine, R; Bertoglio, J; Habib, A; Nasrallah, MS; Nemer, G; Shamseddeen, I | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Kazis, LE; Lee, A; Lee, TA; Li, NC; Wang, SW; Wolozin, B | 1 |
| Chen, C; Lin, J; Smolarek, T; Tremaine, L | 1 |
| Golde, TE; Landreth, G; Ostrowski, SM; Wilkinson, BL | 1 |
| Angri, V; Calabrò, P; Chiariello, M; Cirillo, P; De Rosa, S; Fiorentino, I; Gargiulo, A; Musto D'Amore, S; Pacileo, M; Petrillo, G; Prevete, N; Sasso, L; Ucci, G | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H | 2 |
| Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV | 1 |
| Coleman, CI; Dale, KM; Henyan, NN; Kluger, J; White, CM | 1 |
| Bertacche, V; Milanese, A; Nava, D; Pini, E; Stradi, R | 1 |
| Sylvester, PW; Wali, VB | 1 |
| Bleuming, SA; Hardwick, JC; Hommes, DW; Kodach, LL; Peppelenbosch, MP; van den Brink, GR | 1 |
| Chan, J; Flick, ED; Friedman, GD; Habel, LA; Quesenberry, CP; Udaltsova, N | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Kontoyiannis, DP; Li, R; Liu, W; Qiao, J; Wan, Z | 1 |
| Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA | 1 |
| Brophy, MT; Farwell, WR; Fiore, LD; Gaziano, JM; Lawler, EV; Lew, RA; Scranton, RE | 1 |
| Clynes, M; Eustace, AJ; Glynn, SA; O'Donovan, N; O'Sullivan, D | 1 |
| Chen, H; Hoque, A; Xu, XC | 1 |
| Chen, L; Li, F; Qin, F; Wang, D | 1 |
| Ivanova, MV; Kaminnyi, AI; Konovalova, GG; Kukharchuk, VV; Lankin, VZ; Tikhaze, AK | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Huupponen, R; Irjala, K; Klaukka, T; Laine, K; Ryynänen, A; Tirkkonen, T; Vahlberg, T | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Beales, IL; Ogunwobi, OO | 1 |
| Hawk, ET; Viner, JL | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL | 1 |
| Xiao, H; Yang, CS | 1 |
| Backman, JT; Neuvonen, PJ; Niemi, M | 1 |
| Gan, C; Yang, Z | 1 |
| Chihara, K; Inoue, Y; Kaji, H; Naito, J; Sowa, H; Sugimoto, T | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Hanson, M; Hoffman, R; Strony, J; Veltri, E | 1 |
| Abel, T; Fehér, J | 1 |
| Horna, A; Kulichová, B; Lopéz, SA; Nováková, L; Satínský, D; Solich, P; Solichová, D | 1 |
| Bhagavan, NV; Ha, CE; Ha, JS; Theriault, AG | 1 |
| Kang, S; Kim, ES; Moon, A | 1 |
| Fonseca, AC; Oliveira, CR; Pereira, CM; Proença, T; Resende, R | 1 |
| Brañes, J; Carvajal, J; Chen-Lin, K; Cuello, M; Gejman, R; Kato, S; Oliva, B; Owen, GI; Sadarangani, A; Smalley, S | 1 |
| Cardaba, CM; Mueller, A | 1 |
| Hohenegger, M; Minichsdorfer, C | 1 |
| Hao, B; He, J; Li, S; Li, W; Mao, T; Yu, Z | 1 |
| Fitzgerald, K; Kashanin, D; O'Dowd, F; Robinson, AJ; Walsh, GM; Williams, V | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Barrios-González, J; Miranda, RU | 1 |
| Fessler, MB | 1 |
| Gaggioli, C; Hooper, S; Sahai, E | 1 |
| Charland, SL; Malone, DC | 1 |
| Attia, KA; Kaddah, MM; Nassar, MW; Sharaf El-Din, MM | 1 |
| Campbell, CD; Vederas, JC | 1 |
| Chang, LC; Chen, JS; Hwang, JC; Lin, YF; Shui, HA | 1 |
| Barter, MJ; Catterall, JB; Cawston, TE; Hui, W; Lakey, RL; Young, DA | 1 |
| Gander, H; Gruenbacher, G; Nussbaumer, O; Nussbaumer, W; Rahm, A; Thurnher, M | 1 |
| Ahn, T; Jung, HC; Kang, JY; Kim, D; Kim, DH; Kim, KH; Lee, YJ; Pan, JG; Park, KD; Park, SH; Yun, CH | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Berkowitz, DE; Bhunia, A; Chang, F; Romer, LH; Ryoo, S; Shoukas, A | 1 |
| Chung, HJ; Jeong, BC; Kim, IS; Kim, OS; Kim, YJ; Koh, JT; Lee, KN; Lee, SE | 1 |
| Heasman, SJ; Infante, E; Ridley, AJ | 1 |
| Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA | 1 |
| Arora, S; Azorsa, DO; Briollais, L; Choi, YH; Gonzales, IM; Henderson, MC; Ibrahim-Zada, I; Jarjanazi, H; Ozcelik, H; Savas, S; Tuzmen, S | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Shi, J; Xue, Z | 1 |
| Brinton, EA; Jiang, P; Kashyap, ML; Padley, RJ; Thakkar, RB; Vo, AN | 1 |
| Choi, DH; Choi, JS; Yang, SH | 1 |
| Inamadugu, JK; Mullangi, R; Nallapati, IK; Pilli, NR; Rao, JV | 1 |
| Azor, MH; da Silva Duarte, AJ; de Brito, CA; dos Santos, JC; Futata, EA; Maruta, CW; Rivitti, EA; Sato, MN | 1 |
| Guan, YQ; Shi, YJ; Wang, Q | 1 |
| Hong, SJ; Kim, PS; Ko, JH; Mustoe, TA; Zhao, Y | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| de Oliveira, RB; Oliveira, MA; Silva, TD; Vianna-Soares, CD | 1 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Bosia, A; Couraud, P; Garzón, R; Ghigo, D; Pinzón-Daza, M; Riganti, C; Romero, Ia; Weksler, B | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Bosch, J; García-Cardeña, G; García-Pagán, JC; Gracia-Sancho, J; Hide, D; Marrone, G; Rosado, E; Russo, L | 1 |
| Kitzmiller, JP; Phelps, MA; Sadee, W; Sullivan, DM; Wang, D | 1 |
| Dinicolantonio, JJ; Serebruany, VL | 1 |
| Hu, N; Khera, S | 1 |
| Abdoli, N; Azarmi, Y; Eghbal, MA; Heidari, R | 1 |
| Baumgarten, G; Frede, S; Hilbert, T; Hoeft, A; Klaschik, S; Knuefermann, P; Poth, J | 1 |
| Atehortúa, L; Chegwin-Angarita, C; Diaz, GJ; Jeannette Nieto-Ramirez, I; Rojas L, JR; Sepúlveda, L | 1 |
| Ding, X; Fang, C; Zhang, QY; Zhu, Y | 1 |
| Fan, J; Jiang, L; Kong, X; Li, Z; Wu, T; Yuan, H | 1 |
| Duleba, AJ; Ortega, I; Sokalska, A; Stanley, SD; Villanueva, JA | 1 |
| Abdoli, N; Azarmi, Y; Eghbal, MA | 1 |
| Hou, X; Li, F; Ma, X; Wang, L; Zhao, L; Zhao, P | 1 |
| Andreux, PA; Auwerx, J; Bichet, S; Houtkooper, RH; Jovaisaite, V; Mottis, A; Mouchiroud, L; Moullan, N; Wang, X | 1 |
| Baba, A; Kazama, I; Maruyama, Y | 1 |
| Horoshko, OM; Zamors'kyĭ, II; Zeleniuk, VH | 1 |
| Davison, KM; Kaplan, BJ | 1 |
| Bauer, CA; Grimme, S | 1 |
| Albers, M; Baumeister, SE; Kroemer, HK; Meyer zu Schwabedissen, HE; Nauck, M; Rimmbach, C; Siegmund, W; Völzke, H; Wallaschofski, H | 1 |
| Kao, CH; Lin, CL; Lin, WM; Sung, FC; Yang, TY | 1 |
| Cha, GS; Choi, DS; Jeong, KJ; Lee, JH; Lee, JK; Lee, SH; Nam, DH; Park, CB; Park, JH; Yun, CH | 1 |
| Kitzmiller, JP; Luzum, JA; Phelps, MA; Wang, J | 1 |
| Carr, AJ; Cornell, HR; Hulley, PA; Kuzma-Kuzniarska, M; Moneke, MC | 1 |
| Gerner, C; Grunt, T; Haider, F; Karlic, H; Proestling, K; Thaler, R; Varga, F | 1 |
| Chang, J; Cooper, RM; Difronzo, AL; Huang, B; Jeon, CY; Ngor, EW; Pandol, SJ; Wu, BU | 1 |
| Addabbo, F; Bonfrate, L; Carmosino, M; Castorani, L; Di Ciaula, A; Mastrofrancesco, L; Portincasa, P; Procino, G; Svelto, M | 1 |
| Chen, CJ; Chen, YA; Feng, CL; Hsu, YM; Kao, CH; Kao, MC; Lai, CH; Liao, WC; Lin, CJ; Lin, CL; Lin, HJ | 1 |
| Desai, M; Hedlin, H; Kapphahn, K; Manson, JA; Martin, L; Simon, M; Stefanick, ML; Strickler, H; Tang, JY; Wactawski-Wende, J; Wang, A | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Albert, ND; Bellanger, AP; Gebremariam, T; Ibrahim, AS; Kontoyiannis, DP; Lewis, RE; Shirazi, F; Tatara, AM | 1 |
| Archibugi, L; Capurso, G; Delle Fave, G | 1 |
| Graham, ES; Griffin, JM; Kho, D; Nicholson, LF; O'Carroll, SJ | 1 |
| Hwang, HJ; Kim, KS; Lee, EJ; Song, KJ | 1 |
| Corkum, A; Fisher, J; Minard, LV; Saleh, A; Sketris, I; Zhang, Y | 1 |
| Amento, EP; Bigos, M; Madasamy, S; Shivasubramani, U; Villanueva, J; Wu, AH | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Chen, C; Deng, X; He, G; Rosol, TJ; Song, L; Yan, S; Yao, H | 1 |
| Añino Alba, A; Fernandez-Esteban, I; Fernandez-Tabera, JM; Gómez Álvarez, P; Izquierdo-Palomares, JM; Martin-Carrillo, P; Pinar López, Ó; Plana, MN; Saiz, LC | 1 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Lum, CJ; Nakagawa, K; Seto, TB; Shohet, RV; Taira, DA | 1 |
| Jang, J; Kim, ML; Shin, JA; Sung, KR; Young Yoon, J | 1 |
| D'Acunto, WC; Gbelcová, H; Knejzlík, Z; Kolář, M; Repiská, V; Rimpelová, S; Ruml, T; Šáchová, J; Strnad, H; Vítek, L | 1 |
| Bastami, F; Hosseinpour, S; Kamali, A; Oryan, A; Shahrezaee, M; Shahrezaee, MH | 1 |
| Battaglia, RA; Herrmann, H; Kabiraj, P; Madden, VJ; Snider, NT; Trogden, KP | 1 |
| Kaleağasıoğlu, F; Olcay, E; Onur, R | 1 |
| Cook, RL; Dave, CV; Hartzema, AG; Park, H; Winterstein, AG | 1 |
| Dai, Y; Jin, Y; Wang, M; Wang, Y; Xia, Y; Yun, X | 1 |
| Chen, YC; Chiu, HT; Lin, JH; Shen, LJ; Wang, CC | 1 |
| Bond, CM; Tang, Y | 1 |
| Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Krychtiuk, KA; Lenz, M; Pentz, R; Stojkovic, S; Thaler, B; Wojta, J; Zuckermann, A | 1 |
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Duleba, AJ; Hawkins, AB; Sokalska, A; Yamaguchi, T | 1 |
| Aganov, A; Galiullina, LF; Huster, D; Klochkov, V; Scheidt, HA | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Au, A; Basu, S; Collier, VJ; Hopkin, G; Naci, H; Yudkin, JS | 1 |
| Beeson, CC; Beeson, GC; Christie, CF; Fang, D; Heslop, KA; Hunt, EG; Maldonado, EN; Morris, ME; Rovini, A | 1 |
| Abdul Rahman, H; Ahmad, Z; C Thambiah, S; Chew, BH; Hasan, S; Meor Anuar Shuhaili, MFR; Samsudin, IN; Stanslas, J | 1 |
| de Fijter, JW; Dekker, FW; Dekkers, OM; Esmeijer, K; Hoogeveen, EK | 1 |
| Du Plessis, J; Du Plessis, LH; Du Preez, JL; Gerber, M; Marais, S | 1 |
| Attalah Nee Rezkallah, C; Chen, QM; Thongkum, A; Zhu, C | 1 |
| Kim, ML; Kwon, J; Shin, JA; Sung, KR | 1 |
| Rao, PS; Rao, US | 1 |
| Brunicardi, FC; Chen, C; Chen, F; Kong, D; Li, Z; Liu, SH; Luo, H; Shui, J; Wang, K; Wu, H; Xu, Y; Yu, J; Zhang, Z; Zou, L | 1 |
| Aksoy, HN; Ceylan, C | 1 |
| Abdel Hakiem, AF; Ali, HRH; Mohamed, NA | 1 |
| Goyal, P; Malik, R; Pandey, J; Srivastava, S; Verma, N | 1 |
| Beton, K; Brożek-Płuska, B | 1 |
| Archunan, G; Balraj, J; Dhanapal, AR; Jairaman, K; Jayaraman, A; Kalieswaran, V; Murugesan, T | 1 |
| Holzgrabe, U; Walther, R | 1 |
| Atay, MS; Bodur, E; Sari, S | 1 |
| Buchwald, ZS; Burnham, AJ; Kansal, V; Kinney, BLC; Lesinski, GB; Paulos, C; Saba, NF; Schmitt, NC | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
| Bose, D; Carda-Broch, S; Durgbanshi, A; García-López, L; Peris-Vicente, J | 1 |
| Fu, R; Lou, D; Ma, X; Wu, F; Zhang, X; Zheng, D | 1 |
| Manousi, N; Tzanavaras, PD; Zacharis, CK | 1 |
| Dai, S; Lou, D; Wang, D; Wang, S; Wang, T; Zheng, Z | 1 |
| Casale, F; Dong, J; Peach, A; Walters, N | 1 |
128 review(s) available for simvastatin and lovastatin
| Article | Year |
|---|---|
The Medicinal Chemistry of Dengue Virus.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dengue; Dengue Virus; Humans; Molecular Conformation; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
Topics: Animals; Biological Products; Chemistry, Pharmaceutical; Humans | 2018 |
Lipid lowering agents of natural origin: An account of some promising chemotypes.
Topics: Animals; Biological Products; Dyslipidemias; Humans; Hypolipidemic Agents | 2017 |
[Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin].
Topics: Adult; Animals; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Guinea Pigs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Pravastatin; Rats; Risk Factors; Simvastatin; Time Factors | 1992 |
Cholesterol and mevalonic acid modulation in cell metabolism and multiplication.
Topics: Animals; Cell Division; Cholesterol; Glioma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Muscles; Simvastatin | 1992 |
[Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature].
Topics: Aged; Anticholesteremic Agents; Female; Humans; Lovastatin; Rhabdomyolysis; Simvastatin | 1992 |
Clinical implications of new drugs for lowering plasma cholesterol concentrations.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1991 |
[Hypercholesterolemia: therapeutic approach].
Topics: Adult; Aged; Anticholesteremic Agents; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin | 1991 |
Simvastatin: a review of its pharmacology and clinical use.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Simvastatin | 1991 |
Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Receptors, LDL; Simvastatin | 1991 |
Long-term clinical tolerance of lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Cholesterol; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Simvastatin | 1990 |
Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
Topics: Animals; Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1990 |
HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Reductase inhibitor therapy of hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Rhabdomyolysis; Simvastatin | 1991 |
Simvastatin to lower cholesterol.
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1990 |
[Maximal treatment of hypercholesteremia: what is possible?].
Topics: Anticholesteremic Agents; Combined Modality Therapy; Extracorporeal Circulation; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1990 |
Lovastatin and simvastatin prevention studies.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1990 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors.
Topics: Animals; Cataract; Dogs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Necrosis; Rabbits; Rats; Simvastatin; Species Specificity; Stomach; Testis | 1989 |
Efficacy and tolerability of simvastatin (MK-733).
Topics: Adrenal Cortex; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Topics: Anticholesteremic Agents; Arteriosclerosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1988 |
HMG CoA reductase inhibitors. Current clinical experience.
Topics: Eye Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Muscular Diseases; Simvastatin | 1988 |
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1987 |
The clinical efficacy and safety of lovastatin and MK-733--an overview.
Topics: Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Lovastatin; Simvastatin | 1987 |
[Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?].
Topics: Adult; Aged; Bezafibrate; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Simvastatin | 1995 |
Angiographic trials of lipid-lowering therapy: end of an era?
Topics: Adult; Clinical Trials as Topic; Coronary Angiography; Coronary Disease; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1995 |
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Topics: Anticholesteremic Agents; Biological Availability; Comorbidity; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1995 |
Statins: is there a need for alternative or adjunctive therapy?
Topics: Anticholesteremic Agents; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Simvastatin | 1995 |
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.
Topics: Clinical Trials as Topic; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Pharmacology of competitive inhibitors of HMG-CoA reductase.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cattle; Cells, Cultured; Chick Embryo; Cholesterol; Cricetinae; Dogs; Guinea Pigs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lipoproteins; Lovastatin; Mevalonic Acid; Mice; Organ Specificity; Rabbits; Rats; Simvastatin | 1995 |
The fibrates in clinical practice: focus on micronised fenofibrate.
Topics: Adolescent; Adult; Aged; Cholesterol, LDL; Coronary Disease; Drug Compounding; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Topics: Anticholesteremic Agents; Cardiovascular System; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipoproteins; Lovastatin; Pravastatin; Simvastatin | 1995 |
Graft vessel disease: the impact of immunosuppression and possible treatment strategies.
Topics: Animals; Coronary Disease; Graft Rejection; Heart Transplantation; Immunosuppressive Agents; Interferon-gamma; Lovastatin; Male; Oligopeptides; Peptides, Cyclic; Rats; Rats, Inbred BN; Rats, Inbred Lew; Simvastatin; Somatostatin | 1993 |
Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rhabdomyolysis; Risk Factors; Simvastatin; Species Specificity; Structure-Activity Relationship; Tissue Distribution | 1993 |
Clinical pharmacokinetics and practical applications of simvastatin.
Topics: Anticholesteremic Agents; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1993 |
[Psychiatric disorders with use of simvastatin].
Topics: Adult; Anticholesteremic Agents; Anxiety Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Middle Aged; Psychoses, Substance-Induced; Simvastatin | 1993 |
[Side effects of cholesterol synthesis inhibitors].
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Middle Aged; Pravastatin; Rhabdomyolysis; Simvastatin | 1993 |
Statin therapy in clinical practice: new developments.
Topics: Angina Pectoris; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Middle Aged; Myocardial Infarction; Simvastatin | 1995 |
Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.
Topics: Administration, Oral; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Interactions; Drug Synergism; Drug Tolerance; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Simvastatin | 1995 |
[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Lovastatin; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
The 4S study. Implications for prescribing.
Topics: Anticholesteremic Agents; Cholesterol; Controlled Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Diet; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Longitudinal Studies; Lovastatin; Simvastatin | 1996 |
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Topics: Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of lipids. Implications for the general practitioner.
Topics: Family Practice; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.
Topics: Anticholesteremic Agents; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Postoperative Complications; Pravastatin; Registries; Simvastatin; Treatment Outcome | 1996 |
The new paradigm for coronary artery disease: altering risk factors, atherosclerotic plaques, and clinical prognosis.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antioxidants; Coronary Angiography; Coronary Artery Disease; Endothelium, Vascular; Exercise Test; Humans; Hypercholesterolemia; Inflammation; Lovastatin; Platelet Aggregation Inhibitors; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 1996 |
The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
Topics: Animals; Anticholesteremic Agents; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Simvastatin | 1996 |
Statins do more than just lower cholesterol.
Topics: Anticholesteremic Agents; Arteries; Arteriosclerosis; Blood; Cholesterol; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Topics: Carotid Artery Diseases; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin | 1996 |
Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Topics: Aged; Cholesterol; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Male; Pravastatin; Pregnancy; Simvastatin | 1996 |
Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Simvastatin; Survival Analysis | 1996 |
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Topics: Anticholesteremic Agents; Arteriosclerosis; Brain; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Food-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver; Lovastatin; Pravastatin; Simvastatin | 1997 |
Reductase inhibitor monotherapy and stroke prevention.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Models, Biological; Simvastatin | 1997 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1997 |
Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Longevity; Lovastatin; Niacin; Simvastatin | 1997 |
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as Topic; Coronary Disease; Drug Therapy, Combination; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Triglycerides; Weight Loss | 1998 |
[Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diet; Endothelium, Vascular; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Mevalonic Acid; Middle Aged; Physical Exertion; Primary Prevention; Simvastatin; Time Factors | 1998 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins | 1998 |
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Topics: Animals; Antithrombins; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Endothelium, Vascular; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lovastatin; Muscle, Smooth, Vascular; Platelet Aggregation; Pravastatin; Simvastatin; Thromboplastin; Thrombosis | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
Current and future treatment of hyperlipidemia: the role of statins.
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pyridines; Safety; Simvastatin; Treatment Outcome | 1998 |
[Statins have other beneficial properties besides their cholesterol lowering effect].
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Coagulation; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Lovastatin; Pravastatin; Simvastatin | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
[Are there differences in various statins?].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Topics: Adult; Arteriosclerosis; Cerebrovascular Disorders; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
Topics: Coronary Disease; Cost-Benefit Analysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1997 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome | 2000 |
[Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 2000 |
Biological basis for statin therapy in stroke prevention.
Topics: Animals; Humans; Lovastatin; Pravastatin; Simvastatin; Stroke | 2000 |
Bridging the treatment gap.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Self Medication; Simvastatin; United States | 2000 |
"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Practice Guidelines as Topic; Risk Factors; Simvastatin | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.
Topics: Blood Coagulation; Blood Platelets; Blood Pressure; Blood Viscosity; Cholesterol; Coronary Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth; Pravastatin; Simvastatin | 2000 |
Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.
Topics: Cardiovascular Diseases; Coronary Vessels; Endothelin-1; Endothelins; Endothelium, Vascular; Fibrinolytic Agents; Free Radical Scavengers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Neutrophil Infiltration; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Protein Precursors; Simvastatin | 2001 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
[Statins do not prevent restenosis after coronary angioplasty: where to go from here?].
Topics: Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Brachytherapy; Cholesterol; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Primary Prevention; Rabbits; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Simvastatin | 2001 |
Statins and bone formation.
Topics: Animals; Bone Development; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lovastatin; Neoplasms; Nitric Oxide Synthase; Pyridines; Simvastatin | 2001 |
[Substantiation of increasing doses of statins in clinical practice].
Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2001 |
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Gemfibrozil; Humans; Lovastatin; Myocardial Ischemia; Pravastatin; Risk Factors; Simvastatin; Smoking | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.
Topics: Aged; Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Drug Interactions; Enzyme Inhibitors; Female; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Isoenzymes; Itraconazole; Lovastatin; Male; Middle Aged; Muscular Diseases; Pravastatin; Rhabdomyolysis; Simvastatin | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Benefits and menaces related to the use of statins in patients after renal transplantation.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin | 2002 |
[Primary and secondary prevention of coronary disease by statins].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 1999 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Statin-associated memory loss: analysis of 60 case reports and review of the literature.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Memory Disorders; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Cholesterol (and cardiovascular risk) in adolescence.
Topics: Adolescent; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Humans; Lovastatin; Obesity; Risk Factors; Simvastatin | 2004 |
Statins and osteoporosis: a clinical review.
Topics: Aged; Bone and Bones; Bone Density; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Middle Aged; Osteogenesis; Osteoporosis; Simvastatin; Treatment Outcome; United States | 2005 |
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Risk Factors; Simvastatin | 2005 |
Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
Topics: Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2005 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension.
Topics: Apoptosis; Dichloroacetic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lovastatin; MAP Kinase Kinase Kinase 5; Microtubule-Associated Proteins; Muscle, Smooth, Vascular; Neoplasm Proteins; Pancreatic Elastase; PPAR gamma; Protein Serine-Threonine Kinases; Pulmonary Circulation; Receptor, Bradykinin B2; rho-Associated Kinases; Simvastatin; Survivin; Thrombosis; Vasoconstriction | 2006 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin | 2007 |
Impact of statin dosing intensity on transaminase and creatine kinase.
Topics: Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Transaminases | 2007 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Topics: Animals; Biological Availability; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Nonprescription Drugs; Pharmacogenetics; Pravastatin; Simvastatin | 2008 |
[Biosynthesis of simvastatin--a mini-review].
Topics: Acyltransferases; Anticholesteremic Agents; Catalysis; Escherichia coli; Fermentation; Lovastatin; Naphthalenes; Simvastatin; Transformation, Bacterial | 2008 |
Biotechnological production and applications of statins.
Topics: Acyltransferases; Anticholesteremic Agents; Aspergillus; Biotechnology; Fermentation; Lovastatin; Pravastatin; Simvastatin | 2010 |
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin | 2010 |
Biosynthesis of lovastatin and related metabolites formed by fungal iterative PKS enzymes.
Topics: Cytochalasins; Lactones; Lovastatin; Polyketide Synthases; Pyrrolidinones; RNA, Catalytic; Simvastatin; Tetrahydronaphthalenes | 2010 |
Lipid-lowering agents for nephrotic syndrome.
Topics: Adult; Child; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Nephrotic Syndrome; Randomized Controlled Trials as Topic; Simvastatin | 2013 |
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Triple-negative breast cancer: is there a treatment on the horizon?
Topics: Anthracyclines; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Molecular Targeted Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Simvastatin; Taxoids; Triple Negative Breast Neoplasms | 2017 |
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Drug Chronotherapy; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.
Topics: Atorvastatin; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lovastatin; Network Meta-Analysis; Pravastatin; Proteinuria; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2019 |
Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Neoplasms; Lovastatin; Simvastatin | 2024 |
Association between statins exposure and risk of skin cancer: an updated meta-analysis.
Topics: Carcinoma, Basal Cell; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin; Skin Neoplasms | 2023 |
Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis.
Topics: Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Porokeratosis; Simvastatin | 2023 |
256 trial(s) available for simvastatin and lovastatin
| Article | Year |
|---|---|
Coronary atheroma regression trials. MAAS Steering Committee.
Topics: Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Blood Coagulation Tests; Cholesterol; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Synthase; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Plasminogen Inactivators; Simvastatin | 1992 |
Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Colestipol; Double-Blind Method; Drug Therapy, Combination; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lovastatin; Simvastatin; Treatment Outcome; Triglycerides | 1992 |
Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Apolipoproteins; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). The European Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1992 |
Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin | 1992 |
Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Treatment of hypercholesterolemia and prevention of coronary artery disease after heart transplantation by combination of low-dose simvastatin and HELP-LDL-apheresis.
Topics: Adult; Anticholesteremic Agents; Blood Component Removal; Chemical Precipitation; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Transplantation; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1992 |
The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Topics: Adult; Apolipoprotein E2; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Hyperlipoproteinemias; Lipids; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Simvastatin; Triglycerides | 1992 |
Lens opacity in patients with hypercholesterolemia and ischaemic heart disease. Electronic lens opacity measurements.
Topics: Adult; Aged; Cataract; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Ophthalmology; Reproducibility of Results; Simvastatin | 1992 |
Beneficial effect of simvastatin in patients with drug resistant familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Drug Administration Schedule; Drug Resistance; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin; Triglycerides | 1992 |
Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.
Topics: Adult; Albuminuria; Analysis of Variance; Apolipoproteins; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Lovastatin; Male; Simvastatin; Triglycerides | 1992 |
The cost of simvastatin therapy in treatment of hypercholesterolaemia in a hospital lipid clinic.
Topics: Anticholesteremic Agents; Drug Costs; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Middle Aged; Simvastatin | 1992 |
Effect of simvastatin in patients with type I (insulin-dependent) diabetes mellitus and hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 1; Female; Hormones; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Effects of combined bezafibrate-simvastatin appraised in healthy subjects.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lipids; Lovastatin; Male; Muscles; Pain; Phosphatidylcholine-Sterol O-Acyltransferase; Simvastatin | 1992 |
A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Female; Fenofibrate; Humans; Hypercholesterolemia; In Vitro Techniques; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Bile; Cholesterol; Cholic Acid; Cholic Acids; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinetics; Lipid Metabolism; Liver; Lovastatin; Male; Middle Aged; Simvastatin; Ursodeoxycholic Acid | 1992 |
Is fat restriction needed with HMGCoA reductase inhibitor treatment?
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans.
Topics: Administration, Oral; Adult; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Simvastatin | 1992 |
Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolaemia. An Italian multicentre double-blind placebo-controlled study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Worldwide experience with simvastatin/lovastatin.
Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Lovastatin; Rhabdomyolysis; Simvastatin | 1992 |
[Effect of HMG-CoA reductase inhibitors on the erythrocyte membrane].
Topics: Cholesterol; Erythrocyte Membrane; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Simvastatin; Sodium-Potassium-Exchanging ATPase | 1991 |
Simvastatin and proteinuria.
Topics: Anticholesteremic Agents; Drug Administration Schedule; Drug Evaluation; Humans; Lovastatin; Proteinuria; Simvastatin | 1991 |
Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heart Transplantation; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Postoperative Care; Simvastatin; Triglycerides | 1991 |
[Comparison about the efficacy and tolerability between simvastatin and bezafibrate in the treatment of hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lens, Crystalline; Lipids; Liver; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Lipoprotein particle analysis comparing simvastatin and fenofibrate.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins B; Double-Blind Method; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Lovastatin; Middle Aged; Simvastatin | 1991 |
[Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
Topics: Anticholesteremic Agents; Cholesterol; Creatine Kinase; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Simvastatin; Single-Blind Method; Transaminases; Triglycerides | 1991 |
Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; New Zealand; Simvastatin | 1991 |
Long-term safety and efficacy profile of simvastatin.
Topics: Aged; Anticholesteremic Agents; Cataract; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Liver; Lovastatin; Male; Middle Aged; Muscles; Simvastatin | 1991 |
Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol Esters; Double-Blind Method; Fatty Acids; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Lovastatin; Male; Middle Aged; Phospholipids; Simvastatin; Triglycerides | 1991 |
Cortisol secretion in patients on simvastatin.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Adrenocortical function in patients on simvastatin.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Anticholesteremic Agents; Clinical Trials as Topic; Humans; Hydrocortisone; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1990 |
Monitoring compliance in clinical trials.
Topics: Anticholesteremic Agents; Chronic Disease; Clinical Trials as Topic; Humans; Hyperlipoproteinemia Type II; Lovastatin; Microcomputers; Patient Compliance; Simvastatin | 1990 |
Partial remission of nephrotic syndrome in patient on long-term simvastatin.
Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Remission Induction; Simvastatin | 1990 |
Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Cholesterol; Female; Hemostasis; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
[Treatment of hypercholesterolemic patients of different age with simvastatin: 1-year study].
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Middle Aged; Simvastatin; Time Factors | 1991 |
A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis.
Topics: Adult; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Kidney Failure, Chronic; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Renal Dialysis; Simvastatin | 1991 |
Simvastatin in severe hypercholesterolaemia: a placebo controlled trial.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Blood Pressure; Blood Viscosity; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Leukocytes; Lipids; Liver; Lovastatin; Male; Middle Aged; Simvastatin; Transaminases; Triglycerides | 1991 |
Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics.
Topics: Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Humans; Insulin; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Double-Blind Method; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Lens changes in matched normals and hyperlipidemic patients treated with simvastatin for 2 years.
Topics: Adult; Aged; Cataract; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lens, Crystalline; Lovastatin; Male; Middle Aged; Simvastatin; Vacuoles | 1990 |
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Naphthalenes; Phenotype; Pravastatin; Simvastatin; Time Factors | 1990 |
The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Heterozygote; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Leukocytes, Mononuclear; Lipoproteins; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Receptors, LDL; Simvastatin | 1990 |
[Therapy of hypercholesterolemia and hypertriglyceridemia. Comparison of the lipid-lowering effect of simvastatin and tiadenol].
Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Double-Blind Method; Fatty Alcohols; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
[Comparison of the lowering effect on blood cholesterol of clofibrate and simvastatin].
Topics: Aged; Anticholesteremic Agents; Clofibrate; Drug Evaluation; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors | 1990 |
[The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Tolerance; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Simvastatin | 1990 |
Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apoproteins; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Australia; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1990 |
Lovastatin and simvastatin prevention studies.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1990 |
Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Colestipol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Sleep Wake Disorders | 1990 |
[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Gemfibrozil; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Simvastatin in the treatment of hypercholesterolaemia in patients with essential hypertension.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Dietary Fats, Unsaturated; Female; Humans; Hypercholesterolemia; Hypertension; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin | 1990 |
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Cataract; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Cataract; Cholesterol; Cholestyramine Resin; Creatine Kinase; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1990 |
Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin.
Topics: Adult; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Apoproteins; Cholestyramine Resin; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin; Time Factors | 1989 |
Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Humans; Hypercholesterolemia; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Propionates; Simvastatin; Triglycerides | 1989 |
Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Phenols; Probucol; Random Allocation; Simvastatin | 1989 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
[A multicenter study of cholesterol reduction by simvastatin].
Topics: Cholesterol; Clinical Trials as Topic; Humans; Lovastatin; Multicenter Studies as Topic; Simvastatin | 1989 |
Simvastatin (MK 733): an effective treatment for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin | 1989 |
Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Random Allocation; Simvastatin | 1989 |
Simvastatin and cholestyramine in the long-term treatment of hypercholesterolaemia.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin; Time Factors | 1989 |
Comparison between low-dose simvastatin and cholestyramine in moderately severe hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Simvastatin | 1989 |
[Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Middle Aged; Multicenter Studies as Topic; Simvastatin; Single-Blind Method; Switzerland | 1989 |
[Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia].
Topics: Anticholesteremic Agents; Apolipoproteins; Clinical Trials as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors | 1989 |
Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Random Allocation; Simvastatin | 1988 |
Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1989 |
[Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Apoproteins; Cholestyramine Resin; Clinical Trials as Topic; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin | 1988 |
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Dogs; Double-Blind Method; Drug Evaluation; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipoproteins, HDL; Lipoproteins, VLDL; Lovastatin; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Triglycerides | 1987 |
Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin; Sterol O-Acyltransferase | 1988 |
Clinical experience with simvastatin compared with cholestyramine.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors | 1988 |
[The Scandinavian Simvastatin Survival Study: the clinical consequences].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Scandinavian and Nordic Countries; Simvastatin; Survivors | 1995 |
Simvastatin added to ursodeoxycholic acid does not enhance disappearance of gallstone fragments after shock wave therapy.
Topics: Anticholesteremic Agents; Cholagogues and Choleretics; Cholelithiasis; Cholesterol; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lithotripsy; Lovastatin; Simvastatin; Ursodeoxycholic Acid | 1995 |
Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS).
Topics: Aged; Anticholesteremic Agents; Calcium; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Felodipine; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Research Design; Simvastatin; Tomography, X-Ray Computed | 1995 |
Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S).
Topics: Adult; Aged; Anticholesteremic Agents; Australia; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Myocardial Ischemia; New Zealand; Pravastatin; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 1995 |
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Myocardial Infarction; Risk Factors; Scandinavian and Nordic Countries; Sex Factors; Simvastatin; Survival Rate | 1995 |
Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholesterol; Delayed-Action Preparations; Diet; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pravastatin; Receptors, LDL; Simvastatin | 1995 |
Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Anticholesteremic Agents; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diclofenac; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Glyburide; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insulin; Lovastatin; Placebos; Simvastatin; Tolbutamide | 1995 |
Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia.
Topics: Adult; Aged; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Female; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Efficacy and pharmacokinetics of simvastatin in heart transplant recipients.
Topics: Adult; Cholesterol; Cyclosporine; Drug Interactions; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunosuppression Therapy; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1995 |
Effect of simvastatin on Lp(a) concentrations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Linear Models; Lipoprotein(a); Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin | 1995 |
[The Scandinavian Simvastatin Survival Study (4S): old wine in new bottles].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1995 |
[The simvastatin study--was the consumption of wine considered?].
Topics: Alcohol Drinking; Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin; Wine | 1995 |
Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides | 1995 |
Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine.
Topics: Adolescent; Adult; Cyclosporine; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Vitamin E in kidney transplantation: effect of treatment with simvastatin in hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Cyclosporine; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides; Vitamin E | 1995 |
[Real results of The Scandinavian Simvastatin Survival Study (4S)].
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Lovastatin; Male; Scandinavian and Nordic Countries; Simvastatin | 1995 |
[The Scandinavian Simvastatin Survival Study (4S): hasty conclusions].
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Lovastatin; Male; Scandinavian and Nordic Countries; Simvastatin | 1995 |
[Unfortunate presentation of statin therapy in the mass media].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Mass Media; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
[Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Female; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Postoperative Complications; Prospective Studies; Simvastatin | 1995 |
Simvastatin decreases mortality.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Middle Aged; Simvastatin; Treatment Outcome | 1995 |
Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapy.
Topics: Adult; Creatine Kinase; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Myoglobin; Physical Exertion; Simvastatin | 1995 |
[The Scandinavian Simvastatin Survival Study (4S)].
Topics: Anticholesteremic Agents; Coronary Disease; Drug Evaluation; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1995 |
A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients.
Topics: Adult; Anticholesteremic Agents; Double-Blind Method; Ergometry; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Muscles; Permeability; Pravastatin; Prospective Studies; Simvastatin; Statistics as Topic | 1995 |
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Lovastatin; Male; Middle Aged; Risk; Simvastatin | 1995 |
Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Lovastatin; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Simvastatin; Thromboxane A2 | 1995 |
Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
Topics: Apolipoproteins B; Apoproteins; Blood Platelets; Cholesterol; Coenzymes; Cross-Over Studies; Electrocardiography; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Myoglobin; Oxidation-Reduction; Simvastatin; Treatment Outcome; Triglycerides; Ubiquinone | 1994 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1995 |
[Therapeutic trial of simvastatin versus fenofibrate in primary hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
[Simvastatin in the treatment of familial hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Prevention and treatment of graft vessel disease after heart transplantation.
Topics: Adult; Arteriosclerosis; Blood Component Removal; Cholesterol; Double-Blind Method; Female; Graft Occlusion, Vascular; Graft vs Host Disease; Heart Transplantation; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Oligopeptides; Peptides, Cyclic; Prospective Studies; Risk Factors; Simvastatin; Somatostatin; Tissue Donors | 1995 |
Is a reduction of graft vessel disease by maximal treatment of hypercholesterolemia after heart transplantation possible?
Topics: Adult; Coronary Disease; Cyclosporine; Female; Graft Occlusion, Vascular; Graft Rejection; Heart Transplantation; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Early response of hyperlipidemic subjects to simvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Probucol; Renal Dialysis; Simvastatin | 1994 |
Validity of the 4S simvastatin trial.
Topics: Adult; Anticholesteremic Agents; Controlled Clinical Trials as Topic; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Synthase; Lovastatin; Middle Aged; Research Design; Simvastatin | 1995 |
Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.
Topics: Acyl Coenzyme A; Adult; Anticholesteremic Agents; Cholesterol; Chromatography, High Pressure Liquid; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Muscles; Simvastatin; Ubiquinone | 1995 |
[The Scandinavian Simvastatin Survival Study].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Lovastatin; Male; Middle Aged; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Topics: Adult; Apolipoproteins B; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Simvastatin; Triglycerides | 1995 |
Gender and diet interactions with simvastatin treatment.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Sex Factors; Simvastatin; Triglycerides | 1994 |
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipids; Lovastatin; Male; Middle Aged; Myocardial Infarction; Simvastatin; Treatment Outcome | 1994 |
HBPRCA Astra Award. Therapeutic restoration of endothelial function in hypercholesterolaemic subjects: effect of fish oils.
Topics: Acetylcholine; Adult; Australia; Awards and Prizes; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Endothelium, Vascular; Female; Fish Oils; Forearm; Humans; Hypercholesterolemia; Hypertension; Lovastatin; Male; Middle Aged; Regional Blood Flow; Simvastatin | 1994 |
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
Topics: Aged; Body Weight; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Gemfibrozil; Glucose Tolerance Test; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Lipoprotein Lipase; Lipoprotein(a); Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
[Moderate hypercholesterolemia and coronary disease: the MAAS study and the 4S study].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Synthase; Hypercholesterolemia; Lovastatin; Middle Aged; Primary Prevention; Risk Factors; Simvastatin | 1995 |
Lack of interaction between ramipril and simvastatin.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Biological Availability; Child; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; Hypolipidemic Agents; Lovastatin; Male; Ramipril; Simvastatin | 1994 |
[Can hyperlipidemia after heart transplantation be optimally and safely treated?].
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Female; Heart Transplantation; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin | 1994 |
[Statin prevents coronary disease. The 4S study changes the therapeutic practice].
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Scandinavian and Nordic Countries; Simvastatin | 1995 |
[The 4S study is convincing--without explanation].
Topics: Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Endothelium, Vascular; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1995 |
The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans.
Topics: Adult; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Forearm; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Probucol; Regional Blood Flow; Simvastatin; Vitamin E | 1994 |
Dose-response of simvastatin in primary hypercholesterolemia.
Topics: Anticholesteremic Agents; Diet; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
Topics: Adult; Blood Component Removal; Cholestyramine Resin; Colestipol; Coronary Angiography; Coronary Artery Disease; Data Interpretation, Statistical; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoprotein(a); Lipoproteins, LDL; Lovastatin; Middle Aged; Odds Ratio; Simvastatin | 1995 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Simvastatin | 1994 |
Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients.
Topics: Adrenocorticotropic Hormone; Adult; Anticholesteremic Agents; Chorionic Gonadotropin; Hormones; Humans; Hypercholesterolemia; Hypothalamo-Hypophyseal System; Lipid Metabolism; Lovastatin; Male; Middle Aged; Pituitary-Adrenal System; Simvastatin; Steroids; Testis; Time Factors | 1994 |
Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Creatinine; Cyclosporine; Follow-Up Studies; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Time Factors; Triglycerides | 1994 |
Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Ubiquinone | 1994 |
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Myocardial Infarction; Risk Factors; Simvastatin; Survival Analysis | 1994 |
Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1994 |
Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Placebos; Risk Factors; Simvastatin | 1994 |
Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Liver Function Tests; Lovastatin; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 1994 |
Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.
Topics: Adult; Aged; Apolipoproteins B; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hemostasis; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lovastatin; Male; Middle Aged; Prognosis; Simvastatin; Triglycerides | 1994 |
Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Tolerance; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1993 |
The effect of dietary fat content on plasma noncholesterol sterol concentrations in patients with familial hypercholesterolemia treated with simvastatin.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Sterols | 1994 |
A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
Topics: Analysis of Variance; Bezafibrate; Colestipol; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Factor VII; Factor VIII; Female; Fibrinogen; Fibrinolysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin | 1994 |
Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome.
Topics: Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Simvastatin | 1994 |
[Clinical evaluation of simvastatin in the treatment of hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Brain; Cholesterol; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory, Brain Stem; Female; Humans; Liver; Lovastatin; Male; Pravastatin; Psychomotor Performance; Simvastatin; Sleep; Test Anxiety Scale | 1994 |
[Efficacy and tolerability of simvastatin and omega-3 fatty acid combination in patients with coronary disease, hypercholesterolemia and hypertriglyceridemia].
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Drug Tolerance; Fatty Acids, Omega-3; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Apolipoproteins B; Biomarkers; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Female; Fructosamine; Glomerular Filtration Rate; Glycated Hemoglobin; Hexosamines; Humans; Hypercholesterolemia; Insulin; Kidney; Lovastatin; Male; Placebos; Simvastatin; Time Factors | 1993 |
Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes.
Topics: Adolescent; Adult; Cholesterol; Erythrocyte Membrane; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Membrane Fluidity; Membrane Lipids; Pravastatin; Simvastatin; Sodium-Potassium-Exchanging ATPase | 1993 |
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Double-Blind Method; Female; Humans; Hypercholesterolemia; Inulin; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Placebos; Proteinuria; Simvastatin; Triglycerides | 1993 |
Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Topics: Adult; Aged; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1993 |
Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
Topics: Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors | 1993 |
Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Topics: Adult; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Lipids; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Simvastatin | 1993 |
[Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
Topics: Anticholesteremic Agents; Cholesterol; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1993 |
[Comparison of the efficacy between simvastatin and gemfibrozil in primary hypercholesterolemia].
Topics: Adult; Aged; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients.
Topics: Adult; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin; Single-Blind Method; Triglycerides | 1993 |
Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Double-Blind Method; Ethics, Medical; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Infarction; Scandinavian and Nordic Countries; Simvastatin; Time Factors | 1993 |
HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Body Mass Index; Body Weight; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunosuppression Therapy; Kidney Transplantation; Lipids; Lipoproteins; Lovastatin; Male; Postoperative Complications; Proteinuria; Simvastatin; Triglycerides | 1993 |
Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Digestive System Diseases; Drug Tolerance; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Safety; Simvastatin; Triglycerides | 1993 |
Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
Topics: Adult; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Ubiquinone | 1993 |
The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
Topics: Adult; Aged; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Polysomnography; Pravastatin; Simvastatin; Sleep; Sleep Wake Disorders | 1993 |
[Effectiveness and tolerability of simvastatin in subjects with primary hypercholesterolemia. Multicenter study].
Topics: Aged; Anticholesteremic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Blood Pressure; Energy Metabolism; Exercise; Exercise Test; Exercise Tolerance; Fatty Acids, Nonesterified; Gemfibrozil; Heart Rate; Humans; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lovastatin; Male; Oxidation-Reduction; Oxygen Consumption; Pyrazines; Random Allocation; Simvastatin; Single-Blind Method | 1993 |
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Sleep; Treatment Outcome | 1993 |
Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Corneal Opacity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Simvastatin; Visual Acuity | 1995 |
[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
Topics: Anticholesteremic Agents; Drug Tolerance; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Pravastatin; Simvastatin | 1995 |
Statin therapy and CHD.
Topics: Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Simvastatin | 1996 |
Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
Topics: Anticholesteremic Agents; Bile; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Gallbladder; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin; Ultrasonography | 1995 |
[Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
What is the role of lipid lowering therapy in heart-allograft failure?
Topics: Coronary Angiography; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Retrospective Studies; Risk Factors; Simvastatin; Transplantation, Homologous | 1995 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism.
Topics: Adult; Apolipoproteins B; Colestipol; Drug Combinations; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1996 |
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Double-Blind Method; Female; Health Care Costs; Humans; Lovastatin; Male; Middle Aged; Simvastatin | 1996 |
LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Component Removal; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Enzyme Inhibitors; Exercise Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin | 1996 |
Fish oil supplementation in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cross-Over Studies; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Olive Oil; Plant Oils; Simvastatin; Time Factors | 1996 |
[Statin therapy of individuals with high risk for coronary disease].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Male; Pravastatin; Risk Factors; Scotland; Simvastatin | 1996 |
[A new study on hypercholesterolemia. Statin is effective against heart disease].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Humans; Lovastatin; Male; Middle Aged; Pravastatin; Scandinavian and Nordic Countries; Scotland; Simvastatin | 1996 |
Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group.
Topics: Adult; Affect; Aged; Anticholesteremic Agents; Cholesterol; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Mood Disorders; Placebos; Simvastatin | 1996 |
Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment.
Topics: Androgens; Anticholesteremic Agents; Apolipoproteins; Chorionic Gonadotropin; Estradiol; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Testis; Testosterone | 1996 |
Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Acyl Coenzyme A; Blood Viscosity; Cholesterol; Enzyme Inhibitors; Female; Fibrinogen; Hematocrit; Hemorheology; Humans; Hyperlipoproteinemias; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1996 |
Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1995 |
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia.
Topics: Analysis of Variance; Angina Pectoris; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Electrocardiography; Exercise Test; Forearm; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Regional Blood Flow; Simvastatin; Single-Blind Method | 1996 |
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Double-Blind Method; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Simvastatin | 1996 |
Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Topics: Adult; Aged; Cholesterol; Combined Modality Therapy; Cross-Over Studies; Diet, Fat-Restricted; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Simvastatin; Triglycerides | 1996 |
Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Female; Humans; Lovastatin; Male; Middle Aged; Placebos; Reproducibility of Results; Simvastatin; Sleep Wake Disorders; Surveys and Questionnaires | 1996 |
A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Combined Modality Therapy; Enzyme Inhibitors; Follow-Up Studies; Glomerulonephritis, Membranous; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nephrotic Syndrome; Prospective Studies; Serum Albumin; Simvastatin; Time Factors | 1996 |
Effects of HMG-CoA reductase inhibition on erythrocyte membrane cholesterol and acyl chain composition.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Erythrocyte Membrane; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Lipids; Osmotic Fragility; Simvastatin | 1996 |
Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).
Topics: Adult; Aged; Angiography, Digital Subtraction; Anticholesteremic Agents; Blood Component Removal; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1996 |
Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Enzyme Inhibitors; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Peripheral Vascular Diseases; Simvastatin | 1996 |
Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Topics: Adult; Analysis of Variance; Clofibric Acid; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Fibric Acids; Fibrinogen; Follow-Up Studies; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Morbidity; Prospective Studies; Safety; Simvastatin; Survival Rate; Treatment Outcome; Ultracentrifugation | 1996 |
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
Topics: Adult; Aged; Anticholesteremic Agents; Cross-Over Studies; Double-Blind Method; Drug Tolerance; Female; Humans; Lovastatin; Male; Middle Aged; Simvastatin | 1997 |
Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group.
Topics: Adolescent; Adult; Aged; Cholesterol Esters; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis; Simvastatin; Sterol O-Acyltransferase | 1997 |
The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin; Treatment Outcome | 1997 |
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Topics: Adult; Aged; Chromatography, Thin Layer; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Factor VII; Factor XII; Fatty Acids, Nonesterified; Female; Fibrinogen; Follow-Up Studies; Hemostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Prospective Studies; Prothrombin; Risk Factors; Simvastatin; Single-Blind Method | 1997 |
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.
Topics: Acetylcholine; Anticholesteremic Agents; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nitroprusside; omega-N-Methylarginine; Placebos; Plethysmography; Regional Blood Flow; Simvastatin; Time Factors; Vasodilator Agents | 1997 |
Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
Topics: Adult; Aged; B-Lymphocytes; Cell Division; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Leukemia, Lymphoid; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Mitogens; Pravastatin; Simvastatin; Thymidine; Tumor Cells, Cultured | 1997 |
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Topics: Adult; Aged; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines; Simvastatin; Treatment Outcome; Triglycerides | 1997 |
No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia.
Topics: Blood Platelets; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Platelet Aggregation; Rest; Simvastatin; Stress, Psychological; Thromboxane B2; Thyroglobulin | 1997 |
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Lovastatin; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Placebos; Prognosis; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Time Factors; Triglycerides | 1997 |
Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
Topics: Aged; Canada; Coronary Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Health Resources; Health Services Research; Humans; Hypolipidemic Agents; Lovastatin; Middle Aged; Models, Economic; Prognosis; Simvastatin; Survival Analysis; Time Factors | 1997 |
A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cross-Over Studies; Dietary Fats; Gemfibrozil; Genotype; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Lipids; Lipoprotein(a); Lipoproteins; Lovastatin; Predictive Value of Tests; Simvastatin; Triglycerides | 1997 |
[Long term treatment of moderate to severe hypercholesterolemia with low dose statin. Comparison of simvastatin and pravastatin].
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Severity of Illness Index; Simvastatin; Time Factors | 1996 |
Effect of simvastatin therapy on cell membrane cholesterol content and membrane function as assessed by polymorphonuclear cell NADPH oxidase activity.
Topics: Adult; Anticholesteremic Agents; Cell Membrane; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; NADPH Oxidases; Neutrophils; Simvastatin | 1997 |
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides | 1997 |
Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia.
Topics: Aged; Anticholesteremic Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperinsulinism; Hypertension; Lovastatin; Male; Patient Compliance; Simvastatin | 1997 |
Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Enalapril; Female; Humans; Lovastatin; Male; Middle Aged; Research Design; Simvastatin; Treatment Outcome; Ventricular Function, Left | 1997 |
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin | 1997 |
Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cross-Over Studies; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1997 |
Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Cross-Over Studies; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Hypercholesterolemia; Linear Models; Lovastatin; Medroxyprogesterone; Middle Aged; Postmenopause; Simvastatin; Triglycerides | 1997 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Disease; Echocardiography; Female; Graft Rejection; Heart Transplantation; Humans; Incidence; Lovastatin; Male; Middle Aged; Mortality; Postoperative Complications; Prospective Studies; Simvastatin; Survival Analysis | 1997 |
Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Fish Oils; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Simvastatin; Triglycerides | 1997 |
Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Carbon Isotopes; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isomerism; Leucine; Lipoproteins; Liver; Lovastatin; Male; Middle Aged; Random Allocation; Reference Values; Regression Analysis; Simvastatin | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Topics: Adult; Aged; Antioxidants; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Myocardial Revascularization; Niacin; Simvastatin; Treatment Outcome; Vitamins | 1998 |
Clinical efficacy of cerivastatin: phase IIa dose-ranging and dose-scheduling studies.
Topics: Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyridines; Safety; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Topics: Adolescent; Adult; Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Safety; Simvastatin; Treatment Outcome | 1998 |
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia.
Topics: Anticholesteremic Agents; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1997 |
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Policy; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin; United States | 1998 |
Efficacy of three statins at lower maintenance doses.
Topics: Adult; Aged; Anticholesteremic Agents; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1999 |
[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1999 |
[Effect of xuezhikang on the treatment of primary hyperlipidemia].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1997 |
Effect of cholesterol lowering treatment on positive exercise tests in patients with hypercholesterolaemia and normal coronary angiograms.
Topics: Adult; Analysis of Variance; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Diet, Fat-Restricted; Exercise Test; Exercise Tolerance; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1999 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Effects of cholestyramine on vitamin E levels in patients treated with statins.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Cholesterol, LDL; Cholestyramine Resin; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Vitamin E | 2000 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States | 2001 |
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
Topics: Adult; Apolipoproteins B; Cross-Over Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 2002 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
Statin-associated myopathy with normal creatine kinase levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Determination of Simvastatin in human plasma by liquid chromatography-mass spectrometry.
Topics: Adult; Calibration; Chromatography, Liquid; Cross-Over Studies; Flow Injection Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Methanol; Quality Control; Reference Standards; Reproducibility of Results; Simvastatin; Solutions; Solvents; Spectrometry, Mass, Electrospray Ionization | 2003 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors | 2003 |
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Brain; Cholesterol 24-Hydroxylase; Female; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Simvastatin; Steroid Hydroxylases; Treatment Outcome | 2003 |
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Blood Platelets; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pravastatin; Protein Processing, Post-Translational; Simvastatin; Single-Blind Method | 2003 |
Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells.
Topics: Adult; Animals; Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Lovastatin; Male; Myocytes, Cardiac; Pyrroles; Rats; Simvastatin | 2004 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers:gut hydrolysis of lovastatin is twice that of simvastatin.
Topics: Adult; Digestive System; Female; Humans; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Molecular Structure; Sex Characteristics; Simvastatin | 2003 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis.
Topics: Adult; Apoptosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Lymphocytes; Male; Middle Aged; Pravastatin; Pyridines; Simvastatin; Thyroid Gland; Thyroiditis, Autoimmune | 2005 |
Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan.
Topics: Aged; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2006 |
Beneficial effect of statins in multiple sclerosis: is it dose-dependent?
Topics: Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lovastatin; Multiple Sclerosis; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Arthralgia; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Headache; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Patient Dropouts; Pravastatin; Respiratory Tract Infections; Simvastatin; Sinusitis; Treatment Outcome; Triglycerides | 2008 |
Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection.
Topics: Adult; Atorvastatin; Choice Behavior; Decision Support Techniques; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Patient Preference; Pilot Projects; Pravastatin; Precision Medicine; Psychometrics; Rosuvastatin Calcium; Self Efficacy; Simvastatin | 2019 |
771 other study(ies) available for simvastatin and lovastatin
| Article | Year |
|---|---|
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.
Topics: Amino Acid Sequence; Animals; Anion Transport Proteins; Base Sequence; Biological Transport; Carrier Proteins; Dehydroepiandrosterone Sulfate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Molecular Sequence Data; Pravastatin; Rats; Taurocholic Acid | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2001 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dogs; Estradiol; Fluoresceins; Heptanoic Acids; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Permeability; Pyrroles; Simvastatin; Structure-Activity Relationship | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum.
Topics: Animals; Antimalarials; Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Inhibitory Concentration 50; Malaria, Falciparum; Microbial Sensitivity Tests; Plasmodium falciparum; Pyrroles; Structure-Activity Relationship | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis.
Topics: Carboxylesterase; Carboxylic Ester Hydrolases; Enzyme Inhibitors; Humans; Ketones; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs.
Topics: Blotting, Western; Caco-2 Cells; Carrier Proteins; Gene Expression; Gene Knockdown Techniques; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; RNA, Small Interfering | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Molecular; Protein Conformation | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
Topics: Animals; Cell Line; Dehydrocholesterols; Dose-Response Relationship, Drug; Fibroblasts; Homeostasis; Humans; Mice; Molecular Conformation; Neurons; Oxidoreductases Acting on CH-CH Group Donors; Small Molecule Libraries; Sterols; Structure-Activity Relationship | 2016 |
Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection.
Topics: Blood Proteins; Chromatography, High Pressure Liquid; Humans; Hypolipidemic Agents; Lovastatin; Protein Binding; Simvastatin; Spectrophotometry, Ultraviolet | 1992 |
Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Luteinizing Hormone; Male; Middle Aged; Progesterone; Simvastatin; Testosterone; Triglycerides | 1992 |
An overview: long-term tolerability of lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Simvastatin | 1992 |
[2,700 reported adverse effects of drugs in 1991. A large spectrum of new antidepressive agents].
Topics: Adult; Antidepressive Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Lovastatin; Male; Simvastatin; Sulfonamides; Sumatriptan; Sweden | 1992 |
Simvastatin and lipoprotein(a)
Topics: Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Simvastatin use in children.
Topics: Adolescent; Anticholesteremic Agents; Child; Child, Preschool; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1992 |
Simvastatin during warfarin therapy in hyperlipoproteinaemia.
Topics: Female; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lovastatin; Middle Aged; Simvastatin; Warfarin | 1992 |
Effect of simvastatin in CAPD patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Simvastatin | 1992 |
Bioconversion of the sodium salt of simvastatin (MK-733) to 6-desmethyl-6-alpha-hydroxymethyl simvastatin.
Topics: Actinomycetales; Anticholesteremic Agents; Culture Media; Fermentation; Hydrogen-Ion Concentration; Kinetics; Lovastatin; Magnesium Sulfate; Simvastatin | 1991 |
Using changes in attributable risk to predict long-term efficacy of simvastatin treatment.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin | 1992 |
Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat.
Topics: Animals; Autoradiography; Carbon Radioisotopes; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Organ Specificity; Pravastatin; Rats; Rats, Wistar; Simvastatin; Spleen; Sterols; Testis; Tissue Distribution | 1992 |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin and the human lens. Clinical results of a 3-year follow-up.
Topics: Adult; Aged; Cataract; Cholesterol; Cholesterol, HDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lens, Crystalline; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Efficacy and tolerability of medium-term treatment with simvastatin in primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Enzymes; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 9. The synthesis and biological evaluation of novel simvastatin analogs.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Disease Models, Animal; Dogs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Magnetic Resonance Spectroscopy; Rats; Simvastatin; Structure-Activity Relationship | 1992 |
Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Radioimmunoassay; Simvastatin | 1992 |
One year experience in the treatment of familial hypercholesterolaemia with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infusion Pumps, Implantable; Injections, Subcutaneous; Lovastatin; Pravastatin; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Simvastatin | 1992 |
Zocor, the postmarketing experience.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Drug Evaluation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Patient Compliance; Pilot Projects; Product Surveillance, Postmarketing; Safety; Simvastatin; South Africa | 1992 |
Experimental simvastatin-induced myopathy in rabbits.
Topics: Administration, Oral; Animals; Electromyography; Enzymes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Muscles; Muscular Diseases; Rabbits; Simvastatin | 1992 |
Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cushing Syndrome; Cytochrome P-450 Enzyme System; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Mevalonic Acid; Middle Aged; Mitotane; Simvastatin | 1992 |
Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin.
Topics: Adult; Aged; Aging; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Sex Characteristics; Simvastatin | 1992 |
Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation.
Topics: Animals; Anticholesteremic Agents; Cell Division; Cells, Cultured; Humans; Lovastatin; Myocardium; Pravastatin; Rats; Simvastatin | 1992 |
[Mid-term clinical study of the effectiveness of and tolerability to simvastatin ++ in dyslipidemic patients].
Topics: Adult; Aged; Cholesterol; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
[Diabetes mellitus, hypercholesterolemia, and therapeutic prospects with simvastatin. General considerations and personal contribution].
Topics: Adult; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1992 |
Lupuslike syndrome associated with simvastatin.
Topics: Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Lupus Erythematosus, Systemic; Simvastatin | 1992 |
[Simvastatin-induced hepatitis].
Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Heterozygote; Hormones; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Single-Blind Method; Spermatozoa; Testis | 1992 |
[Dyslipidemia in the uremic patient: the therapeutic role played by simvastatin].
Topics: Aged; Anticholesteremic Agents; Combined Modality Therapy; Drug Evaluation; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Renal Dialysis; Simvastatin; Uremia | 1992 |
[The hypotriglyceridemic action of the combination of L-carnitine + simvastatin vs. L-carnitine and vs. simvastatin].
Topics: Aged; Anticholesteremic Agents; Carnitine; Combined Modality Therapy; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hypertriglyceridemia; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Renal Dialysis; Simvastatin | 1992 |
Clinical investigation on the hypolipidemic effect of simvastatin in primary hypercholesterolemia.
Topics: Anticholesteremic Agents; Capsules; Drug Evaluation; Fasting; Humans; Hypercholesterolemia; Lipids; Lovastatin; Simvastatin; Time Factors | 1992 |
Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Cataract; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Pravastatin; Rabbits; Simvastatin | 1992 |
Increased thromboxane biosynthesis in type IIa hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Thromboxane A2 | 1992 |
Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.
Topics: Cost-Benefit Analysis; Drug Evaluation; Female; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Pravastatin, simvastatin, and lovastatin for lowering serum cholesterol concentrations.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1992 |
Response to treatment with simvastatin in a compound FH heterozygote.
Topics: Adult; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1992 |
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Topics: Acetates; Animals; Anticholesteremic Agents; Apolipoproteins B; Cell Line; Cholesterol; Clofibric Acid; Dose-Response Relationship, Drug; Fibric Acids; Gene Expression Regulation; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Liver; Lovastatin; Mevalonic Acid; Rats; Receptors, LDL; RNA, Messenger; Simvastatin | 1992 |
[Simvastatin in the treatment of hypercholesterolemia in the aged. An epidemiological and clinical study].
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin; Time Factors; Triglycerides | 1992 |
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Benzylamines; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Fibrinogen; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Nifedipine; Platelet-Derived Growth Factor; Pravastatin; Simvastatin; Sterols; Swine; Thiophenes | 1992 |
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Topics: Anticholesteremic Agents; Carmustine; Cell Count; Cell Division; Culture Media; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Humans; Hydroxymethylglutaryl CoA Reductases; Interferon-beta; Lovastatin; Simvastatin; Tumor Cells, Cultured | 1992 |
Massive rhabdomyolysis and simvastatin.
Topics: Aged; Anticholesteremic Agents; Female; Humans; Lovastatin; Rhabdomyolysis; Simvastatin | 1992 |
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Topics: Animals; Anticholesteremic Agents; Cyclosporine; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Muscular Diseases; Necrosis; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Structure-Activity Relationship | 1992 |
Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
Topics: Acetates; Anticholesteremic Agents; Benzylamines; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Cycloheximide; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Mevalonic Acid; Nucleic Acid Hybridization; Oxygenases; RNA, Neoplasm; Simvastatin; Squalene Monooxygenase; Thiophenes | 1991 |
HMG CoA reductase inhibitors affect Na(+)-H+ antiport activity in human lymphoblasts.
Topics: Blastomeres; Carrier Proteins; Extracellular Space; Humans; Hydrogen-Ion Concentration; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Membranes; Lovastatin; Lymphocytes; Mevalonic Acid; Simvastatin; Sodium-Hydrogen Exchangers | 1991 |
The prediction of the therapeutic response to cholesterol lowering drugs in an 11-year-old boy with homozygous familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Child; Cholesterol; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Lymphocytes; Male; Predictive Value of Tests; Receptors, Cell Surface; Receptors, Lipoprotein; Simvastatin; Triglycerides | 1991 |
Effect of simvastatin on receptor mediated metabolism of low density lipoprotein in guinea pigs.
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Galactose; Guinea Pigs; Humans; Iodine Radioisotopes; Lipoproteins, LDL; Lovastatin; Male; Receptors, Cell Surface; Receptors, Lipoprotein; Simvastatin | 1991 |
Poor response to simvastatin in familial defective apo-B-100.
Topics: Anticholesteremic Agents; Apolipoproteins B; Humans; Hyperlipoproteinemia Type II; Lovastatin; Receptors, LDL; Simvastatin | 1991 |
Simvastatin-induced protein-losing enteropathy.
Topics: Aged; Anticholesteremic Agents; Diarrhea; Female; Humans; Lovastatin; Protein-Losing Enteropathies; Simvastatin | 1992 |
Effect of simvastatin on the synthesis and secretion of lipoproteins in relation to the metabolism of cholesterol in cultured hepatocytes.
Topics: Animals; Animals, Newborn; Cells, Cultured; Cholesterol; Cholesterol Esters; Fatty Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Liver; Lovastatin; Male; Methionine; Rats; Rats, Inbred Strains; Simvastatin; Triglycerides | 1991 |
Simvastatin and side effects.
Topics: Adult; Aged; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Surveys and Questionnaires | 1991 |
[Quality of treatment in hypercholesterolemia in ambulatory patients].
Topics: Adult; Anticholesteremic Agents; Cholesterol, Dietary; Cohort Studies; Decision Making; Female; Humans; Hypercholesterolemia; Long-Term Care; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Studies on the metabolic inversion of the 6'chiral center of simvastatin.
Topics: Animals; Anticholesteremic Agents; Bile; Biotransformation; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dogs; Hydrolysis; Isomerism; Lovastatin; Male; Mass Spectrometry; Molecular Structure; Radioisotope Dilution Technique; Rats; Rats, Inbred Strains; Simvastatin; Tritium | 1991 |
Dual effect of lovastatin and simvastatin on LDL-macrophage interaction.
Topics: Animals; Anticholesteremic Agents; Electrophoresis, Polyacrylamide Gel; Fibroblasts; Humans; Lipoproteins, LDL; Lovastatin; Macrophages; Mice; Radioimmunoassay; Receptors, LDL; Simvastatin | 1991 |
Effects of simvastatin, a lipoprotein-lowering drug, on the hepatic enzymes involved in drug metabolism in the Wistar rat.
Topics: Animals; Body Weight; Enzyme Induction; Epoxide Hydrolases; Fatty Acids; Glycerolphosphate Dehydrogenase; Hypolipidemic Agents; In Vitro Techniques; Liver; Lovastatin; Male; Mixed Function Oxygenases; Organ Size; Oxidoreductases; Phosphatidylcholines; Rats; Rats, Inbred Strains; Simvastatin; Subcellular Fractions | 1991 |
Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Particle Size; Regression Analysis; Simvastatin; Triglycerides | 1991 |
Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat.
Topics: Adenoma; Animals; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy; Liver; Lovastatin; Microsomes, Liver; Organ Size; Phenobarbital; Rats; Rats, Inbred Strains; Simvastatin; Thyroid Gland; Thyroid Hormones; Thyroid Neoplasms; Thyroxine; Time Factors | 1991 |
[Simvastatin-induced acute pancreatitis: two cases].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Male; Pancreatitis; Simvastatin | 1991 |
[A new case of simvastatin-induced acute pancreatitis].
Topics: Acute Disease; Anticholesteremic Agents; Female; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Pancreatitis; Simvastatin | 1991 |
Plasma high density lipoprotein particle size alteration by simvastatin treatment in patients with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Cholesterol, VLDL; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Particle Size; Simvastatin; Triglycerides | 1991 |
[The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
Topics: Adult; Cataract; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lovastatin; Middle Aged; Pravastatin; Refraction, Ocular; Risk Factors; Simvastatin; Visual Acuity | 1991 |
Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Topics: Anticholesteremic Agents; Chromatography, High Pressure Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Solubility; Structure-Activity Relationship | 1991 |
Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency.
Topics: Child, Preschool; Cholesterol Ester Storage Disease; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Simvastatin | 1991 |
Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
Topics: Animals; Anticholesteremic Agents; Clofibric Acid; Fibric Acids; Hypolipidemic Agents; Lipids; Liver; Lovastatin; Male; Microbodies; Mixed Function Oxygenases; Rats; Simvastatin | 1991 |
Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Phenotype; Simvastatin; Triglycerides | 1991 |
[Evaluation of the addition of fenofibrate to the simvastatin-cholestyramine combination].
Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Simvastatin | 1991 |
[Simvastatin in the treatment of hypercholesterolemia].
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cholesterol; Drug Evaluation; Eye; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Anticholesteremic Agents; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Mevalonic Acid; Middle Aged; Simvastatin | 1991 |
[Effects of simvastatin on atherogenic blood lipid pattern].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1991 |
Acute cholestatic hepatitis during simvastatin administration.
Topics: Acute Disease; Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Cholestasis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Middle Aged; Simvastatin | 1991 |
[A patient with the homozygote form of familial hypercholesterolemia].
Topics: Anticholesteremic Agents; Child; Exercise Test; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Simvastatin; Triglycerides | 1991 |
Long-term effects of simvastatin in familial dysbetalipoproteinaemia.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type III; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1991 |
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lipoproteins; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Simvastatin; Triglycerides | 1991 |
3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives.
Topics: Acetates; Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Cholesterol; Dogs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Male; Molecular Conformation; Molecular Structure; Oxygen; Rats; Simvastatin; Structure-Activity Relationship | 1991 |
Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol.
Topics: Adolescent; Adult; Anticholesteremic Agents; Colestipol; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Simvastatin | 1991 |
Hypolipidemic effects of NB-598 in dogs.
Topics: Animals; Anticholesteremic Agents; Benzylamines; Bile; Bile Acids and Salts; Cholesterol; Dogs; Feces; Lipids; Lipoproteins; Lovastatin; Male; Oxygenases; Phospholipids; Simvastatin; Squalene; Squalene Monooxygenase; Thiophenes; Triglycerides | 1991 |
Pravastatin and simvastatin for hypercholesterolemia.
Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Muscular Diseases; Naphthalenes; Pravastatin; Simvastatin | 1991 |
Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Hypercholesterolemia; Leukocytes; Lovastatin; Middle Aged; Naphthalenes; Pravastatin; Simvastatin | 1991 |
[Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
Topics: Adult; Age Factors; Anticholesteremic Agents; Cholestyramine Resin; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Netherlands; Sex Factors; Simvastatin | 1991 |
Comparison of different HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Triglycerides | 1991 |
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
Topics: Animals; Biliary Tract; Cholestasis; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Microsomes, Liver; Muscular Diseases; Naphthalenes; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin | 1991 |
Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes.
Topics: Animals; Aorta; Cell Division; Cells, Cultured; Depression, Chemical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscle, Smooth, Vascular; Naphthalenes; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Thymidine | 1991 |
Rapid verification of identity and content of drug formulations using mid-infrared spectroscopy.
Topics: Anticholesteremic Agents; Chemistry, Pharmaceutical; Enalapril; Lovastatin; Simvastatin; Software; Spectrophotometry, Infrared | 1991 |
Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.
Topics: Acetates; Animals; Cholesterol; Cricetinae; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lens, Crystalline; Liver; Lovastatin; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Time Factors | 1991 |
Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form.
Topics: Animals; Cholesterol; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Dogs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Osmotic Pressure; Simvastatin; Solubility; Tablets | 1991 |
Simvastatin.
Topics: Anticholesteremic Agents; Contraindications; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pregnancy; Simvastatin | 1991 |
Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo.
Topics: Adult; Aged; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Deoxycholic Acid; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin; Ursodeoxycholic Acid | 1991 |
Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry.
Topics: Adolescent; Adult; Anticholesteremic Agents; Female; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mevalonic Acid; Middle Aged; Simvastatin | 1991 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on human gut mucosa.
Topics: Anticholesteremic Agents; Cell Division; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Mucosa; Jejunum; Lovastatin; Male; Middle Aged; Mitotic Index; Simvastatin | 1991 |
Management of non-nephrotic hyperlipidaemia of chronic renal failure with simvastatin.
Topics: Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin | 1991 |
Regulation of squalene epoxidase in HepG2 cells.
Topics: Binding, Competitive; Carcinoma, Hepatocellular; Cholesterol; Detergents; Enzyme Induction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, LDL; Liver; Liver Neoplasms; Lovastatin; Mevalonic Acid; Microsomes, Liver; Octoxynol; Oxygenases; Polyethylene Glycols; Simvastatin; Squalene Monooxygenase; Tumor Cells, Cultured | 1990 |
Nephrotic syndrome and simvastatin.
Topics: Albuminuria; Anticholesteremic Agents; Follow-Up Studies; Humans; Lovastatin; Nephrotic Syndrome; Simvastatin | 1990 |
Apolipoprotein(a) and ischaemic heart disease.
Topics: Anticholesteremic Agents; Apolipoproteins A; Coronary Disease; Heptanoic Acids; Humans; Liver; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Simvastatin and ursodeoxycholic acid for rapid gallstone dissolution.
Topics: Adult; Cholelithiasis; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin; Time Factors; Ursodeoxycholic Acid | 1990 |
Proteinuria as complication of simvastatin treatment.
Topics: Albuminuria; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Proteinuria; Simvastatin; Transferrin | 1990 |
Rhabdomyolysis and simvastatin.
Topics: Anticholesteremic Agents; Humans; Lovastatin; Male; Middle Aged; Rhabdomyolysis; Simvastatin | 1991 |
Serum pseudocholinesterase activity in rabbits fed simvastatin.
Topics: Animals; Anticholesteremic Agents; Butyrylcholinesterase; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Cholinesterase Inhibitors; Diet; Lovastatin; Male; Rabbits; Simvastatin | 1991 |
Cholesterol-lowering simvastatin achieves listing as a pharmaceutical benefit.
Topics: Adult; Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Pharmacopoeias as Topic; Simvastatin | 1991 |
Cerebrotendinous xanthomatosis: treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings.
Topics: Adult; Anticholesteremic Agents; Brain Diseases; Chenodeoxycholic Acid; Female; Humans; Lovastatin; Muscular Diseases; Simvastatin; Tendons; Tomography, X-Ray Computed; Xanthomatosis | 1991 |
Effect of simvastatin (MK-733) on plasma triacylglycerol levels in rats.
Topics: Adipose Tissue; Animals; Body Weight; Clofibrate; Energy Intake; Lipoprotein Lipase; Lipoproteins; Liver; Lovastatin; Male; Muscles; Organ Size; Rats; Rats, Inbred Strains; Simvastatin; Triglycerides | 1991 |
[Simvastatin: a new drug responsible for acute pancreatitis?].
Topics: Acute Disease; Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pancreatitis; Simvastatin | 1991 |
[A case of hepatitis caused by simvastatin].
Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Humans; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Rhabdomyolysis with simvastatin use.
Topics: Acute Kidney Injury; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Pancreatitis; Rhabdomyolysis; Simvastatin | 1991 |
In vivo effect of simvastatin on lipoprotein cholesteryl ester metabolism in normocholesterolemic volunteers.
Topics: Adult; Anticholesteremic Agents; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Humans; Kinetics; Lipoproteins; Lovastatin; Male; Models, Biological; Simvastatin | 1991 |
[Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits].
Topics: Animals; Anticholesteremic Agents; Cholesterol, Dietary; Coronary Artery Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Rabbits; Simvastatin | 1991 |
L-669,262, a potent HMG-CoA reductase inhibitor.
Topics: Animals; Fermentation; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Nocardia; Rats; Simvastatin; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet | 1991 |
The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity.
Topics: 17-Hydroxysteroid Dehydrogenases; Aged; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Oxidoreductases; Prostatic Neoplasms; Simvastatin; Steroids; Testis; Testosterone | 1991 |
Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Topics: Adult; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Male-specific metabolism of simvastatin by rat liver microsomes.
Topics: Animals; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Microsomes, Liver; Rats; Rats, Inbred Strains; Sex Factors; Simvastatin | 1991 |
Liver side effects associated with simvastatin therapy.
Topics: Anticholesteremic Agents; Female; Humans; Liver; Liver Function Tests; Lovastatin; Middle Aged; Simvastatin | 1991 |
Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Topics: Animals; Cells, Cultured; Cholesterol; Dogs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Rats; Simvastatin; Tissue Distribution | 1990 |
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Topics: Cholestyramine Resin; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Niacin; Simvastatin | 1990 |
[The problem of hypercholesterolemia in the aged].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor).
Topics: Aminopyrine N-Demethylase; Animals; Bile Ducts; Body Weight; Cholesterol; Colestipol; Cytochrome P-450 Enzyme System; Eating; Guinea Pigs; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Necrosis; Simvastatin | 1990 |
The effect of 3-hydroxy 3-methylglutaryl-CoA reductase inhibitor on the subfractions of high-density lipoprotein of the rabbit.
Topics: Animals; Cholesterol, HDL; Cholesterol, VLDL; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lovastatin; Rabbits; Simvastatin | 1990 |
Effects of simvastatin (MK-733) on branched pathway of mevalonate.
Topics: Animals; Anticholesteremic Agents; Cell Line; Cholesterol; DNA; Dolichols; Humans; Liver Neoplasms, Experimental; Lovastatin; Mevalonic Acid; Proteins; Simvastatin; Thymidine; Tumor Cells, Cultured; Tyrosine; Ubiquinone | 1990 |
No lens changes caused by simvastatin results from a prospective drug safety study.
Topics: Adult; Aged; Cataract; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intraocular Pressure; Lens, Crystalline; Lovastatin; Male; Middle Aged; Photography; Prospective Studies; Simvastatin; Visual Acuity | 1990 |
Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits.
Topics: Animals; Bile; Cholesterol; Cholesterol, Dietary; Heptanoic Acids; Hypercholesterolemia; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Microsomes, Liver; Naphthalenes; Pravastatin; Rabbits; Receptors, LDL; Simvastatin; Statistics as Topic; Sterol O-Acyltransferase | 1990 |
Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Lovastatin; Male; Middle Aged; Netherlands; Risk Factors; Simvastatin | 1990 |
Lipid lowering drugs.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Acetates; Acetic Acid; Animals; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileum; Kinetics; L Cells; Lens, Crystalline; Liver; Lovastatin; Male; Mice; Mice, Inbred C57BL; Naphthalenes; Pravastatin; Rats; Simvastatin; Spleen | 1990 |
Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Binding, Competitive; Brain; Cyclooxygenase Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Naphthalenes; Pravastatin; Rats; Simvastatin | 1990 |
[The treatment of refractory hyperlipoproteinemias].
Topics: Anticholesteremic Agents; Cholesterol; DEAE-Dextran; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Drugs recently released in Belgium. Omeprazole--simvastatin.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Omeprazole; Simvastatin | 1990 |
Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
Topics: Anticholesteremic Agents; Carcinoma, Hepatocellular; Cholesterol; Cholesterol Esters; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Progesterone; Receptors, LDL; Simvastatin; Tumor Cells, Cultured | 1990 |
Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
A selected ion monitoring method for quantifying simvastatin and its acid form in human plasma, using the ferroceneboronate derivative.
Topics: Ferrous Compounds; Gas Chromatography-Mass Spectrometry; Humans; Lovastatin; Metallocenes; Methylation; Organometallic Compounds; Simvastatin | 1990 |
Muscle side effects associated with simvastatin therapy.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Female; Humans; Lovastatin; Male; Middle Aged; Mitochondria, Muscle; Muscular Diseases; Pain; Simvastatin | 1990 |
[The effects of the cholesterol synthesis inhibitor simvastatin in patients with hypercholesterolemia with and without diabetes mellitus].
Topics: Anticholesteremic Agents; Cholesterol; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Effects of therapy with diet and simvastatin on atherosclerosis in hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis].
Topics: Aged; Alanine Transaminase; Arteriosclerosis; Cholesterol; Cholesterol, LDL; Creatine Kinase; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lipids; Lovastatin; Male; Simvastatin | 1990 |
The politics of cholesterol lowering drugs.
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; New Zealand; Politics; Simvastatin | 1990 |
Misconceptions about cholesterol.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Attitude; Cholesterol; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; New Zealand; Simvastatin | 1990 |
Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Tolerance; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Simvastatin; Single-Blind Method; Triglycerides | 1990 |
[Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
Topics: Aged; Anticholesteremic Agents; Apoproteins; Cholesterol; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Regioselectivity and stereoselectivity in the metabolism of HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Biotransformation; Chromatography, High Pressure Liquid; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Magnetic Resonance Spectroscopy; Male; Microsomes, Liver; Phenobarbital; Rats; Rats, Inbred Strains; Simvastatin; Spectrophotometry, Ultraviolet; Structure-Activity Relationship | 1990 |
On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Biphenyl Compounds; Cataract; Cholesterol; Dogs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrans; Pyrones; Simvastatin | 1990 |
[HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
[A case of familial hypercholesterolemia with therapeutic difficulties].
Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic Acids; Simvastatin | 1990 |
Applications of oxygen polarography to drug stability testing and formulation development: solution-phase oxidation of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
Topics: Antioxidants; Chemistry, Pharmaceutical; Drug Stability; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Oxidation-Reduction; Oxygen; Oxygen Consumption; Polarography; Simvastatin | 1990 |
Decreased mitogenic activity in hypercholesterolaemic plasma.
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Apolipoproteins B; Cells, Cultured; Cholesterol; DNA; Female; Humans; Hypercholesterolemia; Lipoproteins; Lovastatin; Male; Middle Aged; Mitogens; Muscle, Smooth, Vascular; Rats; Simvastatin | 1990 |
Effect of simvastatin (MK-733) on sterol and bile acid excretion in rabbits.
Topics: Animals; Bile; Bile Acids and Salts; Cholesterol, Dietary; Cholestyramine Resin; Feces; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Liver; Lovastatin; Male; Rabbits; Simvastatin; Sterols | 1990 |
The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
Topics: Adult; Apolipoproteins; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
[Drug treatment of hypercholesterolemia. Confusing discrepancies in guidelines of an advertising campaign].
Topics: Advertising; Anticholesteremic Agents; Drug Industry; Drug Information Services; Humans; Lovastatin; Simvastatin; Sweden | 1990 |
Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hyperlipoproteinemia Type III; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
[Maximal therapy of hypercholesterolemia in coronary heart disease].
Topics: Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Plasma Exchange; Simvastatin | 1990 |
Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Sex Factors; Simvastatin | 1990 |
[Selective elimination of atherogenic lipoproteins using dextran-sulfate cellulose. Experiences in 2 patients with heterozygote familial hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Cellulose; Combined Modality Therapy; Dextran Sulfate; Dextrans; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Plasmapheresis; Simvastatin | 1989 |
Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
Topics: Adenosine Triphosphate; Adult; Aged; Anticholesteremic Agents; Blood Platelets; Cyclic AMP; Epoprostenol; Humans; Hyperlipoproteinemia Type II; Iloprost; Lipids; Lovastatin; Middle Aged; Platelet Aggregation; Receptors, Epoprostenol; Receptors, Prostaglandin; Simvastatin; Thromboxane B2 | 1989 |
Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
Topics: Cataract; Cholesterol; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.
Topics: Adrenal Glands; Animals; Gastric Mucosa; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver; Lovastatin; Male; Naphthalenes; Pravastatin; Rats; Simvastatin; Spleen; Testis; Tissue Distribution | 1989 |
Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine.
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Lovastatin; Male; Middle Aged; Netherlands; Simvastatin | 1989 |
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lens, Crystalline; Liver; Lovastatin; Male; Naphthalenes; Organ Specificity; Pravastatin; Rabbits; Rats; Rats, Inbred Strains; Simvastatin; Species Specificity | 1989 |
The cost of new drugs in the treatment of hypertension--the Australian experience.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Australia; Cost-Benefit Analysis; Humans; Lovastatin; Simvastatin | 1989 |
HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Cholesterol; Female; Humans; Hydrocortisone; Hypercholesterolemia; Hypothalamo-Hypophyseal System; Insulin; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pituitary-Adrenal System; Placebos; Simvastatin | 1989 |
Transient symptomatic hypotension in patients on simvastatin.
Topics: Adult; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypotension; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors | 1989 |
Tolerability of simvastatin.
Topics: Humans; Lovastatin; Simvastatin | 1989 |
Simvastatin in the media.
Topics: Advertising; Anticholesteremic Agents; Humans; Hyperlipidemias; Lovastatin; Simvastatin | 1989 |
Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins B; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Male; Models, Biological; Receptors, LDL; Simvastatin | 1989 |
[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk].
Topics: Aged; Cardiovascular Diseases; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Risk; Simvastatin | 1989 |
Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoenzyme Techniques; Lipoproteins; Lovastatin; Male; Middle Aged; Phospholipids; Simvastatin; Triglycerides | 1989 |
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Hypercholesterolemia; Lipids; Liver; Lovastatin; Male; Myocardium; Rabbits; Simvastatin | 1989 |
The porphyrinogenic effect of simvastatin in experimental systems.
Topics: Aminolevulinic Acid; Animals; Anticholesteremic Agents; Chick Embryo; Chromatography, Thin Layer; Feces; Liver; Lovastatin; Male; Porphyrias; Porphyrins; Rats; Rats, Inbred Strains; Simvastatin | 1989 |
Effects of MK-733 (simvastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on intestinal acylcoenzyme A:cholesterol acyltransferase activity in rabbits.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Cytosol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Intestinal Mucosa; Lipids; Lovastatin; Male; Microsomes; Rabbits; Simvastatin; Sterol Esterase; Sterol O-Acyltransferase | 1989 |
Tolerability of simvastatin.
Topics: Anticholesteremic Agents; Eye; Humans; Liver; Lovastatin; Muscles; Simvastatin | 1989 |
Simvastatin influences linoleic acid metabolism.
Topics: Adult; Anticholesteremic Agents; Blood Platelets; Cholesterol; Cholesterol, LDL; Erythrocytes; Fatty Acids, Nonesterified; Female; Humans; Linoleic Acids; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Simvastatin: a one-a-day treatment for hypercholesterolemia. Symposium. June 10 to 12, 1988, Pebble Beach, California.
Topics: Animals; Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1989 |
Simvastatin: the clinical profile.
Topics: Aged; Creatine Kinase; Drug Therapy, Combination; Eye; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Middle Aged; Simvastatin; Transaminases | 1989 |
Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Platelet Aggregation; Simvastatin; Thromboxane B2 | 1989 |
Cholesterol synthesis inhibitors in hyperlipidaemia.
Topics: Anticholesteremic Agents; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
[Efficacy and safety of simvastatin, a new cholesterol-lowering drug].
Topics: Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1989 |
Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor.
Topics: Adult; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
[Type IIa dyslipoproteinemia. Effects of simvastatin and bezafibrate on atherogenic and non-atherogenic lipoprotein particles].
Topics: Bezafibrate; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Simvastatin | 1988 |
Effects of MK-733, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, on absorption and excretion of [3H]cholesterol in rabbits.
Topics: Administration, Oral; Animals; Cholesterol; Cholesterol, Dietary; Feces; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Rabbits; Simvastatin; Sitosterols | 1988 |
Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.
Topics: Anticholesteremic Agents; Biomarkers; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Isomerism; Lovastatin; Male; Simvastatin | 1988 |
[Therapeutic possibilities of a newly registered lipid suppressor].
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Lovastatin; Simvastatin | 1988 |
Pseudocholinesterase and lipoproteins.
Topics: Anticholesteremic Agents; Butyrylcholinesterase; Cholinesterases; Humans; Lipoproteins; Lovastatin; Simvastatin | 1988 |
L-type lipase activity in ovaries of superovulated rats. Relation to cholesterol homeostasis.
Topics: Aminoglutethimide; Animals; Cholesterol; Female; Homeostasis; Lipase; Lipids; Lovastatin; Ovary; Ovulation; Rats; Simvastatin; Superovulation | 1988 |
Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Statins prevent coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 1995 |
Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.
Topics: Animals; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Mice; Mice, Inbred C57BL; Organ Specificity; Pravastatin; Simvastatin; Spleen; Sterols; Testis | 1995 |
Management of patients with dyslipidaemia.
Topics: Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1995 |
High retinol/retinol-binding protein ratio in noninsulin-dependent diabetes mellitus.
Topics: Anticholesteremic Agents; Antioxidants; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; beta Carotene; Blood Glucose; Carotenoids; Cholesterol; Diabetes Mellitus, Type 2; Diterpenes; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Retinol-Binding Proteins; Retinyl Esters; Sex Characteristics; Simvastatin; Triglycerides; Vitamin A | 1995 |
Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Blood Pressure; Carbohydrate Metabolism; Cholesterol; Dogs; Energy Metabolism; Female; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myocardial Stunning; Myocardium; Pravastatin; Simvastatin; Ventricular Function, Left | 1993 |
Chinese hamster ovary cells expressing a novel type of acetylated low density lipoprotein receptor. Isolation and characterization.
Topics: Albumins; Animals; Binding, Competitive; Cell Adhesion Molecules; CHO Cells; Cricetinae; Dextran Sulfate; Dextrans; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gene Expression; Heparin; Humans; Kinetics; Lipoproteins, LDL; Liposomes; Lovastatin; Microscopy, Fluorescence; Poly I; Polysaccharides; Receptors, LDL; Receptors, Scavenger; Serum Albumin, Bovine; Simvastatin | 1995 |
Lowering patients' cholesterol. Excluding patients from trials increases uncertainty.
Topics: Anticholesteremic Agents; Cholesterol; Humans; Lovastatin; Myocardial Infarction; Research Design; Simvastatin | 1995 |
Lowering patients' cholesterol. Extrapolating results of trial of simvastatin gives room for doubt.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Lovastatin; Risk Factors; Simvastatin | 1995 |
Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/macrophages.
Topics: Cells, Cultured; Cholesterol Esters; Cytokines; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Macrophages; Male; Monocytes; Simvastatin | 1995 |
Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Drug Interactions; Female; Fenofibrate; Humans; Hypolipoproteinemias; Lovastatin; Male; Middle Aged; Probucol; Simvastatin | 1995 |
Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Cost Control; Cost-Benefit Analysis; Health Care Costs; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1994 |
[Is treatment of hypercholesterolemia able to reduce total mortality?].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin | 1995 |
Low-density-lipoprotein apheresis.
Topics: Anticholesteremic Agents; Blood Component Removal; Cholestyramine Resin; Colestipol; Combined Modality Therapy; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Simvastatin | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Cohort Studies; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Randomized Controlled Trials as Topic; Risk; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Doctors, research funds and marketing.
Topics: Advertising; Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1995 |
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Cholesterol Esters; Diterpenes; Farnesol; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Macrophages, Peritoneal; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis.
Topics: Adult; Anticholesteremic Agents; Cholestasis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis, Biliary; Lovastatin; Simvastatin | 1995 |
The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation.
Topics: Acute Disease; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Cell Death; Cells, Cultured; Humans; Leukemia, Myeloid; Lovastatin; Remission Induction; Simvastatin; Transplantation, Autologous | 1995 |
Depression-induced absenteeism in relation to antihyperlipidemic treatment: a study using GAZEL cohort data.
Topics: Absenteeism; Adult; Cohort Studies; Depression; Diet, Fat-Restricted; Female; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Occupations; Pharmacoepidemiology; Prevalence; Risk Factors; Simvastatin; Surveys and Questionnaires | 1995 |
[Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].
Topics: Anticholesteremic Agents; Cyclosporine; Cytochrome P-450 Enzyme Inhibitors; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Lovastatin; Male; Middle Aged; Rhabdomyolysis; Simvastatin | 1995 |
Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.
Topics: Age Factors; Animals; Aorta; Aorta, Thoracic; Arteriosclerosis; Carbachol; Cholesterol; Endothelium, Vascular; Heterozygote; Homozygote; Hyperlipoproteinemia Type II; Lovastatin; Phenylephrine; Rabbits; Simvastatin; Vasoconstriction; Vasodilation | 1995 |
[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
Topics: Aged; Alcoholism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Porphyria Cutanea Tarda; Pravastatin; Simvastatin | 1994 |
Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication.
Topics: Adult; Arginine; Blood Pressure; Cholesterol; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Forearm; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Infusions, Intravenous; Lovastatin; Male; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Serotonin; Simvastatin; Vasodilation | 1995 |
Pravastatin versus simvastatin--what happens in the real world?
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Product Surveillance, Postmarketing; Simvastatin | 1995 |
Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prospective Studies; Risk Factors; Simvastatin | 1995 |
Effect of systemic treatment with cholesterol-lowering drugs on the skin barrier function in humans.
Topics: Adult; Aged; Anticholesteremic Agents; Biological Availability; Cholesterol; Erythema; Female; Galvanic Skin Response; Humans; Hypercholesterolemia; Irritants; Lovastatin; Male; Middle Aged; Patch Tests; Permeability; Pravastatin; Simvastatin; Skin; Sodium Dodecyl Sulfate; Water Loss, Insensible | 1995 |
Non-invasive management of coronary artery disease. Report of a meeting at the University of Texas Medical School at Houston.
Topics: Aged; Anticholesteremic Agents; Aspirin; beta Carotene; Carotenoids; Cholesterol, Dietary; Coronary Disease; Diet, Fat-Restricted; Diltiazem; Drug Therapy, Combination; Enalapril; Humans; Lovastatin; Male; Simvastatin; Tomography, Emission-Computed; Vitamins | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages.
Topics: Animals; Carbocyanines; Cholesterol Esters; Diterpenes; Endocytosis; Fatty Acids, Monounsaturated; Fluorescent Dyes; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Lovastatin; Macrophages, Peritoneal; Mevalonic Acid; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Simvastatin | 1995 |
Low-density-lipoprotein apheresis.
Topics: Anticholesteremic Agents; Blood Component Removal; Combined Modality Therapy; Coronary Disease; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Simvastatin | 1995 |
Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Creatinine; Graft Survival; Heart Transplantation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Rats; Rats, Inbred BN; Rats, Inbred Lew; Simvastatin; Tacrolimus; Transplantation, Homologous; Transplantation, Isogeneic | 1993 |
Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Aorta, Thoracic; Cholesterol; Endothelium, Vascular; Hypercholesterolemia; In Vitro Techniques; Lovastatin; Male; Pravastatin; Rabbits; Simvastatin; Vasodilation | 1994 |
[Unfortunate report on simvastatin therapy in the mass media].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Mass Media; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Familial xanthomatous hypercholesterolemia: abnormal exogenous lipid metabolism evidenced by the vitamin A test.
Topics: Adult; Apolipoproteins B; Eating; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Lipids; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides; Vitamin A; Wolman Disease | 1994 |
Ocular drug safety and HMG-CoA-reductase inhibitors.
Topics: Color Perception; Contrast Sensitivity; Eye; Female; Fenofibrate; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intraocular Pressure; Lens, Crystalline; Lovastatin; Male; Middle Aged; Photography; Refraction, Ocular; Safety; Simvastatin; Visual Acuity | 1994 |
Simvastatin inhibits the cellular signaling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells.
Topics: Animals; Arginine Vasopressin; Calcium; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cells, Cultured; DNA; Dose-Response Relationship, Drug; Glomerular Mesangium; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol 1,4,5-Trisphosphate; Kinetics; Lovastatin; Male; Mevalonic Acid; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Signal Transduction; Simvastatin; Tetradecanoylphorbol Acetate; Thymidine | 1995 |
Perspective on cataractogenic potential of HMG-CoA reductase inhibitors.
Topics: Animals; Cataract; Dogs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rabbits; Rats; Simvastatin | 1995 |
Descriptive study of lipid-modulating drug use in a French professional population.
Topics: Adult; Cross-Sectional Studies; Female; Follow-Up Studies; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Occupations; Pharmacoepidemiology; Simvastatin; Thyroid Diseases | 1994 |
Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Trypanosoma brucei.
Topics: Acetates; Animals; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Rats; Rats, Wistar; Simvastatin; Subcellular Fractions; Trypanosoma brucei brucei | 1995 |
Peripheral neuropathy associated with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Female; Humans; Lovastatin; Male; Middle Aged; Neural Conduction; Peripheral Nervous System Diseases; Reaction Time; Simvastatin | 1995 |
[Do we kill our cardiac patients with statin therapy? Coenzyme Q10, what do we know?].
Topics: Coenzymes; Heart Failure; Humans; Lovastatin; Simvastatin; Ubiquinone | 1994 |
Cholesterol-lowering, simvastatin, and coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Simvastatin; Survival Rate | 1995 |
[Ischemic heart disease: is it really time to change therapeutic routines?].
Topics: Anticholesteremic Agents; Humans; Lovastatin; Myocardial Ischemia; Scandinavian and Nordic Countries; Simvastatin | 1995 |
[Detection of the Arg 3500-->Gln mutation of B apolipoprotein. Value in clinical practice].
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Contraceptives, Oral, Combined; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Polymerase Chain Reaction; Simvastatin | 1995 |
Hyperlipidemia in renal transplant recipients: does it matter and can we treat it?
Topics: Adult; Female; Graft Occlusion, Vascular; Humans; Hyperlipidemias; Kidney Transplantation; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Simvastatin | 1995 |
Relation between membrane fluidity and signal transduction in the human megakaryoblastic cell line MEG-01.
Topics: Adenylyl Cyclases; Carbocyanines; Cell Line; Cholesterol; Fluorescent Dyes; Humans; Lipid Metabolism; Lovastatin; Megakaryocytes; Membrane Fluidity; Mevalonic Acid; Phospholipids; Signal Transduction; Simvastatin; Type C Phospholipases | 1995 |
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts.
Topics: Adenosine Diphosphate; Animals; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Mitochondria, Heart; Myocardial Ischemia; Oxygen Consumption; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Fluvastatin cost considerations.
Topics: Drug Costs; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1994 |
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in rat liver during ischemia.
Topics: Adenosine Diphosphate; Animals; Cell Fractionation; Glutamic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Liver; Lovastatin; Male; Mitochondria, Liver; Oxygen Consumption; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Succinates | 1994 |
Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types.
Topics: Blotting, Northern; Cells, Cultured; Endothelium, Vascular; Female; Granulosa Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Pigment Epithelium of Eye; RNA, Messenger; Simvastatin; Sterols; Umbilical Veins | 1995 |
Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Administration, Oral; Anticholesteremic Agents; Blood Platelets; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Simvastatin; Ubiquinone | 1994 |
In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.
Topics: Animals; Astrocytoma; Carmustine; Cell Cycle; Cell Division; Cell Line; DNA, Neoplasm; Drug Synergism; Flow Cytometry; Glioma; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mevalonic Acid; Rats; Rats, Sprague-Dawley; Simvastatin; Tumor Cells, Cultured | 1995 |
[Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia].
Topics: Adult; Calcitriol; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Simvastatin; Vitamin D | 1994 |
Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Child; Cholesterol; Drug Therapy, Combination; Fasting; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Treatment of myocardial infarction and angina. Advice on reducing cholesterol should be included.
Topics: Angina Pectoris; Anticholesteremic Agents; Cholesterol; Humans; Lovastatin; Myocardial Infarction; Simvastatin | 1995 |
Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Topics: Animals; Anticholesteremic Agents; Blood Proteins; Cells, Cultured; Cholesterol; Drug Stability; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Mevalonic Acid; Muscle, Skeletal; Pravastatin; Pregnancy; Protein Binding; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Chorionic Gonadotropin; Gonadal Steroid Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Testis | 1995 |
Cholesterol lowering does have a role in secondary prevention.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Diet; Humans; Life Style; Lovastatin; Middle Aged; Simvastatin | 1995 |
Cholesterol hypothesis vindicated by simvastatin study. Why did it take so long?
Topics: Animals; Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1995 |
Biliary lipid secretion: immunolocalization and identification of a protein associated with lamellar cholesterol carriers in supersaturated rat and human bile.
Topics: Amino Acid Sequence; Aminopeptidases; Animals; Bile; Carrier Proteins; CD13 Antigens; Centrifugation, Density Gradient; Cholesterol; Diosgenin; Humans; Immunoblotting; Immunohistochemistry; Liver; Lovastatin; Male; Metrizamide; Microscopy, Electron; Molecular Sequence Data; Proteins; Rabbits; Rats; Rats, Wistar; Simvastatin | 1993 |
Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1994 |
Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Anticarcinogenic Agents; Carcinogens; Cholesterol; Colonic Neoplasms; Dimethylhydrazines; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred ICR; Pravastatin; Simvastatin | 1994 |
[Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance].
Topics: Aged; Cholesterol; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1994 |
Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.
Topics: Aldehydes; Animals; Anticholesteremic Agents; Antigen-Antibody Complex; Basement Membrane; Cholesterol; Collagen; Disease Models, Animal; Epithelial Cells; Glomerulonephritis; Kidney Glomerulus; Lipid Peroxidation; Lovastatin; Lysine; Male; Malondialdehyde; Probucol; Proteinuria; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Simvastatin | 1994 |
Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
Topics: Adult; Aged; Apolipoprotein E2; Apolipoprotein E3; Apolipoproteins E; Carrier Proteins; Cholesterol Ester Transfer Proteins; Female; Glycoproteins; Humans; Hyperlipoproteinemia Type III; Lipoproteins; Lovastatin; Male; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Reference Values; Simvastatin | 1994 |
Proof arrives: antilipids save lives.
Topics: Clinical Trials as Topic; Humans; Hypolipidemic Agents; Lovastatin; Simvastatin | 1994 |
Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin.
Topics: Acute Disease; Bone Marrow Cells; Cell Division; Cell Survival; Cholesterol; Clone Cells; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Lovastatin; Neoplastic Stem Cells; Simvastatin; Time Factors; Tumor Cells, Cultured | 1994 |
Treatment of cerebrotendinous xanthomatosis.
Topics: Brain Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Middle Aged; Rhabdomyolysis; Simvastatin; Xanthomatosis | 1994 |
Dropping cholesterol--safely.
Topics: Cholesterol; Controlled Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1994 |
Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome.
Topics: Administration, Oral; Bezafibrate; Bilirubin; Colestipol; Gilbert Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Liver; Liver Function Tests; Lovastatin; Male; Middle Aged; Pravastatin; Pyrazines; Simvastatin | 1994 |
Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells.
Topics: Actins; Adenine; Analysis of Variance; Autoradiography; Cell Division; Cells, Cultured; Cholesterol, LDL; Desmin; DNA; Farnesol; Fibroblasts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isopentenyladenosine; Liver; Lovastatin; Mevalonic Acid; Simvastatin | 1994 |
[The effects of plasma cholesterol reduction on vasoconstriction due to sympathetic activation in patients with moderate primary hypercholesterolemia].
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cold Temperature; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linear Models; Lovastatin; Male; Middle Aged; Plethysmography; Simvastatin; Sympathetic Nervous System; Vasoconstriction | 1994 |
Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors.
Topics: Adult; Aged; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine.
Topics: Anticholesteremic Agents; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Heart Transplantation; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Simvastatin; Treatment Outcome | 1994 |
Hyperlipidemia in renal transplant recipients: natural history and response to treatment.
Topics: Adolescent; Adult; Aged; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1994 |
Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
Topics: Action Potentials; Animals; Electric Stimulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myotonia; Pravastatin; Rabbits; Simvastatin | 1994 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1994 |
Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors.
Topics: Animals; Calcium; Cell Survival; Cells, Cultured; Cytosol; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Pravastatin; Rats; Simvastatin | 1994 |
Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene.
Topics: Adenocarcinoma; Animals; Base Sequence; Cell Cycle; Codon; Cricetinae; DNA, Neoplasm; Genes, ras; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Molecular Sequence Data; Pancreatic Neoplasms; Point Mutation; Protein Prenylation; Proto-Oncogene Proteins p21(ras); Sensitivity and Specificity; Simvastatin; Tumor Cells, Cultured | 1994 |
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes.
Topics: Animals; Babesia; Erythrocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Plasmodium falciparum; Simvastatin | 1994 |
Variation in the estimation of gallbladder volume using the sum-of-cylinders method.
Topics: Bezafibrate; Body Mass Index; Gallbladder; Gallbladder Emptying; Humans; Hypolipidemic Agents; Lovastatin; Middle Aged; Reproducibility of Results; Simvastatin; Ultrasonography | 1994 |
Enhancement of migration activity in cholesterol-poor endothelial cells by pre-treating with HMG-CoA reductase inhibitors.
Topics: Animals; Blood; Carotid Arteries; Cattle; Cell Movement; Cholesterol; Culture Media; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Depressive symptoms and cholesterol-lowering drugs.
Topics: Adult; Anticholesteremic Agents; Depressive Disorder; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Middle Aged; Simvastatin | 1993 |
In vivo regulation of hepatic lipase activity and mRNA levels by diets which modify cholesterol influx to the liver.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Cholic Acid; Cholic Acids; Diet; Female; Hydroxymethylglutaryl CoA Reductases; Lipase; Lipid Metabolism; Lipids; Liver; Lovastatin; Rats; Rats, Zucker; RNA, Messenger; Simvastatin | 1994 |
Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects.
Topics: Aged; Analysis of Variance; Bile; Bile Acids and Salts; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver; Lovastatin; Male; Middle Aged; Phospholipids; Simvastatin | 1994 |
Aberrant hypothalamic-pituitary-ovarian axis in the Watanabe heritable hyperlipidemic rabbit.
Topics: Animals; Cholesterol; Estradiol; Female; Fertility; Follicle Stimulating Hormone; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypothalamo-Hypophyseal System; Lovastatin; Luteinizing Hormone; Male; Ovary; Progesterone; Rabbits; Receptors, LDL; Simvastatin; Sperm-Ovum Interactions | 1994 |
Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
Topics: Acetylation; Animals; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Cholesterol Esters; Diterpenes; Dose-Response Relationship, Drug; Esterification; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Lovastatin; Macrophages, Peritoneal; Mevalonic Acid; Mice; Mice, Inbred BALB C; Simvastatin | 1993 |
Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells.
Topics: Apoptosis; Cell Division; Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Lovastatin; Mevalonic Acid; Protein Prenylation; Simvastatin; Thymidine; Time Factors; Tumor Cells, Cultured | 1994 |
Myxoedema revealed by simvastatin induced myopathy.
Topics: Adult; Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Male; Muscular Diseases; Myxedema; Simvastatin | 1994 |
Simvastatin-associated dermatomyositis.
Topics: Dermatomyositis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
Topics: Animals; Blood-Brain Barrier; Cattle; Cells, Cultured; Cerebral Cortex; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Rats; Rats, Wistar; Simvastatin | 1994 |
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin.
Topics: Anticholesteremic Agents; Cholesterol; Double-Blind Method; Humans; Lovastatin; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
[Effects of simvastatin on plasma lipoproteins].
Topics: Adult; Aged; Cholesterol; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin | 1994 |
Simvastatin-sodium delays cell death of anoxic cardiomyocytes by inhibition of the Na+/Ca2+ exchanger.
Topics: Animals; Calcium; Carrier Proteins; Cell Death; Cell Hypoxia; Cells, Cultured; Heart; L-Lactate Dehydrogenase; Lovastatin; Myocardium; Rats; Simvastatin; Sodium; Sodium-Calcium Exchanger | 1994 |
Biochemical diagnosis of myocardial infarction? Cardiac enzymes or caveat emptor.
Topics: Creatine Kinase; Diagnosis, Differential; Humans; Lovastatin; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Simvastatin | 1994 |
PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment.
Topics: Animals; Astrocytoma; Cell Cycle; Demecolcine; Glioma; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyurea; Lovastatin; Mevalonic Acid; Protein Kinase C; Rats; Simvastatin; Tumor Cells, Cultured | 1994 |
Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Topics: Acyclic Monoterpenes; Animals; Aorta; Cell Division; Cells, Cultured; Cholesterol; Diterpenes; Dose-Response Relationship, Drug; Farnesol; Fatty Acids, Monounsaturated; Femoral Artery; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Squalene; Terpenes | 1993 |
[Use and effect of simvastin in patients with type II diabetes].
Topics: Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
Simvastatin influences testicular steroidogenesis in human.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hypothalamo-Hypophyseal System; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Testicular Hormones; Testis; Triglycerides | 1993 |
Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells.
Topics: Cells, Cultured; DNA; Enzyme Activation; Gene Expression; Glomerular Mesangium; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Platelet-Derived Growth Factor; Protein Kinase C; Simvastatin; Type C Phospholipases | 1993 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Arteries; Blood Pressure; Body Mass Index; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Dietary Fats; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Simvastatin; Triglycerides; Ultrasonography; Weight Gain | 1993 |
Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.
Topics: Adult; Aged; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Ubiquinone | 1993 |
Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.
Topics: Acetates; Acetic Acid; Animals; Biological Transport; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Cattle; Cells, Cultured; Endothelium, Vascular; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Perfusion; Pravastatin; Rats; Rats, Wistar; Sensitivity and Specificity; Simvastatin; Temperature | 1993 |
Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.
Topics: Administration, Oral; Animals; Cholesterol; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lovastatin; Male; Muscles; Muscular Diseases; Pravastatin; Rabbits; Simvastatin; Ubiquinone | 1993 |
Effect of simvastatin treatment on plasma apolipoproteins and hepatic apolipoprotein mRNA levels in the genetically hypercholesterolemic rat (RICO).
Topics: Animals; Apolipoproteins E; Apoproteins; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Liver; Lovastatin; Male; Phospholipids; Rats; Rats, Inbred Strains; RNA, Messenger; Simvastatin; Time Factors; Triglycerides | 1994 |
Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin.
Topics: Adult; Aged; Cyclosporine; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Lovastatin; Male; Middle Aged; Rhabdomyolysis; Simvastatin | 1993 |
Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
Topics: Adult; Animals; Delayed-Action Preparations; Dogs; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Simvastatin | 1993 |
Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Cholesterol; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Niacin; Pedigree; Polymorphism, Genetic; Probucol; Receptors, LDL; Simvastatin | 1993 |
The effects of hypercholesterolaemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells.
Topics: Anticholesteremic Agents; Cholesterol; Dietary Fats; Gold Colloid; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; In Vitro Techniques; Leukocytes, Mononuclear; Lipoproteins, LDL; Lovastatin; Receptors, LDL; Simvastatin | 1993 |
3-Hydroxy-3-methyl glutaryl coenzyme A reductase inhibition modulates vasopressin-stimulated Ca2+ responses in rat A10 vascular smooth muscle cells.
Topics: Animals; Calcium; Calcium Channels; Cell Line; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol Phosphates; Intracellular Membranes; Lovastatin; Manganese; Mevalonic Acid; Muscle, Smooth, Vascular; Rats; Simvastatin; Vasopressins | 1994 |
Determination of changes in serum lathosterol during treatment with simvastatin to evaluate the role of lathosterol as a parameter for whole body cholesterol synthesis.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Chromatography, Gas; Female; Half-Life; Humans; Isomerism; Kinetics; Lovastatin; Male; Mevalonic Acid; Simvastatin | 1993 |
Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation.
Topics: Adult; Anticholesteremic Agents; Cholesterol, Dietary; Cholesterol, LDL; Coronary Disease; Female; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin; Survival Analysis | 1994 |
Simvastatin-induced lichenoid drug eruption.
Topics: Anticholesteremic Agents; Drug Eruptions; Female; Humans; Lichenoid Eruptions; Lovastatin; Middle Aged; Simvastatin | 1994 |
Musculoskeletal manifestations during simvastatin therapy.
Topics: Anticholesteremic Agents; Cholesterol; Female; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Musculoskeletal Diseases; Simvastatin | 1993 |
Effects of NB-598, a potent squalene epoxidase inhibitor, on the apical membrane uptake of cholesterol and basolateral membrane secretion of lipids in Caco-2 cells.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Benzylamines; Cell Line; Cell Membrane; Cholesterol; Cholesterol Esters; Enzyme Activation; Humans; Linoleic Acids; Lipids; Lovastatin; Microsomes; Oleic Acid; Oleic Acids; Oxygenases; Polyunsaturated Alkamides; Simvastatin; Squalene Monooxygenase; Sterol O-Acyltransferase; Thiophenes; Tritium; Tumor Cells, Cultured | 1993 |
Simvastatin, pravastatin and lovastatin: three options for lowering cholesterol.
Topics: Anticholesteremic Agents; Drug Costs; Drug Interactions; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1993 |
Plasma VLDL cholesterol and egg cholesterol are resistant to change in the laying hen.
Topics: Animals; Chickens; Cholesterol; Cholesterol, VLDL; Cholestyramine Resin; Eggs; Hydroxymethylglutaryl CoA Reductases; Ketocholesterols; Lovastatin; Simvastatin | 1993 |
Coordinate changes in the low density lipoprotein receptor activity of liver and mononuclear cells in the rabbit.
Topics: Animals; Bile; Cholesterol; Hypolipidemic Agents; Leukocytes, Mononuclear; Lipids; Liver; Lovastatin; Male; Pravastatin; Rabbits; Receptors, LDL; Simvastatin | 1993 |
Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages.
Topics: Drug Interactions; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Macrophage Activation; Macrophages; Mevalonic Acid; Monocytes; Oxidation-Reduction; Simvastatin; Superoxides; Tetradecanoylphorbol Acetate | 1993 |
Simvastatin and intracellular pH regulation by the Na+/H+ antiport of SV40-virus-transformed human MRC5 fibroblasts.
Topics: Carrier Proteins; Cell Line, Transformed; Cell Transformation, Viral; Cholesterol; Fibroblasts; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Mevalonic Acid; Simvastatin; Sodium-Hydrogen Exchangers | 1993 |
Dislipemia in patients undergoing continuous ambulatory peritoneal dialysis: pharmacological therapy (simvastatin) versus hemodialysis.
Topics: Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis; Retrospective Studies; Simvastatin; Uremia | 1993 |
The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Drug Evaluation; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Simvastatin | 1993 |
Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome.
Topics: Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; MELAS Syndrome; Middle Aged; Rhabdomyolysis; Simvastatin | 1993 |
Effects of simvastatin on apoB metabolism and LDL subfraction distribution.
Topics: Adult; Apolipoproteins B; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Topics: Anticholesteremic Agents; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Trimethylsilyl Compounds | 1993 |
Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cell Membrane; Cholesterol; Fatty Acids; Humans; Lens Cortex, Crystalline; Lens, Crystalline; Lovastatin; Microsomes; Middle Aged; Organ Culture Techniques; Pravastatin; Simvastatin | 1993 |
Effect of simvastatin on desaturase activities in liver from lean and obese Zucker rats.
Topics: Animals; Anticholesteremic Agents; Delta-5 Fatty Acid Desaturase; Fatty Acid Desaturases; Fatty Acids; Fatty Acids, Unsaturated; In Vitro Techniques; Linoleoyl-CoA Desaturase; Lovastatin; Male; Microsomes, Liver; Obesity; Phospholipids; Rats; Rats, Zucker; Simvastatin | 1993 |
Effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on triglyceride kinetics in chronically streptozotocin-diabetic rats.
Topics: Animals; Cholesterol; Chronic Disease; Diabetes Mellitus, Experimental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipids; Lovastatin; Male; Rats; Rats, Wistar; Reference Values; Simvastatin; Triglycerides | 1993 |
Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Mutation; Receptors, LDL; Simvastatin; South Africa | 1993 |
Simvastatin does not increase lipid peroxidation in uremic patients.
Topics: Adult; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lovastatin; Male; Malondialdehyde; Middle Aged; Simvastatin; Uremia | 1993 |
Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat.
Topics: Animals; Apolipoproteins; Apolipoproteins B; Cholestyramine Resin; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Rats; RNA, Messenger; Simvastatin | 1993 |
HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
Topics: Animals; Carotid Arteries; Cell Division; Cholesterol; Fatty Acids, Monounsaturated; Fluorescent Antibody Technique; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Indoles; Lovastatin; Male; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Reference Values; Simvastatin | 1993 |
Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion.
Topics: Adult; Aged; Apolipoprotein C-II; Apolipoproteins B; Apolipoproteins C; Apolipoproteins E; Cholesterol; Cholesterol, VLDL; Chylomicrons; Diterpenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipoprotein Lipase; Lovastatin; Middle Aged; Retinyl Esters; Simvastatin; Triglycerides; Vitamin A | 1993 |
Aldosterone secretion in patients treated with simvastatin and ACE inhibitors.
Topics: Aldosterone; Anticholesteremic Agents; Drug Interactions; Enalapril; Humans; Lovastatin; Simvastatin | 1993 |
Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
Topics: Aging; Animals; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lens, Crystalline; Lovastatin; Microsomes, Liver; Organ Culture Techniques; Pravastatin; Rats; Rats, Wistar; Simvastatin; Time Factors | 1993 |
Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects.
Topics: Adult; Apolipoproteins; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Electrophoresis, Polyacrylamide Gel; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Benzylamines; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Oxygenases; Simvastatin; Squalene; Squalene Monooxygenase; Thiophenes; Triglycerides; Tumor Cells, Cultured | 1993 |
Lipoprotein(a) plasma concentrations associated with lipolytic activities in eight kindreds with familial combined hyperlipidemia and normolipidemic subjects.
Topics: Adult; Aged; Aged, 80 and over; Fatty Acids; Female; Heparin; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Injections, Intravenous; Lipase; Lipolysis; Lipoprotein(a); Lovastatin; Male; Middle Aged; Simvastatin; Time Factors | 1993 |
[Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Risk Factors; Severity of Illness Index; Simvastatin | 1993 |
Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Drug Eruptions; Epidermis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Skin Diseases, Eczematous | 1993 |
Skin lesions due to treatment with simvastatin (Zocor)
Topics: Anticholesteremic Agents; Drug Eruptions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Topics: Cholesterol; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; RNA, Messenger; Simvastatin; Tumor Cells, Cultured; Up-Regulation | 1993 |
Beneficial effects of simvastatin may be due to non-lipid actions.
Topics: Anticholesteremic Agents; Arteriosclerosis; Coronary Disease; Humans; Lovastatin; Simvastatin | 1995 |
Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study.
Topics: Adult; Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diet Therapy; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1995 |
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts.
Topics: Animals; Blood Pressure; Dogs; Enzyme Inhibitors; Female; Hydroxymethylglutaryl CoA Reductases; Lovastatin; Male; Mitochondria, Heart; Myocardial Ischemia; Pravastatin; Simvastatin; Time Factors | 1995 |
Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
Topics: Animals; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Membrane Potentials; Muscle, Skeletal; Pravastatin; Rats; Rats, Wistar; Simvastatin | 1995 |
The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rat. off.
Topics: Animals; Cholesterol; Cholestyramine Resin; Cytosol; Diet; Enzyme Inhibitors; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Microsomes, Liver; Rats; Rats, Wistar; Simvastatin; Sterol Esterase; Sterol O-Acyltransferase | 1995 |
Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Endothelium, Vascular; Humans; Lovastatin; Male; Middle Aged; Reference Values; Simvastatin; Ultrasonography; Vasodilation | 1996 |
Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin.
Topics: Aged; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Mitochondria, Muscle; Mitochondrial Myopathies; Pravastatin; Simvastatin | 1995 |
Cost of lipid-lowering statin drugs.
Topics: Anticholesteremic Agents; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia.
Topics: Base Sequence; Blotting, Southern; Child; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Dietary Fats; Drug Therapy, Combination; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Molecular Sequence Data; Mutation; Pedigree; Receptors, LDL; Simvastatin | 1995 |
Cholesterol lowering and the risk of stroke.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Risk; Simvastatin | 1996 |
Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Neutrophil Activation; Pancreatic Elastase; Simvastatin; Thrombin; Thromboxanes | 1995 |
Mevalonate pathway and isoprenoids regulate human bronchial myocyte proliferation.
Topics: Bronchi; Cell Division; Diterpenes; Enzyme Inhibitors; Humans; Lovastatin; Lung; Mevalonic Acid; Muscle, Smooth; Simvastatin | 1995 |
Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mevalonic Acid; Microsomes, Liver; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
[The 4-S study--a turning point in the cholesterol debate. Work Group Lipids and Atherosclerosis of the Swiss Society for Cardiology].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Exogenous and endogenous sources of sterols in the culture-adapted procyclic trypomastigotes of Trypanosoma brucei.
Topics: Adaptation, Physiological; Animals; Culture Media; Endocytosis; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipoproteins, LDL; Lovastatin; Microscopy, Electron; Simvastatin; Sterols; Trypanosoma brucei brucei | 1995 |
Radiation reaction recall following simvastatin therapy: a new observation.
Topics: Anticholesteremic Agents; Female; Gallbladder Neoplasms; Humans; Lovastatin; Middle Aged; Radiodermatitis; Simvastatin; Skin; Time Factors | 1995 |
Treating hypercholesterolemia aggressively.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Humans; Hypercholesterolemia; Lovastatin; Practice Guidelines as Topic; Simvastatin | 1996 |
Statins, cholesterol, and mevalonate pathways?
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Mevalonic Acid; Simvastatin | 1996 |
Implementation of the 4S study in first myocardial infarction.
Topics: Anticholesteremic Agents; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Simvastatin | 1996 |
Simvastatin-oral anticoagulant interaction.
Topics: Acenocoumarol; Aged; Anticholesteremic Agents; Anticoagulants; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Simvastatin; Thrombosis | 1996 |
Primary prevention of stroke.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Oxidoreductases; Pravastatin; Simvastatin | 1996 |
Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.
Topics: Breast Neoplasms; Cell Cycle; Cell Line; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Estradiol; Estradiol Congeners; Estrogen Antagonists; Female; Fulvestrant; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; RNA, Messenger; Simvastatin; Tamoxifen; Tumor Cells, Cultured | 1996 |
Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Topics: Animals; Calcium; Cell Differentiation; Cell Division; Cells, Cultured; Cholesterol; Creatine Kinase; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoenzymes; Lovastatin; Mevalonic Acid; Muscle Proteins; Muscle, Skeletal; Phospholipids; Pravastatin; Rats; Rats, Wistar; Simvastatin | 1996 |
Are the effects of cholesterol lowering drugs always equal?
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Male; Simvastatin | 1996 |
The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.
Topics: Adenosine Triphosphate; Adult; Anticholesteremic Agents; Antioxidants; Cholesterol, LDL; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Phosphocreatine; Simvastatin; Ubiquinone | 1996 |
17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation.
Topics: Base Sequence; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Cycle; Cell Line; Cell Nucleus; Cholesterol; Enzyme Activation; Enzyme Inhibitors; Estradiol; Female; G1 Phase; Genes, fos; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Oligodeoxyribonucleotides; Proto-Oncogene Mas; Proto-Oncogene Proteins c-fos; Receptors, Estradiol; Simvastatin; Transcriptional Activation; Tumor Cells, Cultured | 1996 |
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
[Simvastatin].
Topics: Anticholesteremic Agents; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1996 |
17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells.
Topics: Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Dactinomycin; DNA; Estradiol; Female; G1 Phase; Gene Expression; Genes, Reporter; Humans; Lovastatin; Luciferases; Oncogene Proteins; Phosphorylation; Proto-Oncogene Proteins; Retinoblastoma Protein; RNA, Messenger; Simvastatin; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1996 |
[Current developments in prevention of coronary heart disease].
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Survival Rate | 1996 |
Photosensitivity to simvastatin with an unusual response to photopatch and photo tests.
Topics: Dermatitis, Photoallergic; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Patch Tests; Simvastatin | 1995 |
Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro.
Topics: Cells, Cultured; Cholesterol; Culture Media; Enzyme Inhibitors; Female; Follicle Stimulating Hormone; Granulosa Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Luteinizing Hormone; Pravastatin; Progesterone; Simvastatin | 1996 |
[Clinically manifest liver lesions during use of simvastatin].
Topics: Aged; Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jaundice; Lovastatin; Male; Middle Aged; Simvastatin | 1996 |
Incubation of porcine high-density lipoprotein with the apical surface of LLC-PK1 renal tubular cells sustains the properties of orientated monolayers.
Topics: Albumins; Animals; Cell Membrane; Cell Membrane Permeability; Cells, Cultured; Hypolipidemic Agents; Inulin; Kidney Tubules, Proximal; Lipoproteins, HDL; LLC-PK1 Cells; Lovastatin; Mevalonic Acid; Monosaccharide Transport Proteins; Nephrotic Syndrome; Simvastatin; Swine | 1996 |
[The cholesterol hypothesis has been proved true at last].
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Cholesterol; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Infarction; Simvastatin | 1995 |
Addressing the spectrum of hypercholesterolemia.
Topics: Adult; Aged; Algorithms; Anticholesteremic Agents; Coronary Disease; Diet, Fat-Restricted; Exercise; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin; Smoking Cessation | 1996 |
[Limitations of interventions against hypercholesterolemia].
Topics: Adult; Age Factors; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cost-Benefit Analysis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Risk Factors; Sex Factors; Simvastatin | 1996 |
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin | 1996 |
[Zocor lobby?].
Topics: Anticholesteremic Agents; Humans; Hypolipidemic Agents; Lovastatin; Simvastatin | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood.
Topics: Adolescent; Child; Child, Preschool; Cholesterol; Combined Modality Therapy; Creatinine; Diet; Drug Resistance; Enzyme Inhibitors; Feeding Behavior; Female; Glucocorticoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Infant; Lovastatin; Male; Nephrotic Syndrome; Retrospective Studies; Serum Albumin; Simvastatin; Triglycerides | 1996 |
Influence on HMG-COA reductase inhibitors on plaque-forming cell (PFC) response in mice.
Topics: Animals; Antibody Formation; Enzyme Inhibitors; Female; Hemolytic Plaque Technique; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred BALB C; Pravastatin; Simvastatin | 1995 |
Effects of systemic treatment with statins on skin barrier function and stratum corneum water-holding capacity.
Topics: Administration, Oral; Adult; Analysis of Variance; Anticholesteremic Agents; Cell Membrane Permeability; Epidermis; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Water Loss, Insensible | 1996 |
Cerebrotendinous xanthomatosis: a family study of sterol 27-hydroxylase mutations and pharmacotherapy.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Chenodeoxycholic Acid; Child; Child, Preschool; Cholagogues and Choleretics; Cholestanetriol 26-Monooxygenase; Cytochrome P-450 Enzyme System; England; Exons; Female; Humans; Hyperlipidemia, Familial Combined; Lovastatin; Male; Middle Aged; Musculoskeletal Diseases; Mutation; Pedigree; Simvastatin; Steroid Hydroxylases; Tendons; Xanthomatosis | 1996 |
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Lovastatin; Microsomes, Liver; Mixed Function Oxygenases; Pravastatin; Simvastatin; Stereoisomerism; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 1996 |
Determination of apolipoprotein mRNA levels by ribonuclease protection assay.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Cholestyramine Resin; DNA, Complementary; Genetic Vectors; Lipase; Liver; Lovastatin; Rats; Ribonucleases; RNA Probes; RNA, Antisense; RNA, Double-Stranded; RNA, Messenger; RNA, Transfer; Simvastatin | 1996 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Coronary Disease; Diet; Factor VII; Humans; Hyperlipidemias; Lovastatin; Risk Factors; Simvastatin; Smoking | 1995 |
Dermatomyositis with lung involvement in a patient treated with simvastatin.
Topics: Aged; Anticholesteremic Agents; Biopsy; Dermatomyositis; Fatal Outcome; Female; Humans; Hypercholesterolemia; Lovastatin; Lung Diseases; Muscle, Skeletal; Simvastatin | 1995 |
Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Cyclosporine; Drug Interactions; Fenofibrate; Gemfibrozil; Heart Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Lovastatin; Probucol; Simvastatin | 1996 |
Interstitial lung disease with pleural effusion caused by simvastin.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Diseases, Interstitial; Male; Middle Aged; Pleural Effusion; Radiography; Simvastatin | 1996 |
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Topics: Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Time Factors | 1995 |
Improved survival with statin therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
Cost-benefit analysis of lipid lowering therapy.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin; Sweden | 1996 |
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
Topics: Anticholesteremic Agents; Case-Control Studies; Clinical Trials as Topic; Coronary Disease; Cost of Illness; Cost-Benefit Analysis; Evaluation Studies as Topic; Humans; Hypercholesterolemia; Lovastatin; Prospective Studies; Reproducibility of Results; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 1996 |
Reasons for stopping drugs are monitored in New Zealand.
Topics: Adverse Drug Reaction Reporting Systems; Bezafibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; New Zealand; Product Surveillance, Postmarketing; Simvastatin | 1996 |
Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells.
Topics: Benzamides; Cholesterol; Cyclohexylamines; Enzyme Inhibitors; Epoxy Compounds; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Intramolecular Transferases; Isomerases; Liver; Lovastatin; Simvastatin; Squalene; Tumor Cells, Cultured | 1996 |
Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Binding, Competitive; Cells, Cultured; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Receptors, LDL; Simvastatin; Triglycerides | 1996 |
Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate.
Topics: Administration, Oral; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cricetinae; Dietary Fats; Eating; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver; Lovastatin; Male; Mevalonic Acid; Necrosis; Simvastatin | 1995 |
Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture.
Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins; Bile Acids and Salts; Cell Line; Cell Survival; Cholesterol; Female; Humans; Hypolipidemic Agents; Lipid Metabolism; Lipoproteins, HDL; Liver; Liver Neoplasms, Experimental; Lovastatin; Male; Proline; Simvastatin; Tumor Cells, Cultured | 1996 |
Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apoproteins; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools.
Topics: Apolipoproteins B; Carcinoma, Hepatocellular; Enzyme Inhibitors; Furans; Humans; Hypolipidemic Agents; Lipid Metabolism; Lovastatin; Simvastatin; Triglycerides; Tumor Cells, Cultured | 1996 |
Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.
Topics: Aged; Antifungal Agents; Drug Interactions; Humans; Hypolipidemic Agents; Itraconazole; Lovastatin; Male; Rhabdomyolysis; Simvastatin | 1996 |
Japanese and American reports of randomized trials: differences in the reporting of adverse effects.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Cross-Cultural Comparison; Diclofenac; Humans; Japan; Lovastatin; Randomized Controlled Trials as Topic; Simvastatin; United States | 1996 |
Cholesterol lowering and cerebrospinal fluid neurotransmitters: increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Humans; Lovastatin; Male; Neurotransmitter Agents; Reference Values; Simvastatin; Tetragastrin | 1996 |
The statin trials: closing arguments in the case against cholesterol?
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin | 1996 |
Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Topics: Cyclosporine; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interleukin-2; Killer Cells, Natural; Lovastatin; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocytes; Mevalonic Acid; Phytohemagglutinins; Pravastatin; Simvastatin; Sterols | 1996 |
The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Apoproteins; Cholesterol, HDL; Diet, Fat-Restricted; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Drug interaction between simvastatin and cholestyramine in vitro and in vivo.
Topics: Animals; Anticholesteremic Agents; Cholestyramine Resin; Chromatography, High Pressure Liquid; Drug Interactions; Drug Stability; Hydrolysis; Lovastatin; Male; Rats; Rats, Wistar; Simvastatin; Spectrophotometry, Ultraviolet | 1996 |
Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism.
Topics: Aged; Anticholesteremic Agents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Indoles; Lovastatin; Male; Middle Aged; Neuromuscular Diseases; Simvastatin; Thyroxine | 1996 |
Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Circadian Rhythm; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Reproducibility of Results; Simvastatin; Xanthomatosis, Cerebrotendinous | 1996 |
Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation.
Topics: Animals; Anticholesteremic Agents; Bromodeoxyuridine; Carotid Arteries; Cell Division; DNA Replication; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorescent Antibody Technique, Indirect; Fluvastatin; Image Processing, Computer-Assisted; Indoles; Infusion Pumps, Implantable; Injections, Intraperitoneal; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Simvastatin | 1995 |
Simvastatin releases Ca2+ from a thapsigargin-sensitive pool and inhibits InsP3-dependent Ca2+ mobilization in vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Calcium; Calcium-Transporting ATPases; Cells, Cultured; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol 1,4,5-Trisphosphate; Lovastatin; Muscle, Smooth, Vascular; Rats; Simvastatin; Thapsigargin | 1996 |
Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Death, Sudden, Cardiac; Humans; Lovastatin; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1996 |
Cost effectiveness of lowering cholesterol. Study greatly underestimates the cost effectiveness of statin treatment.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Humans; Hypercholesterolemia; Lovastatin; Risk Factors; Simvastatin | 1996 |
Cost effectiveness of lowering cholesterol. Statin treatment should be started early.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Drug-interaction-induced rhabdomyolysis.
Topics: Aged; Anticholesteremic Agents; Antifungal Agents; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Itraconazole; Kidney Transplantation; Lovastatin; Male; Rhabdomyolysis; Simvastatin | 1996 |
HMG-CoA reductase inhibitor treatment in renal insufficiency.
Topics: Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lovastatin; Pravastatin; Rhabdomyolysis; Simvastatin | 1996 |
Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle.
Topics: Acetic Acid; Adenosine Triphosphate; Anticholesteremic Agents; Cell Division; Cell Survival; Cells, Cultured; DNA; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mitochondria; Muscle, Skeletal; Oxidoreductases; Pravastatin; Simvastatin; Sterols | 1996 |
Acute on chronic renal failure induced by simvastatin.
Topics: Acute Disease; Cardiovascular Diseases; Chronic Disease; Humans; Lovastatin; Male; Middle Aged; Renal Insufficiency; Simvastatin | 1996 |
Beneficial effects of statins.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Fibrinogen; Humans; Lovastatin; Pravastatin; Serotonin; Simvastatin | 1996 |
Beneficial effects of statins.
Topics: Anticholesteremic Agents; Fibrinogen; Humans; Hypercholesterolemia; Lovastatin; Platelet Aggregation; Pravastatin; Simvastatin | 1996 |
[Effect of hypercholesteremia on vascular endothelial function and albumin excretion rate in patients with diabetes mellitus].
Topics: Albuminuria; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Tissue Plasminogen Activator; von Willebrand Factor | 1996 |
[Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells].
Topics: Bone Marrow Cells; Enzyme Inhibitors; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Effect of simvastatin on ejection fraction in cardiac transplant recipients.
Topics: Blood Pressure; Calcium Channel Blockers; Echocardiography; Female; Heart; Heart Transplantation; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Prospective Studies; Simvastatin; Stroke Volume | 1996 |
Simvastatin inhibits the division and induces neurite-like outgrowth in PC12 cells.
Topics: Acyl Coenzyme A; Animals; Cell Division; Enzyme Inhibitors; Lovastatin; Mevalonic Acid; Neurites; PC12 Cells; Pravastatin; Rats; Simvastatin | 1996 |
Effects of simvastatin on the number and composition of apoproteinB-containing lipoproteins in hypercholesterolemia: analysis of apoproteinB in each lipoprotein fraction by highly sensitive latex method.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Latex Fixation Tests; Lipoproteins; Lovastatin; Male; Middle Aged; Sensitivity and Specificity; Simvastatin; Triglycerides; Ultracentrifugation | 1996 |
Lipid-lowering for prevention of coronary heart disease: what policy now?
Topics: Adult; Age Factors; Aged; Cholesterol; Coronary Disease; Costs and Cost Analysis; Female; Health Policy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Risk; Simvastatin; United Kingdom | 1996 |
Simultaneous determination of plasma mevalonate and 7alpha-hydroxy-4-cholesten-3-one levels in hyperlipoproteinemia: convenient indices for estimating hepatic defects of cholesterol and bile acid syntheses and biliary cholesterol supersaturation.
Topics: Adult; Aged; Bile; Bile Acids and Salts; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemias; Intestinal Absorption; Liver; Lovastatin; Male; Mevalonic Acid; Middle Aged; RNA, Messenger; Simvastatin | 1997 |
Insulin-like growth factor I enhancement of steroidogenesis by bovine granulosa cells and thecal cells: dependence on de novo cholesterol synthesis.
Topics: Androstenedione; Animals; Anticholesteremic Agents; Cattle; Cell Division; Cells, Cultured; Cholesterol; Cholesterol Side-Chain Cleavage Enzyme; Female; Granulosa Cells; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor I; Lovastatin; Luteinizing Hormone; Mevalonic Acid; Ovary; Progesterone; Simvastatin; Stimulation, Chemical; Theca Cells | 1996 |
Simvastatin increases plasma NO2- and NO3- levels in patients with hypercholesterolemia.
Topics: Administration, Oral; Anticholesteremic Agents; Cholesterol, LDL; Cholesterol, VLDL; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Nitrates; Nitrites; Simvastatin; Ultracentrifugation | 1996 |
Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil.
Topics: Drug Synergism; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Rhabdomyolysis; Risk; Simvastatin | 1996 |
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Cost of Illness; Cost-Benefit Analysis; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Markov Chains; Middle Aged; Proportional Hazards Models; Sex Factors; Simvastatin; Value of Life | 1997 |
Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia.
Topics: Anesthesia; Animals; Bezafibrate; Calcium; Creatine Kinase; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Pravastatin; Rats; Rats, Wistar; Simvastatin; Urethane | 1997 |
Simvastatin inhibits myointimal hyperplasia following carotid artery injury in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Carotid Arteries; Cell Division; Cholesterol, Dietary; Diet, Atherogenic; Hyperplasia; Lovastatin; Rabbits; Simvastatin; Tunica Intima | 1996 |
[Increase of myocardial perfusion during antilipemic treatment in patients with ischemic cardiopathy].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Circulation; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Pilot Projects; Simvastatin; Tomography, Emission-Computed, Single-Photon | 1996 |
Effect of lowering serum cholesterol on the composition of surfactant in adult rat lung.
Topics: Adenine; Animals; Anticholesteremic Agents; Cholesterol; In Vitro Techniques; Lipids; Lovastatin; Lung; Lung Compliance; Male; Organ Size; Phospholipids; Proteolipids; Pulmonary Surfactant-Associated Proteins; Pulmonary Surfactants; Rats; Rats, Inbred Strains; Simvastatin; Surface Tension | 1997 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss | 1997 |
Cost-benefit analysis of lipid lowering therapy.
Topics: Cost-Benefit Analysis; Drug Monitoring; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin; Survival Rate | 1997 |
Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
Topics: Animals; Apolipoprotein B-100; Apolipoproteins A; Apolipoproteins B; Cats; Child, Preschool; Cholesterol, LDL; Female; Follow-Up Studies; Heterozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Immunoblotting; Lovastatin; Male; Middle Aged; Pedigree; Phenotype; Receptors, LDL; Simvastatin; Treatment Outcome | 1997 |
Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Survival; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; HSP70 Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Muscle, Smooth, Vascular; Simvastatin; Tricarboxylic Acids | 1997 |
A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Enzyme Inhibitors; Hematopoietic Stem Cells; HL-60 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia, Myeloid; Lovastatin; Pravastatin; Simvastatin | 1997 |
The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Diabetic Angiopathies; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Triglycerides | 1997 |
Simvastatin further enhances the hypocholesterolemic effect of soy protein in rabbits.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Drug Synergism; Eating; Enzyme Inhibitors; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Liver; Lovastatin; Male; Rabbits; Simvastatin; Soybean Proteins; Triglycerides | 1997 |
Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Fibrinogen; Follow-Up Studies; Hemorheology; Humans; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Simvastatin | 1996 |
Microsample determination of lovastatin and its hydroxy acid metabolite in mouse and rat plasma by liquid chromatography/ionspray tandem mass spectrometry.
Topics: Animals; Calibration; Chromatography, Liquid; Data Collection; Hydroxylation; Hypolipidemic Agents; Lovastatin; Mass Spectrometry; Mice; Rats; Simvastatin | 1997 |
Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Enzyme Inhibitors; Female; Finland; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Morbidity; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Simvastatin | 1997 |
New treatment strategy for Smith-Lemli-Opitz syndrome.
Topics: Anticholesteremic Agents; Dehydrocholesterols; Enzyme Inhibitors; Exchange Transfusion, Whole Blood; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Lovastatin; Simvastatin; Smith-Lemli-Opitz Syndrome | 1997 |
[Lowering LDL cholesterol with Simvastatin. Also, economically reasonable!].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Costs; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1995 |
[Zocor and Sotacor].
Topics: Anti-Arrhythmia Agents; Anticholesteremic Agents; Humans; Lovastatin; Medical Errors; Simvastatin; Sotalol; Terminology as Topic | 1997 |
Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
Topics: Anticholesteremic Agents; Cell Division; Cells, Cultured; Cholesterol; DNA; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; ras Proteins; Simvastatin | 1997 |
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Muscular Diseases; Rhabdomyolysis; Simvastatin | 1997 |
Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.
Topics: Acetates; Animals; Apolipoproteins; Benzophenones; Cholesterol; Cricetinae; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl CoA Reductases; Intramolecular Transferases; Lanosterol; Lipoproteins; Liver; Lovastatin; Myocardium; Osmolar Concentration; Saimiri; Simvastatin; Squalene; Swine; Swine, Miniature; Triglycerides; Tumor Cells, Cultured; Ubiquinone | 1997 |
The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study.
Topics: Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Simvastatin | 1997 |
Polymyositis associated with simvastatin.
Topics: Adult; Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Male; Methylprednisolone; Polymyositis; Simvastatin | 1997 |
Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation.
Topics: Animals; Aorta; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Lovastatin; Male; Mevalonic Acid; Muscle, Smooth, Vascular; Rats; Rats, Sprague-Dawley; Simvastatin | 1997 |
Simvastatin reduces forearm vascular responsiveness to norepinephrine.
Topics: Anticholesteremic Agents; Brachial Artery; Cholesterol; Endothelium, Vascular; Follow-Up Studies; Forearm; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Norepinephrine; Simvastatin; Vasoconstriction; Vasoconstrictor Agents | 1997 |
Simvastatin-induced myopathy in a patient treated for hypercholesterolemia. Morphological aspects.
Topics: Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Simvastatin | 1997 |
Stain therapy and reduced incidence of stroke. Implications of cholesterol-lowering therapy for cerebrovascular disease.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Simvastatin | 1997 |
Results of recent large cholesterol-lowering trials and implications for clinical management.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Randomized Controlled Trials as Topic; Simvastatin | 1997 |
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1997 |
Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Topics: Animals; Bile Ducts; Blood Pressure; Double-Blind Method; Hemodynamics; Hypertension, Portal; Hypolipidemic Agents; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Lovastatin; Male; Pentoxifylline; Portal Vein; Portasystemic Shunt, Surgical; Rats; Rats, Sprague-Dawley; Reference Values; Renal Circulation; Simvastatin; Spironolactone; Vascular Resistance | 1997 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Myocardial Ischemia; Risk Factors; Simvastatin | 1997 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Myocardial Infarction; Pravastatin; Simvastatin | 1997 |
Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
Topics: Anticholesteremic Agents; Cholesterol; Cytochrome P-450 CYP2D6; Debrisoquin; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Polymorphism, Genetic; Simvastatin | 1997 |
Simvastatin in the secondary prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1997 |
The 4S study: a critical review.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Simvastatin | 1997 |
The 4S study: a critical review.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin | 1997 |
Determination of simvastatin and its active metabolite in human plasma by column-switching high-performance liquid chromatography with fluorescence detection after derivatization with 1-bromoacetylpyrene.
Topics: Anticholesteremic Agents; Chromatography, High Pressure Liquid; Fluorescent Dyes; Humans; Lovastatin; Pyrenes; Sensitivity and Specificity; Simvastatin; Spectrometry, Fluorescence | 1997 |
Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin.
Topics: Animals; Anticholesteremic Agents; Carotid Arteries; Cattle; Cell Division; Cells, Cultured; Cholesterol; Endothelium, Vascular; Enzyme Inhibitors; Growth Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Membrane Fluidity; Membrane Lipids; Simvastatin; Stimulation, Chemical | 1997 |
[Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase].
Topics: Electromyography; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Middle Aged; Mitochondrial Myopathies; Simvastatin | 1997 |
Asymptomatic cholesteryl ester storage disease in an adult controlled with simvastatin.
Topics: Adult; Anticholesteremic Agents; Cholesterol Ester Storage Disease; Enzyme Inhibitors; Fibroblasts; Humans; Lipids; Lipoproteins, LDL; Liver; Lovastatin; Male; Simvastatin; Sterol Esterase; Transaminases | 1997 |
The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lovastatin; Male; Middle Aged; Simvastatin; Ubiquinone; Vitamin E | 1997 |
Manipulation of the fate of long chain polyunsaturated fatty acids in cultured cells.
Topics: Arachidonic Acid; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line; Cholesterol; Enzyme Inhibitors; Ethanol; Fatty Acids, Unsaturated; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linoleic Acid; Linoleic Acids; Liver Neoplasms; Lovastatin; Mevalonic Acid; Monocytes; Neuroblastoma; Simvastatin; Tumor Cells, Cultured | 1997 |
Effects of simvastatin on the metabolism of polyunsaturated fatty acids and on glycerolipid, cholesterol, and de novo lipid synthesis in THP-1 cells.
Topics: Acetates; Cell Line; Cholesterol; Diterpenes; Enzyme Inhibitors; Esterification; Fatty Acids, Unsaturated; Glycerol; Glycolipids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Linoleic Acid; Linoleic Acids; Lipids; Lovastatin; Mevalonic Acid; Monocytes; Simvastatin | 1997 |
HMG-CoA reductase inhibitor suppression of glomerular cell proliferation in rats with anti-Thy-1.1 nephritis.
Topics: Actins; Animals; Cell Division; Cells, Cultured; Glomerular Mesangium; Glomerulonephritis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Isoantibodies; Lovastatin; Macrophages; Male; Muscle, Smooth; Rats; Rats, Wistar; Simvastatin | 1997 |
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Topics: Animals; Arteriosclerosis; Cell Division; Cholesterol; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Macrophages; Male; Mevalonic Acid; Mice; Mice, Inbred C3H; Oxidation-Reduction; Pravastatin; Simvastatin | 1997 |
In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.
Topics: Animals; Enzyme Inhibitors; Glioma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipoproteins, LDL; Lovastatin; Mice; Mice, Nude; Simvastatin; Tumor Cells, Cultured | 1997 |
Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Antifungal Agents; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Ketoconazole; Lipids; Lipoprotein(a); Lovastatin; Male; Middle Aged; Simvastatin; Treatment Outcome | 1997 |
The role of nutritional modifications in the prevention of macrovascular complications of diabetes.
Topics: Antioxidants; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diet Therapy; Energy Intake; Energy Metabolism; Humans; Lovastatin; Minerals; Obesity; Simvastatin; Vitamins | 1997 |
[Data on cholesterol level screening of patients with ischemic heart disease in the light of the Scandinavian Simvastatin Survival Study].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Death, Sudden, Cardiac; Drug Costs; Female; Humans; Hungary; Hypercholesterolemia; Lovastatin; Male; Mass Screening; Middle Aged; Myocardial Ischemia; Prevalence; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 1997 |
[The mechanism of action of hypolipidemic drugs].
Topics: Adipose Tissue; Anticholesteremic Agents; Cholesterol, LDL; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipase; Lipid Peroxidation; Lipoproteins, VLDL; Liver; Lovastatin; Microbodies; Nuclear Proteins; Pravastatin; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Simvastatin; Transcription Factors | 1997 |
Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Animals; Dogs; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipids; Liver; Lovastatin; Male; Pravastatin; Quinolines; Rats; Rats, Wistar; Simvastatin; Sterols | 1997 |
Petechial eruptions due to simvastatin in a patient with diabetes mellitus and liver cirrhosis.
Topics: Anticholesteremic Agents; Biopsy, Needle; Diabetes Mellitus, Type 1; Humans; Hypercholesterolemia; Japan; Liver Cirrhosis; Lovastatin; Male; Middle Aged; Purpura; Simvastatin | 1997 |
HMG-CoA reductase inhibitors reduce stroke risk, total mortality.
Topics: Cerebrovascular Disorders; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Mortality; Pravastatin; Simvastatin | 1997 |
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
Topics: Cell Adhesion; Cells, Cultured; Endothelium, Vascular; Fluorescent Antibody Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Macrophage-1 Antigen; Male; Monocytes; Simvastatin | 1997 |
Cholesterol lowering with statin drugs: evidence in women.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Female; Humans; Lovastatin; Risk; Simvastatin | 1997 |
[Favorable effect of treatment with statins on the intima of the common carotid artery in patients with familial hyperlipoproteinemia].
Topics: Anticholesteremic Agents; Carotid Artery, Common; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Lovastatin; Middle Aged; Simvastatin; Tunica Intima; Ultrasonography | 1997 |
Lipid-lowering with statins and fibrinolytic parameters.
Topics: Cholesterol, LDL; Fibrinolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1997 |
Re: Greying of America will foster new strategies in oncology.
Topics: Aging; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Doxorubicin; Drug Synergism; Humans; Lovastatin; Melanoma, Experimental; Mice; Simvastatin | 1998 |
The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell.
Topics: Animals; Anticholesteremic Agents; Clofibric Acid; Female; Fibric Acids; Gastric Mucosa; Gastrins; Gene Expression; Histidine Decarboxylase; Hypolipidemic Agents; Lovastatin; Male; Microbodies; Rats; Rats, Inbred F344; Rats, Wistar; Simvastatin; Somatostatin; Species Specificity | 1998 |
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Topics: Animals; Aorta; Arteriosclerosis; Cattle; Cells, Cultured; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Nitric Oxide Synthase; RNA, Messenger; Saphenous Vein; Simvastatin; Transcription, Genetic | 1998 |
Do statin drugs lower the risk of stroke?
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Lovastatin; Meta-Analysis as Topic; Pravastatin; Risk Factors; Simvastatin | 1998 |
Lipid-lowering therapy in low-risk patients.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Pravastatin; Risk Factors; Simvastatin | 1998 |
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Diterpenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Lovastatin; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Simvastatin; Tumor Cells, Cultured; Up-Regulation | 1998 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
Inhibition of hepatocytic autophagy by adenosine, aminoimidazole-4-carboxamide riboside, and N6-mercaptopurine riboside. Evidence for involvement of amp-activated protein kinase.
Topics: Acetates; Adenosine; Adenosine Triphosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antimetabolites; Autophagy; Cells, Cultured; Cholesterol; Drug Synergism; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Lovastatin; Male; Multienzyme Complexes; Nucleosides; Nucleotides; Pentostatin; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Ribonucleotides; Simvastatin; Thioinosine; Tubercidin | 1998 |
[Is combined statin and fibrate therapy indicated in the management of mixed hyperlipidemia?].
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Simvastatin | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anti-Arrhythmia Agents; Anticholesteremic Agents; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 1999 |
Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Bile Acids and Salts; Cell Fractionation; Cells, Cultured; Cholesterol; Cholesterol Esters; Cholesterol, LDL; Cholesterol, VLDL; Cricetinae; Fatty Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iodine Radioisotopes; Lipoproteins; Liver; Lovastatin; Male; Mesocricetus; Oleic Acid; Simvastatin; Triglycerides | 1999 |
Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
Topics: Cardiovascular Diseases; Cluster Analysis; Costs and Cost Analysis; Databases, Factual; Diagnosis-Related Groups; Female; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Medical Audit; Middle Aged; Pravastatin; Product Surveillance, Postmarketing; Registries; Retrospective Studies; Severity of Illness Index; Simvastatin; United States | 1999 |
The 4S study and its pharmacoeconomic implications.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Humans; Lovastatin; Scandinavian and Nordic Countries; Simvastatin | 1996 |
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Benzimidazoles; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Ketoconazole; Kinetics; Lovastatin; Mibefradil; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyridines; Pyrroles; Simvastatin; Tetrahydronaphthalenes | 1999 |
Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
Topics: Adolescent; Adult; Creatine Kinase; Dose-Response Relationship, Drug; Exercise; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pain; Pravastatin; Prognosis; Risk Assessment; Simvastatin; Sports | 1999 |
Human lens cholesterol concentrations in patients who used lovastatin or simvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol; Chromatography, Gas; Humans; Lens Cortex, Crystalline; Lens Nucleus, Crystalline; Lovastatin; Middle Aged; Simvastatin | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Protein Prenylation; Pyrroles; Rats; Simvastatin | 1999 |
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Topics: Angiotensin II; Animals; Animals, Newborn; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; Cell Division; Cell Membrane; Cells, Cultured; DNA; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Myocardium; Naphthalenes; Pravastatin; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; RNA; Simvastatin | 1999 |
Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Cholesterol, Dietary; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Organ Size; Pravastatin; Simvastatin; Time Factors; Transaminases; Triglycerides | 1999 |
Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Topics: Cell Division; Cells, Cultured; Collagen; DNA; Extracellular Matrix Proteins; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Simvastatin; Thrombospondins; Transcription, Genetic; Transforming Growth Factor beta | 1999 |
Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
Topics: Adrenal Glands; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Transformed; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Flow Cytometry; G1 Phase; Genes, ras; Indoles; Lovastatin; Mitogen-Activated Protein Kinases; Protein Prenylation; ras Proteins; Rats; S Phase; Simvastatin; Time Factors | 1999 |
Stimulation of bone formation in vitro and in rodents by statins.
Topics: Animals; Bone Density; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Line; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mice; Mice, Inbred ICR; Organ Culture Techniques; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Promoter Regions, Genetic; Rats; Recombinant Proteins; Simvastatin; Skull; Transfection; Transforming Growth Factor beta | 1999 |
Cholesterol-lowering drugs may boost bones.
Topics: Animals; Anticholesteremic Agents; Bone Density; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Clinical Trials as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Osteogenesis; Osteoporosis; Rats; Simvastatin; Transforming Growth Factor beta | 1999 |
Relationship between inhibition of mevalonate biosynthesis and reduced fertility in laying hens.
Topics: Animals; Atorvastatin; Chickens; Enzyme Inhibitors; Female; Fertility; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insemination, Artificial; Lovastatin; Mevalonic Acid; Oviposition; Pyrroles; Simvastatin | 1999 |
Characterization of peroxisomal 3-hydroxy-3-methylglutaryl coenzyme A reductase in UT2 cells: sterol biosynthesis, phosphorylation, degradation, and statin inhibition.
Topics: Acetic Acid; Acetyl-CoA C-Acetyltransferase; Adenosine Triphosphate; Animals; Carbon Radioisotopes; Cell Cycle; Cell Survival; CHO Cells; Cholesterol; Clone Cells; Cricetinae; Deuterium Oxide; Enzyme Activation; Fatty Acids, Unsaturated; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Synthase; Lactones; Leupeptins; Lovastatin; Mevalonic Acid; Peroxisomes; Phosphorylation; Simvastatin; Tritium | 2000 |
Effect of statin therapy on restenosis after coronary stent implantation.
Topics: Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease-Free Survival; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperplasia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Stents; Time Factors; Tunica Intima | 2000 |
Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells.
Topics: Anti-Bacterial Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Cloning, Molecular; Disulfides; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Indole Alkaloids; Lovastatin; Mevalonic Acid; Osteoporosis; Osteosarcoma; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured | 2000 |
Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture.
Topics: Animals; Antigens, Nuclear; Aorta; Apoptosis; Cattle; CDC2-CDC28 Kinases; Cell Division; Cell Survival; Cells, Cultured; Coronary Vessels; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Ki-67 Antigen; Lovastatin; Mevalonic Acid; Mice; Mice, Transgenic; Muscle, Smooth, Vascular; Nuclear Proteins; Pravastatin; Protein Serine-Threonine Kinases; Rats; Retinoblastoma Protein; Simvastatin; Tumor Suppressor Protein p53 | 2000 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |
Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Topics: Administration, Oral; Algorithms; Cholesterol, LDL; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Models, Economic; Pravastatin; Simvastatin; Treatment Outcome | 1999 |
Inhibition of monocyte chemotactic protein-1 synthesis by statins.
Topics: Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Lovastatin; Mevalonic Acid; Monocytes; Pravastatin; RNA, Messenger; Simvastatin | 2000 |
The formation and secretion of cholesteryl esters in rat hepatocytes are reduced by lovastatin and simvastatin.
Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Cholesterol Esters; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1998 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic.
Topics: Aged; Ambulatory Care; Blood Glucose; Dose-Response Relationship, Drug; Female; Hospitals, Veterans; Humans; Hyperlipidemias; Liver; Lovastatin; Male; New Mexico; Pharmacy Service, Hospital; Prospective Studies; Simvastatin | 2000 |
Oxidation of HMG-CoA reductase inhibitors by tert-butoxyl and 1, 1-diphenyl-2-picrylhydrazyl radicals: model reactions for predicting oxidatively sensitive compounds during preformulation.
Topics: Bepridil; Biphenyl Compounds; Butanols; Free Radicals; Hydrazines; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Molecular Conformation; Oxidation-Reduction; Picrates; Simvastatin; Temperature | 2000 |
Inhibitory effect of statins on fetal bovine serum-induced proliferation of rat cultured mesangial cells and correlation between their inhibitory effect and transport characteristics.
Topics: Animals; Cattle; Cell Division; Cells, Cultured; Fetal Blood; Glomerular Mesangium; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Male; Pravastatin; Rats; Rats, Sprague-Dawley; Serum Albumin, Bovine; Simvastatin; Temperature | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Lovastatin and simvastatin are modulators of the proteasome.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cysteine Endopeptidases; Growth Inhibitors; Lovastatin; Mice; Multienzyme Complexes; Proteasome Endopeptidase Complex; Simvastatin; Tumor Cells, Cultured | 2000 |
[Which statin is more efficient? Concepts and applications in economic evaluation].
Topics: Anticholesteremic Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Simvastatin | 2000 |
Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Cholesterol Esters; Female; Heptanoic Acids; Lipoproteins, VLDL; Liver; Lovastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2000 |
Fragmentation study of simvastatin and lovastatin using electrospray ionization tandem mass spectrometry.
Topics: Chemical Phenomena; Chemistry, Physical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Molecular Structure; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2001 |
A new simvastatin (mevinolin)-resistance marker from Haloarcula hispanica and a new Haloferax volcanii strain cured of plasmid pHV2.
Topics: DNA, Bacterial; Drug Resistance, Microbial; Genes, Bacterial; Genetic Markers; Haloarcula; Haloferax volcanii; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Molecular Sequence Data; Plasmids; Point Mutation; Promoter Regions, Genetic; Recombination, Genetic; Sequence Alignment; Sequence Analysis, DNA; Simvastatin | 2001 |
Is a statin a statin?
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 2001 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Chromatographic purification of some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Chromatography, High Pressure Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Spectrophotometry, Ultraviolet | 2001 |
Statins and dementia.
Topics: Anticholesteremic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Selection Bias; Simvastatin | 2001 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).
Topics: Actins; Blotting, Northern; Cell Line; Connective Tissue Growth Factor; Cytoskeleton; Dose-Response Relationship, Drug; Gene Expression Regulation; Growth Substances; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lovastatin; Lysophospholipids; Mevalonic Acid; Polyisoprenyl Phosphates; Pravastatin; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; RNA, Messenger; Sesquiterpenes; Simvastatin | 2001 |
In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor.
Topics: Antineoplastic Agents; Cell Division; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Neovascularization, Pathologic; Pyridines; Simvastatin; Tumor Cells, Cultured | 2001 |
Hyperlipidaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperlipidemias; Lovastatin; Nitric Oxide; Pravastatin; Rabbits; Simvastatin | 2001 |
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Dogs; Drug Combinations; Drug Synergism; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Lovastatin; Male; Pravastatin; Simvastatin; Time Factors | 2001 |
The antiinflammatory effects of statins.
Topics: Coronary Disease; Genes, MHC Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Lovastatin; Lymphocyte Function-Associated Antigen-1; Simvastatin; T-Lymphocytes | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; CCAAT-Enhancer-Binding Proteins; Cholesterol; DNA-Binding Proteins; fas Receptor; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lovastatin; Pyrroles; Receptors, LDL; Simvastatin; Sterol Regulatory Element Binding Protein 1; Transcription Factors; Triglycerides; Tumor Cells, Cultured | 2001 |
Statins as immunomodulatory drugs.
Topics: B-Lymphocytes; Cell Adhesion; Endothelium, Vascular; Extracellular Matrix; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Immunosuppressive Agents; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Lymphocyte Activation; Simvastatin; T-Lymphocytes | 2001 |
Therapy and clinical trials.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Neoplasms; Risk Assessment; Simvastatin; Venous Thrombosis | 2002 |
Goals of statin conversion program.
Topics: Anticholesteremic Agents; Drug Utilization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Simvastatin | 2002 |
Simvastatin and lovastatin, but not pravastatin, interact with MDR1.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Digoxin; Drug Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Swine | 2002 |
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Topics: Acute Disease; Cholesterol; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Pravastatin; Proportional Hazards Models; Risk Factors; Simvastatin; Substance Withdrawal Syndrome; Survival Rate; Treatment Outcome; Troponin; United States | 2002 |
Statins and risk of polyneuropathy: a case-control study.
Topics: Aged; Case-Control Studies; Causality; Denmark; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Logistic Models; Lovastatin; Male; Middle Aged; Odds Ratio; Polyneuropathies; Pravastatin; Registries; Risk; Risk Assessment; Simvastatin | 2002 |
Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Aorta, Thoracic; Calcium; Collagen Type VIII; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Lovastatin; Male; Models, Cardiovascular; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents | 1996 |
Immunosuppressive effects of statins.
Topics: Adjuvants, Immunologic; Cells, Cultured; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interferon-gamma; Lovastatin; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
Determination of lovastatin and simvastatin in pharmaceutical dosage forms by MEKC.
Topics: Acetonitriles; Anticholesteremic Agents; Buffers; Chromatography, Micellar Electrokinetic Capillary; Dosage Forms; Drug Stability; Hydrogen-Ion Concentration; Lovastatin; Reproducibility of Results; Simvastatin; Temperature | 2002 |
The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Analysis of Variance; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Circadian Rhythm; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Mevalonic Acid; Middle Aged; Periodicity; Probability; Prospective Studies; Sampling Studies; Simvastatin; Urinalysis | 2002 |
Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Health Services for the Aged; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; New York; Peripheral Vascular Diseases; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase 9; Caspases; Cell Cycle; Cell Division; Cells, Cultured; Cysteine Proteinase Inhibitors; Drug Therapy, Combination; G1 Phase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Keratinocytes; Lovastatin; Membrane Glycoproteins; Oligopeptides; Poly(ADP-ribose) Polymerases; Resting Phase, Cell Cycle; Simvastatin; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Topics: Animals; Bone Resorption; Calcium; Female; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Osteoclasts; Osteogenesis; Parathyroidectomy; Pravastatin; Protein Prenylation; Pyridines; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin; Thyroidectomy | 2003 |
[Treatment with statins: further data from the Heart Protection Study].
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Female; Humans; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2002 |
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cell Line; Cell Survival; Down-Regulation; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Proteins; Inflammation; Lovastatin; Muscle, Smooth, Vascular; NF-kappa B; NF-KappaB Inhibitor alpha; Plasminogen Activator Inhibitor 1; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrroles; RNA, Messenger; Simvastatin; Transcription Factor AP-1; Transcription Factors; Vascular Endothelial Growth Factor A | 2003 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Statin effects on cholesterol micro-domains in brain plasma membranes.
Topics: Animals; Anisotropy; beta-Cyclodextrins; Brain; Cell Membrane; Cholesterol; Cyclodextrins; Diphenylhexatriene; Female; Fluorescent Dyes; Gene Expression; Lovastatin; Membrane Proteins; Mice; Mice, Inbred C57BL; Pyrenes; Simvastatin; Synaptosomes; Trinitrobenzenesulfonic Acid | 2003 |
Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
Topics: Animals; Aorta; Cells, Cultured; Cholesterol, Dietary; Culture Media, Conditioned; Depression, Chemical; Foam Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Metalloproteases; Mevalonic Acid; Muscle, Smooth, Vascular; Polyisoprenyl Phosphates; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Rabbits; Saphenous Vein; Simvastatin; Squalene; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2003 |
Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Mevalonic Acid; Middle Aged; Simvastatin | 2003 |
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells.
Topics: Animals; Cell Division; Collagen Type I; Collagen Type III; Collagen Type IV; Fibronectins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver; Liver Cirrhosis; Lovastatin; Male; Membrane Proteins; Phenotype; ras Proteins; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Simvastatin | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
Mechanism of simvastatin on induction of heat shock protein in osteoblasts.
Topics: 3T3 Cells; Animals; Cycloheximide; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heat-Shock Proteins; Imidazoles; Lovastatin; Mice; Mitogen-Activated Protein Kinases; Osteoblasts; Osteogenesis; p38 Mitogen-Activated Protein Kinases; Pyridines; Reproducibility of Results; RNA, Messenger; Sensitivity and Specificity; Simvastatin | 2003 |
Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3.
Topics: Animals; Aryldialkylphosphatase; Esterases; Fatty Acids; Humans; Lactones; Lovastatin; Mice; Rabbits; Simvastatin; Species Specificity; Substrate Specificity | 2003 |
Lovastatin induces relaxation and inhibits L-type Ca(2+) current in the rat basilar artery.
Topics: Animals; Anticholesteremic Agents; Basilar Artery; Calcium Channel Blockers; Calcium Channels, L-Type; Female; In Vitro Techniques; Lovastatin; Mevalonic Acid; Muscle Relaxation; Muscle, Smooth, Vascular; Patch-Clamp Techniques; Pilot Projects; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
Current perspectives on statins.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Coronary Artery Disease; Female; Humans; India; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Umbilical Veins; Vascular Endothelial Growth Factor A | 2003 |
Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cell Division; Cell Line, Tumor; Cell Survival; Diterpenes; Female; Humans; Lovastatin; Male; Middle Aged; Protein Processing, Post-Translational; Simvastatin | 2003 |
Differential effects of lipid-lowering agents on human cholinesterases.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cohort Studies; Dementia; Humans; Hypolipidemic Agents; Lovastatin; Molecular Structure; Pravastatin; Simvastatin | 2004 |
Toward a role for statins in immunomodulation.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2002 |
Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Blotting, Northern; Cell Line; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Luciferases; Macrophages; Mice; Oxygen; Promoter Regions, Genetic; Pyrroles; RNA, Messenger; Simvastatin; Swiss 3T3 Cells; Time Factors; Transcription, Genetic | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Cell-based screen of HMG-CoA reductase inhibitors and expression regulators using LC-MS.
Topics: Atorvastatin; Biological Assay; Calibration; Cell Line; Chromatography, Liquid; Enzyme Induction; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mass Spectrometry; Mevalonic Acid; Pyrroles; Simvastatin | 2004 |
Class-specific pro-apoptotic effect of statins on human vascular endothelial cells.
Topics: Apoptosis; Atorvastatin; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fas Ligand Protein; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Membrane Glycoproteins; Metabolic Clearance Rate; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Simvastatin; Umbilical Veins | 2004 |
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Topics: Alitretinoin; Animals; Atorvastatin; Base Sequence; Cell Line; Cholesterol; Consensus Sequence; DNA-Binding Proteins; Gene Expression Regulation; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver X Receptors; Lovastatin; Mevalonic Acid; Mice; Orphan Nuclear Receptors; Promoter Regions, Genetic; Proprotein Convertase 9; Proprotein Convertases; Pyridines; Pyrroles; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Regulatory Sequences, Nucleic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Alignment; Sequence Homology, Nucleic Acid; Serine Endopeptidases; Simvastatin; Sp1 Transcription Factor; Species Specificity; Sterol Regulatory Element Binding Protein 2; Transcription Factors; Tretinoin | 2004 |
Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Polymorphism, Genetic; Pyrroles; Simvastatin | 2004 |
Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
Topics: Amino Acid Substitution; Antioxidants; Atorvastatin; Cells, Cultured; Cysteine; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mutagenesis, Site-Directed; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Protein Processing, Post-Translational; Pyrroles; Reactive Oxygen Species; Recombinant Fusion Proteins; S-Nitrosothiols; Simvastatin; Thioredoxins; Transfection; Umbilical Veins | 2004 |
Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured; Cholesterol; Extracellular Matrix; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Leukocytes, Mononuclear; Lipopolysaccharides; Lipoproteins; Lovastatin; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Phagocytosis; Pinocytosis; Receptors, Fc; Simvastatin; Tricarboxylic Acids; Tumor Necrosis Factor-alpha; Vacuoles | 2004 |
Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex.
Topics: Animals; Blood-Brain Barrier; Brain Chemistry; Cell Division; Cerebral Cortex; Cholesterol; Chromatography, Liquid; Female; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mass Spectrometry; Mice; Mice, Inbred C57BL; Neural Pathways; Oligonucleotide Array Sequence Analysis; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Simvastatin | 2005 |
Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia.
Topics: Alzheimer Disease; Animals; CD11b Antigen; Cell Proliferation; Cell Shape; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Mevalonic Acid; Microglia; Polyisoprenyl Phosphates; Rats; Rats, Sprague-Dawley; rho GTP-Binding Proteins; Simvastatin; Terpenes; Tumor Necrosis Factor-alpha | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Lipid metabolism in zebrafish.
Topics: 4-Chloro-7-nitrobenzofurazan; Alkyl and Aryl Transferases; Animals; Annexin A2; Atorvastatin; Azetidines; Boron Compounds; Caveolin 1; Caveolins; Cell Movement; Cholesterol; Diterpenes; DNA; Embryo, Nonmammalian; Ethylnitrosourea; Ezetimibe; Farnesol; Farnesyltranstransferase; Geranyltranstransferase; Germ Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Mevalonic Acid; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Mutation; Phosphatidylethanolamines; Protein Binding; Protein Prenylation; Pyrroles; Simvastatin; Zebrafish | 2004 |
Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sex Factors; Simvastatin; Time Factors; Treatment Outcome; Women's Health | 2004 |
[Effects of withdrawal of statins on nitric oxide production in vascular endothelial cells].
Topics: Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Humans; Lovastatin; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2005 |
Statin drugs and congenital anomalies.
Topics: Abnormalities, Drug-Induced; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant, Newborn; Lovastatin; Pregnancy; Pregnancy Outcome; Pyrroles; Simvastatin | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells.
Topics: Atorvastatin; Cell Proliferation; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Mitogens; Pravastatin; Pyrroles; Simvastatin | 2005 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug.
Topics: Aged; Anticholesteremic Agents; California; Drug Prescriptions; Drugs, Generic; Female; Health Maintenance Organizations; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Practice Patterns, Physicians'; Simvastatin; Treatment Outcome | 2005 |
Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Anticholesteremic Agents; Female; Fetal Death; Humans; Lovastatin; Maternal-Fetal Exchange; Pregnancy; Pregnancy Outcome; Prospective Studies; Retrospective Studies; Simvastatin | 2005 |
Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Cost Savings; Drug Costs; Drugs, Generic; Female; Financing, Personal; Health Maintenance Organizations; Humans; Lovastatin; Male; Patient Compliance; Patients; Retrospective Studies; Simvastatin; Treatment Outcome | 2005 |
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Experience with statin use in patients with chronic hepatitis C infection.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Biomarkers; Cholesterol; Hepatitis C, Chronic; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Prevalence; Simvastatin; Treatment Outcome; United States | 2005 |
Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Topics: Animals; Bone Resorption; Calcitriol; Carrier Proteins; Cell Differentiation; Cells, Cultured; Glycoproteins; Lovastatin; Membrane Glycoproteins; Mice; Mice, Inbred ICR; Osteoclasts; Osteogenesis; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Simvastatin | 2005 |
HMG-CoA reductase inhibitors induce apoptosis in pericytes.
Topics: Animals; Apoptosis; Cell Line; Cells, Cultured; Chromones; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung; Male; Mice; Mice, Inbred BALB C; Morpholines; Pericytes; Simvastatin; Time Factors | 2006 |
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
Topics: Animals; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Pravastatin; Pyrroles; Serotonin; Simvastatin; Swine; Time Factors; Vasoconstriction | 2006 |
Statin wars following coronary revascularization--evidence-based clinical practice?
Topics: Aged; Drug Prescriptions; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myocardial Ischemia; Myocardial Revascularization; Outpatients; Postoperative Care; Pravastatin; Retrospective Studies; Secondary Prevention; Simvastatin; Treatment Outcome | 2006 |
Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma.
Topics: Amides; Antibiotics, Antineoplastic; Bacterial Proteins; Bacterial Toxins; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mesothelioma; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase; Pyridines; Simvastatin | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
Inhibitory effects of statins on human monocarboxylate transporter 4.
Topics: Animals; Atorvastatin; Basigin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lactic Acid; LLC-PK1 Cells; Lovastatin; Monocarboxylic Acid Transporters; Muscle Proteins; Pyridines; Pyrroles; Simvastatin; Swine; Transfection | 2006 |
[Interactions in solution between cyclodextrins and statins].
Topics: Cyclodextrins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Models, Molecular; Molecular Structure; Simvastatin; Solubility; Solutions | 2005 |
Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis.
Topics: Adult; Blood-Brain Barrier; Capillary Permeability; Cell Movement; Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Chemokines, CXC; Endothelial Cells; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Membrane Proteins; Monocytes; Multiple Sclerosis; Occludin; Phosphoproteins; Protein Prenylation; Simvastatin; Tight Junctions; Zonula Occludens-1 Protein | 2006 |
Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticholesteremic Agents; Atorvastatin; Cell Membrane; Central Nervous System; Cholesterol; Ergosterol; Heptanoic Acids; Lovastatin; Male; Mice; Peptide Fragments; Pyrroles; Simvastatin; Synaptosomes | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Cells, Cultured; Cholesterol; Dimerization; Endopeptidases; Humans; Hypolipidemic Agents; Lovastatin; Mevalonic Acid; Models, Biological; Molecular Weight; Palmitic Acid; Protein Prenylation; Protein Transport; Simvastatin; Terpenes | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Fatty Acids, Monounsaturated; Fluvastatin; G1 Phase; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; p21-Activated Kinases; Phosphorylation; Pravastatin; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Simvastatin | 2006 |
Biosynthesis of lovastatin analogs with a broadly specific acyltransferase.
Topics: Acyl Coenzyme A; Acyltransferases; Anticholesteremic Agents; Aspergillus; Catalysis; Escherichia coli; Fungal Proteins; Lovastatin; Mutation; Simvastatin; Substrate Specificity | 2006 |
Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.
Topics: Apolipoproteins E; Cholesterol; Diabetes Mellitus, Type 2; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lovastatin; Simvastatin; Treatment Outcome | 2007 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes.
Topics: Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; Fungi; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Microbial Sensitivity Tests; Penicillium chrysogenum; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spores, Fungal; Sulfonamides | 2007 |
Modulation of COX-2 expression by statins in human monocytic cells.
Topics: Cyclooxygenase 2; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Lovastatin; Membrane Proteins; Mevalonic Acid; Monocytes; NF-kappa B; rac GTP-Binding Proteins; RAC2 GTP-Binding Protein; Simvastatin; U937 Cells | 2007 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases as Topic; Dementia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Parkinson Disease; Proportional Hazards Models; Pyrroles; Simvastatin; United States; Veterans | 2007 |
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Brain; Heptanoic Acids; Lactones; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Pravastatin; Pyrroles; Simvastatin | 2007 |
Statins reduce amyloid-beta production through inhibition of protein isoprenylation.
Topics: Amyloid beta-Peptides; Animals; Bacterial Toxins; Cell Line, Tumor; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lysosomes; Mevalonic Acid; Mice; Mice, Inbred C57BL; Peptide Fragments; Protein Prenylation; rab GTP-Binding Proteins; rho GTP-Binding Proteins; Simvastatin | 2007 |
HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells.
Topics: Atherosclerosis; Cell Adhesion; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelial Cells; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intercellular Adhesion Molecule-1; Leukocytes; Lovastatin; NF-kappa B; Nicotine; Nicotinic Agonists; Pravastatin; Protein Kinase C; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction; Simvastatin; Smoking; Superoxide Dismutase; Time Factors; Vascular Cell Adhesion Molecule-1 | 2007 |
On the factors modulating the effect of statins on malignant cell proliferation.
Topics: Annexin A5; Atorvastatin; Cell Division; Cell Line, Tumor; DNA Fragmentation; DNA, Neoplasm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; K562 Cells; Kinetics; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 2007 |
Structural elucidation of an unknown Simvastatin by-product in industrial synthesis starting from Lovastatin.
Topics: Chromatography, High Pressure Liquid; Lovastatin; Magnetic Resonance Spectroscopy; Molecular Conformation; Simvastatin; Spectroscopy, Fourier Transform Infrared; Tandem Mass Spectrometry | 2007 |
Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromans; Dose-Response Relationship, Drug; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mammary Neoplasms, Animal; MAP Kinase Kinase 4; Mice; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pravastatin; Proto-Oncogene Proteins c-akt; Simvastatin; Vitamin E | 2007 |
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro.
Topics: Adult; Apoptosis; Atorvastatin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Middle Aged; Phagocytes; Phagocytosis; Pravastatin; Pyrroles; Simvastatin | 2008 |
The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Carrier Proteins; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genes, Reporter; HCT116 Cells; HT29 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Luciferases; Mice; Mice, Nude; Signal Transduction; Simvastatin; Smad4 Protein; Transfection; Transforming Growth Factor beta; Up-Regulation; Xenograft Model Antitumor Assays | 2007 |
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients.
Topics: California; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Neoplasms; Risk; Risk Factors; Simvastatin | 2008 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Antifungal activity of statins against Aspergillus species.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Azoles; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Microbial Sensitivity Tests; Simvastatin | 2007 |
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin | 2007 |
The association between statins and cancer incidence in a veterans population.
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pravastatin; Proportional Hazards Models; Research Design; Retrospective Studies; Simvastatin; United States; Veterans | 2008 |
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
Topics: Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Lung Neoplasms; Male; Melanoma; Neoplasm Invasiveness; Simvastatin; Skin Neoplasms | 2008 |
Statin induces apoptosis and cell growth arrest in prostate cancer cells.
Topics: Apoptosis; Blotting, Western; Cell Cycle; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; In Vitro Techniques; Lovastatin; Male; Prostatic Neoplasms; Simvastatin; Tumor Cells, Cultured | 2008 |
Determination of lovastatin in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Lovastatin; Molecular Structure; Reproducibility of Results; Simvastatin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2008 |
Effect of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors and antioxidant vitamins on free radical lipid oxidation in rat liver.
Topics: Animals; Antioxidants; Ascorbic Acid; Free Radicals; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipid Metabolism; Lipid Peroxidation; Liver; Lovastatin; Male; Oxidation-Reduction; Rats; Rats, Wistar; Selenium; Simvastatin; Tocopherols; Vitamins | 2007 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Creatine Kinase; Cytochrome P-450 CYP3A; Databases, Factual; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Finland; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Simvastatin | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Apoptosis; Barrett Esophagus; Caspase 3; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Esophageal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Lovastatin; Mevalonic Acid; Nitrobenzenes; Polyisoprenyl Phosphates; Pravastatin; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sesquiterpenes; Signal Transduction; Simvastatin; Sulfonamides | 2008 |
Statins in esophageal cancer cell lines: promising lead?
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Cell Line, Tumor; Dose-Response Relationship, Drug; Esophageal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Enhancement of drug solubility in supramolecular and colloidal systems.
Topics: beta-Cyclodextrins; Chemistry, Pharmaceutical; Colloids; Computer Simulation; Cyclodextrins; Drug Carriers; Drug Stability; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Models, Chemical; Models, Molecular; Molecular Structure; Pyrrolidinones; Simvastatin; Solubility; Surface Tension; Temperature | 2009 |
Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway.
Topics: Alendronate; Animals; Apoptosis; Cell Line; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Osteoblasts; Quinolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Simvastatin; Smad3 Protein; Transforming Growth Factor beta | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Comparison of UV and charged aerosol detection approach in pharmaceutical analysis of statins.
Topics: Aerosols; Atorvastatin; Chromatography, High Pressure Liquid; Equipment and Supplies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrroles; Simvastatin; Tablets | 2009 |
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells.
Topics: Cardiovascular Diseases; Cell Line; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Serum Albumin; Simvastatin | 2009 |
Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lovastatin; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; ras Proteins; Signal Transduction; Simvastatin | 2009 |
Neuroprotective effects of statins in an in vitro model of Alzheimer's disease.
Topics: Amyloid beta-Peptides; Analysis of Variance; Animals; Calcium; Caspase 3; Cell Survival; Cells, Cultured; Cerebral Cortex; Cholesterol; Dose-Response Relationship, Drug; Drug Interactions; Embryo, Mammalian; Extracellular Signal-Regulated MAP Kinases; In Situ Nick-End Labeling; Lovastatin; Neurons; Neuroprotective Agents; Oncogene Protein v-akt; Peptide Fragments; Rats; Rats, Wistar; Reactive Oxygen Species; Simvastatin; Tetrazolium Salts; Thiazoles; Time Factors | 2009 |
Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelium; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Mevalonic Acid; Ovarian Neoplasms; Polyisoprenyl Phosphates; Pravastatin; Sesquiterpenes; Signal Transduction; Simvastatin; Uterine Cervical Neoplasms; Water | 2010 |
Distinct modes of molecular regulation of CCL3 induced calcium flux in monocytic cells.
Topics: Animals; Anticholesteremic Agents; beta-Cyclodextrins; Calcium; Caveolae; Cell Line; Cell Membrane; Chemokine CCL3; CHO Cells; Cholesterol; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; GTP-Binding Proteins; Humans; Inositol 1,4,5-Trisphosphate Receptors; Kidney; Lovastatin; Membrane Microdomains; Monocytes; Pertussis Toxin; Receptors, CCR5; Receptors, G-Protein-Coupled; Ryanodine; Ryanodine Receptor Calcium Release Channel; Signal Transduction; Simvastatin; Thapsigargin; Time Factors | 2009 |
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Autocrine Communication; Biological Factors; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Melanoma; Pyridines; Pyrroles; Simvastatin; Time Factors | 2009 |
Ultrasound assisted ionic liquid dispersive liquid phase extraction of lovastatin and simvastatin: a new pretreatment procedure.
Topics: Animals; Anticholesteremic Agents; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Lovastatin; Salts; Simvastatin; Ultrasonics; Water | 2009 |
Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions.
Topics: Antibodies, Monoclonal; Apoptosis; Cell Adhesion; Cell Shape; Cell Survival; Dose-Response Relationship, Drug; Eosinophils; Fatty Acids, Monounsaturated; Fluvastatin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intercellular Adhesion Molecule-1; Lovastatin; Macrophage-1 Antigen; Mevalonic Acid; Microfluidic Analytical Techniques; Microfluidics; Pravastatin; Recombinant Proteins; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2009 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |
Simvastatin as a potential therapeutic for acute respiratory distress syndrome.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Lovastatin; Lung; Mevalonic Acid; Mice; Neutrophils; Respiratory Distress Syndrome; Simvastatin | 2009 |
A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion.
Topics: Actomyosin; Carcinoma, Squamous Cell; Extracellular Matrix; Fibroblasts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin alpha5; Lovastatin; Muscle Contraction; Neoplasm Invasiveness; rab GTP-Binding Proteins; Simvastatin | 2010 |
Colorimetric determination of simvastatin and lovastatin in pure form and in pharmaceutical formulations.
Topics: Anticholesteremic Agents; Colorimetry; Hydrogen-Ion Concentration; Hydroxylamine; Limit of Detection; Lovastatin; Pharmaceutical Preparations; Simvastatin; Tablets | 2010 |
Effects of fungal statins on high-glucose-induced mouse mesangial cell hypocontractility may involve filamentous actin, t-complex polypeptide 1 subunit beta, and glucose regulated protein 78.
Topics: Actins; Acyl Coenzyme A; Animals; Cell Division; Endoplasmic Reticulum Chaperone BiP; Glomerular Mesangium; Glucose; Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Lovastatin; Mice; Pravastatin; Simvastatin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetradecanoylphorbol Acetate | 2010 |
Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation.
Topics: Animals; Cartilage, Articular; Cattle; Cells, Cultured; Collagen; Collagenases; Down-Regulation; Gelatinases; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1alpha; Lovastatin; Matrix Metalloproteinases; Mevalonic Acid; Nasal Cartilages; Oncostatin M; Signal Transduction; Simvastatin; Terpenes; Tissue Culture Techniques | 2010 |
IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells.
Topics: Apoptosis; Caspase 1; CD56 Antigen; Cell Line, Tumor; Cells, Cultured; Dendritic Cells; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Interferon-gamma; Interleukin-18; Interleukin-1beta; Interleukin-2; Killer Cells, Natural; Leukocytes, Mononuclear; Lovastatin; Lymphocyte Activation; Molecular Structure; Simvastatin; Time Factors | 2010 |
Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
Topics: Amino Acid Substitution; Bacterial Proteins; Catalysis; Catalytic Domain; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; NADPH-Ferrihemoprotein Reductase; Oxidation-Reduction; Simvastatin; Stereoisomerism | 2011 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling.
Topics: Animals; Arginase; Atherosclerosis; Cells, Cultured; Cholesterol, Dietary; Endothelial Cells; Enzyme Activation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microtubules; Nitric Oxide; Protein Transport; rhoA GTP-Binding Protein; RNA Interference; Scavenger Receptors, Class E; Signal Transduction; Simvastatin; Superoxides; Transfection | 2011 |
Lactone form 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) stimulate the osteoblastic differentiation of mouse periodontal ligament cells via the ERK pathway.
Topics: Alkaline Phosphatase; Animals; Anthraquinones; Blotting, Western; Bone Morphogenetic Protein 2; Butadienes; Calcification, Physiologic; Cell Culture Techniques; Cell Differentiation; Cell Line; Cell Survival; Coloring Agents; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin-Binding Sialoprotein; Lovastatin; Mice; Mitogen-Activated Protein Kinase 1; Nitriles; Osteoblasts; Osteocalcin; Periodontal Ligament; Promoter Regions, Genetic; Simvastatin; Transcriptional Activation | 2011 |
Statins inhibit T-acute lymphoblastic leukemia cell adhesion and migration through Rap1b.
Topics: Blotting, Western; Cell Adhesion; Cell Movement; Cells, Cultured; Endothelium, Vascular; Flow Cytometry; Fluorescent Antibody Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Lovastatin; Lymphocyte Function-Associated Antigen-1; Lymphocytes; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; rap GTP-Binding Proteins; Simvastatin; Umbilical Veins | 2011 |
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population.
Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors | 2011 |
NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells.
Topics: Databases, Factual; Drug Resistance, Neoplasm; Genomics; HCT116 Cells; HT29 Cells; Humans; Lovastatin; Polymorphism, Single Nucleotide; RNA Interference; RNA, Small Interfering; Simvastatin; Transcription Factors | 2011 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
[Retention behavior of statins in microemulsion liquid chromatography].
Topics: Atorvastatin; Chromatography, Liquid; Emulsions; Heptanoic Acids; Lovastatin; Models, Chemical; Pravastatin; Pyrroles; Simvastatin | 2011 |
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Medication Adherence; Middle Aged; Niacin; Simvastatin | 2011 |
Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Topics: Acyl Coenzyme A; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Injections, Intravenous; Losartan; Lovastatin; Male; Rats; Rats, Sprague-Dawley; Rhodamine 123; Simvastatin; Tetrazoles; Time Factors | 2011 |
Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Topics: Chromatography, Liquid; Humans; Hypolipidemic Agents; Limit of Detection; Lovastatin; Male; Niacin; Simvastatin; Tandem Mass Spectrometry | 2012 |
Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria.
Topics: Adaptive Immunity; Adult; Aged; Cell Cycle; Cell Proliferation; Chemokine CCL3; Chronic Disease; Female; Humans; Immunity, Innate; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interleukin-10; Interleukin-17; Interleukin-6; Leukocytes, Mononuclear; Lovastatin; Male; Middle Aged; Phytohemagglutinins; RNA, Messenger; Simvastatin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; T-Lymphocytes; Th1 Cells; Th2 Cells; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Urticaria; Young Adult | 2011 |
[Rhabdomyolysis related to statin and seizures: report of 3 cases].
Topics: Cerebral Infarction; Creatine Kinase; Epilepsy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Rhabdomyolysis; Simvastatin | 2011 |
HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model.
Topics: Animals; Cicatrix, Hypertrophic; Disease Models, Animal; Ear; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rabbits; Simvastatin; Wound Healing | 2012 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Development and validation of a simple and fast HPLC method for determination of lovastatin, pravastatin and simvastatin.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lovastatin; Naphthalenes; Pravastatin; Reproducibility of Results; Sensitivity and Specificity; Simvastatin | 2012 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells.
Topics: ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line; Cell Line, Tumor; Doxorubicin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liposomes; Lovastatin; NF-kappa B; Nitric Oxide Synthase; Nitrites; Receptors, LDL; rho-Associated Kinases; rhoA GTP-Binding Protein; Simvastatin | 2012 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
Topics: Animals; Atorvastatin; Cell Communication; Disease Models, Animal; Endothelial Cells; Gene Expression; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Kruppel-Like Transcription Factors; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Lovastatin; Male; Paracrine Communication; Pyrroles; Rats; Rats, Wistar; Simvastatin; Stress, Mechanical | 2013 |
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control.
Topics: Aged; Atorvastatin; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin | 2013 |
Exploring the ticagrelor-statin interplay in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Simvastatin; Ticagrelor; Ticlopidine | 2013 |
Generation of statin drug metabolites through electrochemical and enzymatic oxidations.
Topics: Anticholesteremic Agents; Cytochrome P-450 Enzyme System; Electrochemical Techniques; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mutation; Oxidation-Reduction; Simvastatin | 2013 |
Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes.
Topics: Animals; Atorvastatin; Cell Death; Cell Survival; Glutathione; Glutathione Disulfide; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lovastatin; Male; Membrane Potential, Mitochondrial; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Simvastatin | 2013 |
Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells.
Topics: Acyl Coenzyme A; Angiopoietin-2; Atherosclerosis; Cell Survival; Cells, Cultured; Endothelial Cells; Exocytosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Simvastatin; Weibel-Palade Bodies | 2013 |
Evaluation of a method using high performance liquid chromatography with ultraviolet detection for the determination of statins in macromycetes of the genus Pleurotus cultivated by fermentation processes.
Topics: Agriculture; Chromatography, High Pressure Liquid; Drug Stability; Fermentation; Limit of Detection; Lovastatin; Pleurotus; Pravastatin; Simvastatin; Waste Products | 2013 |
Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure.
Topics: Age Factors; Animals; Bile Acids and Salts; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fibroblast Growth Factors; Humans; Intestine, Small; Liver; Lovastatin; Male; Mice; Mice, Knockout; Microsomes; NADPH-Ferrihemoprotein Reductase; Organ Specificity; Simvastatin; Up-Regulation | 2014 |
Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Female; Gonadal Steroid Hormones; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Networks and Pathways; Ovary; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Theca Cells | 2014 |
Efficiency of hepatocyte pretreatment with coenzyme Q10 against statin toxicity.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Survival; Hepatocytes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lethal Dose 50; Lipid Peroxidation; Lovastatin; Male; Membrane Potentials; Mitochondria; Protective Agents; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Simvastatin; Ubiquinone | 2014 |
A dispersive liquid-liquid microextraction method based on the solidification of a floating organic drop combined with HPLC for the determination of lovastatin and simvastatin in rat urine.
Topics: Animals; Anticholesteremic Agents; Chromatography, High Pressure Liquid; Liquid Phase Microextraction; Lovastatin; Rats; Simvastatin | 2014 |
A method to identify and validate mitochondrial modulators using mammalian cells and the worm C. elegans.
Topics: Animals; Caenorhabditis elegans; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cluster Analysis; Drug Approval; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Indoles; Lovastatin; MCF-7 Cells; Mice; Mitochondria; Oxidative Phosphorylation; Oxygen Consumption; Pharmaceutical Preparations; Reproducibility of Results; Simvastatin; United States; United States Food and Drug Administration | 2014 |
HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K(+)-channel currents in murine thymocytes.
Topics: Animals; Cell Membrane; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kv1.3 Potassium Channel; Lovastatin; Male; Mice, Inbred Strains; Pravastatin; Simvastatin; Thymocytes | 2014 |
[Renoprotective efficacy of different doses of statins in experimental acute renal failure].
Topics: Acute Kidney Injury; Administration, Topical; Animals; Atorvastatin; Creatine Kinase; Diuresis; Glomerular Filtration Rate; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lovastatin; Pyrroles; Rats; Rhabdomyolysis; Simvastatin; Stomach; Urodynamics | 2014 |
Lipophilic statin use and suicidal ideation in a sample of adults with mood disorders.
Topics: Adult; Bipolar Disorder; Cross-Sectional Studies; Depressive Disorder; Depressive Disorder, Major; Dietary Fats; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Risk Factors; Simvastatin; Suicidal Ideation | 2014 |
First principles calculation of electron ionization mass spectra for selected organic drug molecules.
Topics: Chemistry, Pharmaceutical; Erythromycin; Humans; Lovastatin; Paclitaxel; Prescription Drugs; Simvastatin; Spectrometry, Mass, Electrospray Ionization; Tetrazoles; Valine; Valsartan | 2014 |
Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genetic Association Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver-Specific Organic Anion Transporter 1; Lovastatin; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Risk Assessment; Simvastatin | 2015 |
Correlation between use of simvastatin and lovastatin and female lung cancer risk: a nationwide case-control study.
Topics: Administration, Oral; Adult; Aged; Case-Control Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Middle Aged; Registries; Risk Factors; Simvastatin; Taiwan; Women's Health; Young Adult | 2015 |
Cofactor-free light-driven whole-cell cytochrome P450 catalysis.
Topics: Bacterial Proteins; Biocatalysis; Cytochrome P-450 Enzyme System; Electron Transport; Escherichia coli; Estradiol; Fluorescein; Heme; Humans; Light; Lovastatin; Omeprazole; Oxidation-Reduction; Photosensitizing Agents; Protein Structure, Tertiary; Simvastatin | 2015 |
Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma.
Topics: Adult; Aged; Atorvastatin; Calibration; Chromatography, Liquid; Heptanoic Acids; Humans; Lovastatin; Middle Aged; Pyrroles; Quality Control; Reproducibility of Results; Simvastatin; Tandem Mass Spectrometry | 2015 |
Lovastatin-Mediated Changes in Human Tendon Cells.
Topics: Atorvastatin; Cholesterol; Cytoskeleton; Gap Junctions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrroles; Simvastatin; Tendons | 2015 |
Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diphosphonates; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Epigenesis, Genetic; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Mevalonic Acid; MicroRNAs; NADP; Neoplasms; Protein Processing, Post-Translational; Simvastatin; Vitamin D | 2015 |
Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lovastatin; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Simvastatin; Survival Rate | 2015 |
Simvastatin increases AQP2 urinary excretion in hypercholesterolemic patients: A pleiotropic effect of interest for patients with impaired AQP2 trafficking.
Topics: Adult; Aged; Anticholesteremic Agents; Aquaporin 2; Diuresis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Osmolar Concentration; Simvastatin; Time Factors | 2016 |
Statins Attenuate Helicobacter pylori CagA Translocation and Reduce Incidence of Gastric Cancer: In Vitro and Population-Based Case-Control Studies.
Topics: Adult; Aged; Antigens, Bacterial; Bacterial Proteins; Case-Control Studies; Cell Line; Cell Line, Tumor; Cholesterol; Epithelial Cells; Female; Helicobacter Infections; Helicobacter pylori; Host-Pathogen Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Incidence; Lovastatin; Male; Middle Aged; Phosphorylation; Population Surveillance; Protein Transport; Simvastatin; Stomach Neoplasms; Taiwan | 2016 |
Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative.
Topics: Age Factors; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cohort Studies; Environmental Exposure; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Logistic Models; Longitudinal Studies; Lovastatin; Middle Aged; Odds Ratio; Overweight; Prospective Studies; Pyridines; Risk Factors; Simvastatin; Skin Neoplasms; Smoking; Sunlight; Vitamin D; Vitamins; White People | 2016 |
Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae.
Topics: Animals; Antifungal Agents; Atorvastatin; Diptera; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Microbial Sensitivity Tests; Mucormycosis; Rhizopus; Simvastatin; Spores, Fungal; Texas; Virulence | 2016 |
Statin Use and Survival in Resectable Pancreatic Cancer: Confounders and Mechanisms.
Topics: Carcinoma, Pancreatic Ductal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pancreatic Neoplasms; Simvastatin | 2016 |
Statins Inhibit Fibrillary β-Amyloid Induced Inflammation in a Model of the Human Blood Brain Barrier.
Topics: Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Astrocytes; Blood-Brain Barrier; Cell Death; Cell Line; Chemokine CCL2; Chemokine CCL5; Coculture Techniques; Endothelial Cells; Humans; Interleukin-6; Interleukin-8; Lovastatin; Models, Biological; Peptide Fragments; Simvastatin; Vascular Endothelial Growth Factor A | 2016 |
Effectiveness of atorvastatin in suppressing MUC5AC gene expression in human airway epithelial cells.
Topics: Atorvastatin; Cell Line, Tumor; Cell Membrane; Cholesterol; Epithelial Cells; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1beta; Lovastatin; MAP Kinase Signaling System; Mucin 5AC; RNA, Messenger; Simvastatin | 2016 |
Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Topics: Aged; Aged, 80 and over; Atorvastatin; Clinical Trials as Topic; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Interrupted Time Series Analysis; Lovastatin; Male; Nova Scotia; Pravastatin; Prescription Drugs; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2016 |
Nonenzymatic Mechanism of Statins in Modulating Cholesterol Particles Formation.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Lovastatin; Pilot Projects; Prodrugs; Simvastatin | 2016 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target.
Topics: Atorvastatin; Cost-Benefit Analysis; Cross-Sectional Studies; Drug Costs; Hawaii; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Medicare; Practice Patterns, Physicians'; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; United States | 2017 |
Statins reduce TGF-beta2-modulation of the extracellular matrix in cultured astrocytes of the human optic nerve head.
Topics: Analysis of Variance; Astrocytes; Cells, Cultured; Extracellular Matrix; Eye Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Optic Disk; Simvastatin; Transforming Growth Factor beta2 | 2017 |
Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Line, Tumor; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Profiling; Gene Expression Regulation; Green Fluorescent Proteins; Humans; Indoles; Insulin-Secreting Cells; Lovastatin; Mevalonic Acid; Microarray Analysis; Mutation; Polyisoprenyl Phosphates; Protein Prenylation; Protein Transport; Proto-Oncogene Proteins p21(ras); Recombinant Fusion Proteins; Sesquiterpenes; Signal Transduction; Simvastatin | 2017 |
Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats.
Topics: Animals; Atorvastatin; Bone Density; Female; Femur; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Ovariectomy; Rats; Rats, Sprague-Dawley; Simvastatin; X-Ray Microtomography | 2018 |
An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells.
Topics: Adrenal Gland Neoplasms; Breast Neoplasms; Cell Death; Female; Humans; Lovastatin; MCF-7 Cells; Microscopy, Fluorescence; Neoplasm Proteins; Simvastatin; Vimentin | 2018 |
Statins as potential agents for the prevention and treatment of osteoporosis.
Topics: Animals; Atorvastatin; Bone Density; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Osteoporosis; Rats; Simvastatin | 2018 |
Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Topics: Adult; Aged; Atorvastatin; Depression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Propensity Score; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Suicide, Attempted; United States | 2018 |
Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways.
Topics: Animals; Antirheumatic Agents; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Microsomes, Liver; Morphinans; Rats; Rats, Sprague-Dawley; Simvastatin; Tissue Distribution | 2018 |
Effect of statin use on the risk of medically attended acute respiratory illness among influenza vaccinated elderly.
Topics: Aged; Aged, 80 and over; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza Vaccines; Influenza, Human; Logistic Models; Lovastatin; Male; Respiratory Tract Infections; Retrospective Studies; Simvastatin | 2018 |
Engineering Saccharomyces cerevisiae for production of simvastatin.
Topics: Cytochrome P-450 Enzyme System; Gene Dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Engineering; Plasmids; Polyketides; Saccharomyces cerevisiae; Simvastatin | 2019 |
Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Amides; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cyclohexenes; Cytokines; Diphosphonates; Fibroblasts; Fluvastatin; Gene Expression Regulation; Heart; Heart Diseases; Humans; Interleukin-33; Lovastatin; Mevalonic Acid; Monoterpenes; Myocardium; Myocytes, Cardiac; Pravastatin; Pyridines; rhoA GTP-Binding Protein; Simvastatin; Thiazolidines | 2018 |
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells.
Topics: Atorvastatin; Cell Line; Cell Movement; Cell Proliferation; Endometriosis; Endometrium; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Stromal Cells | 2019 |
Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy.
Topics: Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Bilayers; Lovastatin; Magnetic Resonance Spectroscopy; Phosphatidylcholines; Phospholipids; Pravastatin; Simvastatin | 2019 |
Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content.
Topics: Adenocarcinoma of Lung; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria, Liver; Simvastatin | 2019 |
A pilot study on the association between
Topics: Adult; Dyslipidemias; Female; Humans; Incidence; Liver-Specific Organic Anion Transporter 1; Lovastatin; Malaysia; Male; Middle Aged; Muscular Diseases; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Risk Factors; Simvastatin | 2019 |
Determination of lovastatin, mevastatin, rosuvastatin and simvastatin with HPLC by means of gradient elution.
Topics: Chromatography, High Pressure Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Rosuvastatin Calcium; Simvastatin; Skin Absorption | 2019 |
Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.
Topics: Animals; Atorvastatin; Caspase 3; Caspase 7; Cell Line; Cell Survival; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Myoblasts; Pravastatin; Protective Agents; Rats; Resveratrol; Signal Transduction; Simvastatin | 2020 |
Statins Suppress TGF-β2-Mediated MMP-2 and MMP-9 Expression and Activation Through RhoA/ROCK Inhibition in Astrocytes of the Human Optic Nerve Head.
Topics: Adult; Astrocytes; Atorvastatin; Blotting, Western; Cells, Cultured; Female; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lovastatin; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Myosin-Light-Chain Phosphatase; Optic Disk; Phosphorylation; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Transforming Growth Factor beta2 | 2020 |
Statins decrease the expression of c-Myc protein in cancer cell lines.
Topics: Atorvastatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Neoplasms; Proto-Oncogene Proteins c-myc; Simvastatin | 2021 |
Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer.
Topics: Autophagy; Cell Cycle; Cell Line, Tumor; Cyclin A2; DNA Replication; Drug Screening Assays, Antitumor; Fluvastatin; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pancreatic Neoplasms; RNA-Seq; Signal Transduction; Simvastatin; Transcriptome | 2020 |
Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Lung Neoplasms; Pravastatin; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2021 |
FTIR spectroscopic study of two isostructural statins: Simvastatin and Lovastatin as authentic and in pharmaceuticals.
Topics: Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin; Spectroscopy, Fourier Transform Infrared; Tablets | 2021 |
Inhibition and disintegration of
Topics: Bacillus subtilis; Bacterial Proteins; Biofilms; Humans; Lovastatin; Molecular Docking Simulation; Simvastatin | 2023 |
Biochemistry and Nanomechanical Properties of Human Colon Cells upon Simvastatin, Lovastatin, and Mevastatin Supplementations: Raman Imaging and AFM Studies.
Topics: Biomarkers, Tumor; Caco-2 Cells; Colon; Dietary Supplements; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Microscopy, Atomic Force; Simvastatin | 2022 |
Bioconversion of lovastatin to simvastatin by Streptomyces carpaticus toward the inhibition of HMG-CoA activity.
Topics: Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Phylogeny; RNA, Ribosomal, 16S; Simvastatin | 2023 |
Simplification of pharmacopoeial liquid chromatography methods for related substances of statins by hyphenated ultraviolet and charged aerosol detection.
Topics: Aerosols; Chromatography, High Pressure Liquid; Chromatography, Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Simvastatin | 2023 |
Molecular and Computational Analysis Identify Statins as Selective Inhibitors of Human Butyrylcholinesterase.
Topics: Acetylcholinesterase; Atorvastatin; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Molecular Docking Simulation; Rosuvastatin Calcium; Simvastatin; Structure-Activity Relationship | 2023 |
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.
Topics: Animals; Head and Neck Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immune Checkpoint Inhibitors; Lovastatin; Mice; Simvastatin; Squamous Cell Carcinoma of Head and Neck | 2023 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
Micellar liquid chromatography as a sustainable tool to quantify three statins in oral solid dosage forms.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Chromatography, Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Micelles; Reproducibility of Results; Rosuvastatin Calcium; Simvastatin; Sodium Dodecyl Sulfate | 2023 |
Microextraction based on liquid-solid phase transition of benzoic acid: Extraction of statins from human urine followed by chromatographic analysis.
Topics: Benzoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Phase Transition; Simvastatin | 2024 |